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SUMMARY
This study has investigated the interactions of 
a number of methylenedioxy compounds and some substituted 
benzimidazoles with hepatic microsomal cytochrome P~450.
Various substituted benzimidazoles were found 
to bind to rat hepatic microsomal cytochrome P-450, eliciting 
the formation of different types of binding spectra. A 
series of 2-tt-alkylbenzimidazoles produced either Type I or 
Type RI binding spectra and these compounds inhibited 
monooxygenase reactions.
Several methylenedioxy compounds elicited the 
formation of methylenedioxy metabolite-cytochrome P-450 
complexes in the presence of either NADPH and oxygen or 
cumene hydroperoxide in vitro. Methylenedioxy metabolites 
were bound to the haem iron of cytochrome P-450 and the 
resultant complexes were less stable in the oxidized (Fe3+) 
than the reduced (Fe2+) state. Oxidized isosafrole 
metabolite-cytochrome P-450 complexes formed in vivo following 
the administration of isosafrole to rats were readily 
dissociated in vitro by the addition of certain substrates 
of the monooxygenase system. Such substrates were typically 
lipophilic and had a high affinity for the Type I binding 
site of cytochrome P-450, An apparent increase in cytochrome 
P-450 levels and enhanced cytochrome P-450-mediated enzyme 
activities were observed after the time-dependent dissociation 
had occurred*
When hepatic microsomes from rats which received 
isosafrole in vivo were subjected to sodium dodecyl sulphate- 
polyacrylamide gel electrophoresis, a protein of 54,000 
molecular weight was found to be induced. This protein 
was identified as a haemoprotein and had an electrophoretic 
mobility different from the proteins preferentially induced 
by either phenobarbitone or 20-methylcholanthrene treatment. 
Both the isosafrole-induced protein and the isosafrole 
metabolite-cytochrome P-450 complex were observed in 
microsomal preparations from rats which had received 
phenobarbitone and isosafrole or 20-methylcholanthrene and 
isosafrole,
Isosafrole-related material was also found to 
be apparently irreversibly bound to rat and mouse proteins 
following the administration of [to-14C] isosafrole in vivo.
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CHAPTER 1 
INTRODUCTION
1 . INTRODUCTION
1.1. CYTOCHROME P-450
1.1.1. Historical
In 1949 an accumulation of data led to the 
production of a book by Warburg which showed the importance 
bivalent iron to the binding of oxygen and this led to 
the concept of oxygen activation. Mason et at. (1955) 
later demonstrated the enzyme-mediated direct incorporation 
of molecular oxygen into 3,4-dimethylphenol using a 
heavy oxygen isotope (1802). In the same year, Axelrod 
showed that the major activity for L-amphetamine 
hydroxylation resided in the microsomal cell fraction, 
and Gillette et at. (1957) among others demonstrated 
that NADPH and gaseous oxygen were essential for 
microsomal drug oxidation to occur.
The independent discovery by Klingenberg 
(1958) and Garfinkel (1958) of a microsomal pigment to 
which carbon monoxide bound avidly led Omura and 
Sato (1962; 1964a,b) to the characterization of a unique 
haemoprotein which they termed cytochrome P-450. The 
name is derived from the observation that the carbon 
monoxide complex with the reduced cytochrome shows a 
maximal absorption in the Soret region at 450 nm.
Microsomal enzymes dependent on cytochrome P-450 have
been termed mixed-function oxidases by Mason (1957)
but Hayaishi (1962) suggests the designation monooxygenase.
This latter term gives a clearer impression of the mode 
of action of the enzyme, involving the insertion of a 
single oxygen atom into the substrate molecule.
In the early 1960s, cytochrome P-450 became 
recognized as the terminal oxidase in several hydroxylation 
reactions. The first evidence of participation of 
cytochrome P-450 in steroid hydroxylation was reported 
by Estabrook et at. (1963). Using Warburg's classical 
experimental arrangement for the photochemical action 
spectrum, these authors showed that light of 450 nm 
wavelength was optimal for the reversal of carbon 
monoxide-inhibited C-21 hydroxylation. By 1968, it 
was realized that cytochrome P-450 was of major importance 
in the metabolism of many foreign chemicals including 
drugs, carcinogens, insecticides and in the biotransformation 
of a variety of endogenous substrates including steroid 
hormones and fatty acids.
Much of the currently accepted knowledge 
concerning the properties of cytochrome P-450 comes 
from purified preparations of the soluble NADH-dependent 
cytochrome P-450 isolated from 'Pseudomonas putida 
(Katagiri et at.j 1968; Peterson, 1971). However, the 
membrane-bound mammalian cytochrome P-450 has recently
been isolated by detergent treatment (Lu and Levin,
/
1974) along with the NADPH-dependent cytochrome P-450 
reductase (Levin et at.j 1974). A comparison of the 
properties of the purified cytochrome P-450 and the
membrane-bound haemoprotein has recently been made with 
regard to their physical properties (Stern et al.3 1973; 
Witmer et al.3 1975) and catalytic activities (Conney 
et at.3 1973).
1.1.2. Occurrence
Cytochrome P-450 has been detected in a 
large number .of mammals (including man), various avian, 
amphibian, fish and insect species, yeasts (Candida), 
bacteria such as Pseudomonas putida and Rhizobium 
and some plants. Garfinkel (1963) reported the probable 
presence of cytochrome P-450 in liver, kidney, lung, 
intestinal mucosa, testis, adrenal gland and pancreas. 
These results have since been confirmed and extended 
to skin, heart, brain, pituitary, lymphocytes, platelets, 
placenta and ovarian corpus luteum. The distribution 
of cytochrome P-450 was the subject of a recent review 
by Wickramasinghe (1975).
1.1.3. Structure of cytochrome P-450
Cytochromes are classified as one of three
types (a, b and c) according to their absorption maxima; 
cytochromes of type a absorb at the longest wavelength 
and type c at the shortest. Cytochrome P-450, in common 
with other b-type cytochromes, contains an iron 
protoporphyrin IX prosthetic group. In contrast to b-type 
cytochromes, cytochrome P-450 can react with oxygen, 
carbon monoxide and cyanide (resembling cytochrome oxidase
in this respect) (Mahler and Cordes, 1971). The classical 
difference between cytochrome P-450 and other b cytochromes 
is the intense absorption maximum at 450 nm, observed 
when the reduced haemoprotein is complexed with carbon
kowvdt
monoxide. Conversion of cytochrome P-450 to a.form which
A
is considered metabolically inactive towards most 
cytochrome P-450 substrates, cytochrome P-420, produces 
typical ferrous haemoprotein spectra with a Soret band 
at about 420 nm. The type of substances capable of bringing 
about the cytochrome P-450-cytochrome P-420 transition 
indicate that the cytochrome P-450 haem is bound in a 
highly lipophilic environment (Omura and Sato, 1964a;
Imai and Sato, 1967a), e.g. detergents such as 
deoxycholate (which disrupt hydrophobic bonds) and lipase 
(steapsin) are known to convert cytochrome P-450 to 
cytochrome P-420. However, proteases such as trypsin, 
which primarily cause modification in the native 
conformation of the haemoprotein also bring about the 
conversion of cytochrome P-450 to cytochrome P-420. Thus, 
both the protein and the lipid structure of cytochrome 
P-450 are important for the maintenance of its unusual 
spectral properties (Mason et at.3 1965).
Electron spin (paramagnetic) resonance,
ES(P)R, has been widely used in conjunction with optical 
spectroscopy to study cytochrome P-450. EPR is used to 
detect unpaired electrons and is hence particularly 
useful for transition metal complexes such as haemoproteins.
Cytochrome P-450 has been shown to exist in both high- 
spin (5 unpaired electrons) and low-spin (1 unpaired 
electron) states. Typical g-values (numbers which 
characterize the complexes studied) for ferric high- 
spin complexes are in the range 2.0 - 9.7 and ferric 
low-spin complexes give g-values between 1.4 and 3.1 
(Jefcoate and Gaylor, 1969; Hill et aZ./ 1970). Tsai 
et at. (1970) determined the EPR features of oxidized 
cytochrome P-450 and observed a set of g-values at 
g = 1.91, 2.25 and 2.45, indicative of a low-spin 
haemoprotein. These authors also used various model 
systems in an attempt to characterize the axial ligands 
on the haem iron.
In 1965, Mason et at. suggested that a sulphur 
atom was liganded to the haem of cytochrome P-450, 
following the observation of a loss in EPR low-spin 
character after treatment of hepatic microsomes with 
p-chloromercuribenzoate or other mercaptan-forming 
agents. Subsequent studies with model systems using 
metmyoglobin-n-propylmercaptide (Jefcoate and Gaylor,
1969), metmyoglobin and other thiol agents (Hill et at.9
1970) and thiol-treated ferric haemoglobin (Blumberg 
and Peisach, 1971) showed similar low-spin EPR spectra 
to cytochrome P-450 from mammalian (Jefcoate and Gaylor, 
1969; Peisach et at.3 1972) and bacterial (Tsai et at. > 
1970) sources. In addition, Stern and Peisach (1974) 
synthesized a model compound containing ferrous haem
and thiol in the presence of a strong base. They showed 
that the characteristic absorption maximum at 450 nm 
was generated following addition of carbon monoxide to 
the system, implying that thiolate anion was required 
to produce the 450 nm peak typical of cytochrome P-450.
Thus, the available evidence would appear 
to indicate that one of the axial ligands of cytochrome 
P-450 is a mercaptide, probably from a cysteine residue 
(Hill et at.s 1970; Stern et a L , 1973; Peisach et at. 3 
1973; Collman et at.3 1975; Chang and Dolphin, 1976a,b;
Tang et at.3 1976). The nature of the non-mercaptide 
ligand has been a matter for conjecture since cytochrome 
P-450 has been shown to be heterogenous in the vicinity 
of the haem (Peisach et at.3 1973). Jefcoate and Gaylor 
(1969) - proposed that the other axial ligand was an 
imidazole grouping from a histidine residue. Other 
suggestions have included a hydroxyl group (Nebert et at.3 
1976) and water (Peterson and Griffin, 1973; Griffin 
and Peterson, 1975). However, Tang et at. (1976) were 
unable to detect binding of water to their model compound 
by EPR measurements. These authors proposed various 
amino acids as the 6th ligand (including histidine) and 
commented that all low-spin Fe3+ haemoproteins characterized 
so far contained one or two imidazole (histidine) groupings. 
Chevion et at. (1977), using crystal field analysis of 
EPR data generated both by themselves and Tang et at.
(1976) also proposed that imidazole was the non-mercaptide 
ligand.
Chevion et at. (1977) suggested that 
production of the low-spin Fe2+-carbon monoxide 
complex involved displacement of the sixth ligand 
with retention of the mercaptide ligand in accordance 
with previous suggestions (Peisach et at. 3 1973).
Peisach et at.. (1973) and Peisach and Mannering (1975) 
further proposed that the characteristic double absorption 
maxima at 430 nm and 455 nm seen when ethylisocyanide 
was added to reduced cytochrome P-450 could also be 
explained by the proposed model structure. These authors 
suggested that ethylisocyanide displaced both axial 
ligands from cytochrome P-450, with the 430 nm maximum 
resulting from removal of the mercaptide ligand, and the 
455 nm maximum being due to displacement of the other 
axial ligand. It was suggested (Peisach and Mannering,
1975) that the haem environment (i.e. the region of 
cytochrome P-450 containing the haem prosthetic group) 
determined the relative sizes of the absorption maxima 
since the peak heights could be varied following induction 
or by alteration of the pH.
Control and phenobarbitone-induced microsomal 
preparations contain species of cytochrome P-450 which 
produce a predominantly low-spin EPR signal. However, 
following treatment with 20-methylcholanthrene, an 
increase in the high-spin EPR signal is observed with g-values 
near 8, 3.7 and 1.7 (Peisach et at. 3 1973). The high-spin 
EPR signal was, however, only observed at temperatures below
20 K. Further, the absorption maximum of oxidized 
20-methylcholanthrene microsomes was shifted to 394 nm 
(high-spin) whereas the absorbance maximum of oxidized 
control and phenobarbitone-stimulated microsomes was 
at 418 nm (low-spin) (Estabrook et at.3 1972a).
When purified preparations of cytochrome 
P-450 were compared with microsomes from variously 
pretreated animals, differing results were obtained. 
Purified rat hepatic cytochrome P-450 from control and 
phenobarbitone treated animals were low-spin haemoproteins 
as in microsomes, but the high-spin character of the 
20-methylcholanthrene-induced haemoprotein (cytochrome 
P-448) was greatly decreased on purification (Stern 
et al.s 1973). Purified cytochrome P-448 also showed 
a typical low-spin absorbance peak at 418 nm in common 
with purified control and phenobarbitone-induced cytochrome 
P-450. Despite this difference in spin state and optical 
properties, the reduced-carbon monoxide complex of purified 
cytochrome P-448 remained at 448 nm and both purified 
and membrane-bound (microsomal) preparations retained 
typical 20-methylcholanthrene-induced substrate 
specificity. In contrast to results obtained with rats, 
purified rabbit hepatic microsomal cytochrome P-448 
is a high-spin haemoprotein (Witmer et at.* 1975) but 
does not catalyse typical cytochrome P-448 mediated 
reactions (Kawalek et al.3 1975).
It seems that the spin states of the isolated 
haemoproteins are not solely related to their catalytic 
activities. In the case of cytochrome P-4 48 from rat 
hepatic microsomes, it seems that the presence of 20- 
methylcholanthrene bound in vivo is at least partially 
responsible for the high-spin characteristics of 20- 
methylcholanthrene-stimulated microsomes. However, 
it is well established that the proportion of high-spin 
haemoprotein is increased in the presence of cytochrome 
P-450 or P-448 substrates, regardless of the induction 
state, purity or origin of the haemoprotein. Increased 
high-spin character is also seen following the addition 
of camphor to the soluble cytochrome P-450 from 
Pseudomonas putida.
1.1.4. Cytochrome P-450 dependent spectral changes
Characteristic spectral changes have been 
observed when various endogenous or foreign substances 
are added to microsomal suspensions. These spectra are 
monitored by difference spectroscopy and are the optical 
results obtained when the absorbance of the contents of 
the reference cuvette are subtracted from the absorbance 
of the sample cuvette contents.
The first demonstration of such a spectral 
change was reported by Narasimhulu et at. (1965) who 
showed that 17-hydroxyprogesterone bound to adrenal 
cortex microsomes. Remmer et at. (1966), Imai and Sato 
(1966) and Schenkman et at. (1967) also described
difference spectra following the addition of various 
compounds to hepatic microsomal suspensions. These 
spectral changes were termed Type I , Type II and 
Reverse Type I (Type RI). Compounds were characterized 
as being either Type I, Type II or Type RI by virtue of 
their maxima and minima. . Type I compounds produce a 
maximum at 380-395 nm and a minimum at 415-425 nm 
whereas Type II molecules have a maximum at 425-435 nm 
and a minimum at 395-405 nm. The Type RI spectral 
change is typified by a minimum at 380-395 nm and a maximum 
at about 415-425 nm.
Schenkman et at. (1967) suggested that these 
spectral changes were due to interaction between the added 
compound and oxidized cytochrome P-450. These authors 
described a method for calculating an apparent affinity 
constant for a given compound analogous to the Km value 
obtained for enzyme-substrate complexes. A double 
reciprocal plot (Lineweaver and Burk, 1934) of the 
magnitude of the spectral change (ordinate)versus the 
substrate concentration (abscissa) produced an intercept 
on the "x" axis which these authors termed Ks. Ks is 
defined as the concentration of reactant that results 
in 50% of the maximal spectral change. By definition, 
the Ks value is independent of protein concentration, 
although the magnitude of the spectral change is dependent 
not only on the substrate concentration but also on the 
concentration of cytochrome P-450 in the microsomal
suspension (Estabrook et al.3 1972b). The maximal 
absorbance change (AEmax) is analogous to the maximal 
velocity (Vmax) of enzymic reactions.
The Type I spectral change is elicited by 
a wide variety of endogenous and exogenous substrates 
of cytochrome P-450. Such compounds include barbiturates 
polycyclic hydrocarbons and various endogenous steroids 
and fatty acids. In general, compounds which elicit 
Type I binding spectra are lipophilic and Schenkman and 
Sato (1968) suggested that Type I compounds interact 
with the apoprotein portion of cytochrome P-450. In 
support of this view, treatment of microsomes with 
phospholipase C (Chaplin and Mannering, 1970; Eling 
and DiAugustine, 1971) or extraction with isooctane 
(Leibman and Estabrook, 1971) which removed about 70% 
of the phospholipids present, decreased or eliminated 
Type I binding spectra. In contrast, Vore et at.
(1974) have reported that extraction of microsomes 
with butan-l-ol and acetone removed 80% of the 
phospholipids and increased the binding of some Type I 
substrates. Various other authors (Levin et at.3 1974; 
Narasimhulu, 1975a) have also reported that microsomal 
lipid was not essential for Type I binding, although 
the lipid molecules which remain following extraction 
may be involved in substrate binding (Narasimhulu, 1975b) 
Thus, a conflict of evidence exists regarding the 
requirement of phospholipid for Type I binding.
Investigations using fluorescent probe 
techniques have provided further evidence for the 
lipophilicity of the Type I binding site. DiAugustine 
et at. (1970) used 8-anilinonaphthalene-l-sulphonate 
(ANS) as a probe for the Type I site. Al-Gailany 
et at. (1974) also demonstrated that ANS produced similar 
fluorescent characteristics when added to either 
microsomal suspensions or the highly lipophilic solvent, 
hexane. Al-Gailany (1975) has shown that a direct 
correlation exists between the log Ks and the lipid 
solubility (expressed as the log of the octanol-water 
partition coefficient value, log P) for several series 
of Type I binding compounds including fatty acids and 
n-alkylcarbamates. This indicates an increased affinity 
for cytochrome P-450 as the degree of lipophilicity is 
increased. Thus, the present evidence suggests that 
although lipids or phospholipids may not be essential 
for Type I binding to occur, the region at which binding 
takes place is lipophilic.
Typical Type II binding spectra are produced 
by the interaction of amines with cytochrome P-450 
(Schenkman et at.3 1967; Jefcoate et at.3 1969;
Schenkman, 1970). Other compounds containing nitrogen 
atoms with a lone pair of electrons such as pyridine 
and imidazole also elicit the Type II binding spectrum 
(Temple, 1971). This type of spectral change has been shown 
to be due to ferrihaemochrome formation with nitrogen as the
6th ligand of the cytochrome P-450 haem. Aniline has been 
reported to.compete with carbon monoxide for reduced 
cytochrome P-450 indicating interaction at the haem iron 
(Schenkman et al,3 1967). In addition, aniline produces 
two Soret peaks at about 425 and 445 nm (Imai and Sato, 
1967b) similar to those produced by ethylisocyanide 
for which competition with carbon monoxide has also been 
shown (Omura and Sato, 1964a). Very few compounds which 
give rise to Type II spectra are metabolized by the 
cytochrome P-450 monooxygenase system. Aniline, however, 
is a well-known substrate of cytochrome P-450 but its 
Ks value for Type II binding (360 p.M) to cytochrome 
P-450 is different from its Km for metabolism (40 jiM) 
(Schenkman et al.3 1967). Schenkman (1970) has 
demonstrated the presence of a Type I component in the 
aniline binding spectrum using saturating amounts of 
Type I substrate, and presumably it is this Type I 
component which is related to aniline metabolism.
The Type RI (Reverse (inverse) Type I or 
modified Type II) spectral change has often been likened 
to the Type II difference spectrum (Whysner et al.3 1969) 
and has sometimes erroneously been called a Type II 
interaction (Anders, 1971). However, whereas Type II 
compounds ligand to the haem of cytochrome P-450, Type 
RI compounds do not displace carbon monoxide from reduced 
cytochrome P-450 or alter aniline binding to the oxidized 
haemoprotein (Schenkman et at.3 1973).
Compounds which evoke Type RI spectral changes 
include acetanilide, phenacetin, short-chain monohydric 
alcohols and several allyl-substituted barbiturates.
Many of these compounds are substrates of the microsomal 
enzyme system. Diehl et al. (1970) and Schenkman and 
co-workers (1969,1972a, 1973) have suggested that the 
Type RI spectrum is a reversal of the Type I spectral 
change and is due to the displacement of endogenously 
bound Type I substrates. Diehl et al. (1970) showed 
that butan-l-ol, when added to microsomes containing 
sufficient cyclohexane to saturate the Type I binding 
sites, produced a difference spectrum which was the 
exact mirror image of the cyclohexane (Type I) binding 
spectrum. Schenkman et al. (1973) noted a decrease in the 
Type RI spectral change induced by phenacetin after solvent 
extraction of the microsomal suspension. Similarly,
Vore et al. (1974) reported that the well-known Type RI 
spectrum elicited by the addition of hexobarbitone to 
20-methylcholanthrene-induced rat hepatic microsomes 
appeared to be due to endogenous substrate displacement.
In contrast to the results of Schenkman,
Vore et al. (1974) found increased Type RI binding for 
phenacetin and ethanol using butan-l-ol-acetone extracted 
microsomes which contained no endogenous substrates. 
Al-Gailany (1975) also proposed that Type RI binding 
is due to compounds binding to a specific site of 
cytochrome P-450 rather than simply displacing endogenous 
substrates. This argument was based on data using
fluorescent probes which suggested that the Types I, II 
and RI sites were in differing environments, with respect 
to their lipophilicity.
Yet another hypothesis was proposed by 
Hodgson (1974, 1976). He suggested that since many Type 
RI substrates contain oxygen, the oxygen atoms were 
like nitrogen atoms in that they acted as nucleophiles 
and displaced the 6th ligand of cytochrome P-450. The 
hypsochromic shift from Type II spectral maxima and 
minima exhibited by Type .RI compounds was due to the 
lower nucleophilicity of the groupings involved in Type 
RI binding. Yoshida and Kumaoka (1975) also claimed that 
Type RI binding is due to a haem-ligand interaction, 
between high-spin cytochrome P-450 and the Type RI 
compound; Nebert et al. (1976) have recently reached 
a similar conclusion.
It would seem from the above experimental 
data that the exact nature of the Type RI binding spectrum 
has yet to be fully understood. The mechanism of the 
interaction between haemoprotein and Type RI compound 
may well be due to one or more of the above interpretations 
depending on the nature of the compound and the cytochrome 
P-450 species present. Multiple interactions between 
compounds and various forms of cytochrome P-450 are also 
possible (Yoshida and Kumaoka, 1975) .
It can be shown by using a Type RI compound 
as a modifier (i.e. equal concentrations of Type RI 
compound being present in both sample and reference
cuvettes) that the magnitude of a Type I binding spectrum 
is reduced (Orrenius et al.3 1972). This suggests that 
both Type I and Type RI compounds may be involved in the 
same type of interaction with cytochrome P-450. Indeed, 
some molecules which give rise to Type RI spectral changes 
at moderate concentrations actually produce Type I 
spectra at low substrate concentrations (Jansson et al.3
1972). This suggests that the spectral change observed 
at any particular concentration is a mixture of both a 
Type I and a Type RI difference spectrum. The Ks value 
for the Type I components of such spectra are often in 
good agreement with the Km for the metabolism of the 
substrates. In contrast, the Ks values for the Type RI 
spectral component seem to bear no relationship to the 
Km values (Schenkman et al.3 1973; Fasco et al.3 1977).
1.1.5. Mechanism of <v\QAOo?<x\o^ aAcJr"iQpj
Estabrook et- al. (1972a) proposed a scheme 
for the mechanism of cytochrome P-450-dependent mono­
oxygenation.
Initially, a substrate reacts with the 
low-spin form of the ferric haemoprotein (Fe3+) to form 
a high-spin ferric-substrate complex which is detectable 
by spectral and EPR techniques. A Type I binding spectrum 
is observed concomitant with an increase in the high-spin 
EPR signal. The flavoprotein enzyme NADPH-dependent 
cytochrome P-450 reductase is then reduced by NADPH, 
and the reductase in turn reduces the ferric haemoprotein-
substrate complex, converting the haem iron to the Fe2+ 
state. This Fe2+ complex reacts with oxygen producing 
an oxygenated reduced cytochrome P-450-substrate ternary 
complex. The spectral observation of an absorbance 
maximum at about 440 nm has been attributed to this ternary 
complex (Estabrook et aL, 1971; Werringloer and Estabrook, 
1975; Guengerich et at,3 1976).
The oxycytochrome P-450 complex is then 
further reduced by a second electron, the origin of which 
is uncertain. Several studies have suggested that this 
electron is mediated v'ta NADH-dependent cytochrome b 5 
reductase and cytochrome b5, providing an explanation for 
the synergistic effect of NADH on microsomal monooxygenation 
processes. Recent studies by Lu et at. (1974) suggest 
that NADH synergism is dependent on both the substrate 
and cytochrome P-450 species present. Other workers 
have proposed different mechanisms for the addition of 
the second electron (Correia and Mannering, 1973) and the 
role of cytochrome bs has been recently reviewed by 
Schenkman et at, (1976). The ternary complex is then 
decomposed, yielding hydroxylated substrate, oxidized 
cytochrome P-450 and water. A mechanism for the 
decomposition has been proposed by Staudt et at. (1974), 
but the actual nature of the intermediates involved is 
still unclear.
The nature of the "active oxygen" has 
recently been studied following the original experiments 
of Hrycay and O'Brien (1971a,b) showing that cytochrome 
P-450 can also function as a peroxidase. Organic 
peroxides (cumene hydroperoxide and linoleic acid 
hydroperoxide) and other "active oxygen" containing 
compounds such as sodium periodate and sodium chlorite 
have been shown to support the hydroxylation of various 
steroids and fatty acids in the absence of NADPH and 
molecular oxygen (Hrycay et al,a 1975a,b; 1976). These 
investigators suggested that a ferryl ion complex (Fe4 + 0”) 
was the oxidation state involved in the "activated oxygen" 
species of substrate hydroxylation mediated by cytochrome 
P-450.
1.1.6. Induction and multiplicity of cytochrome P-450
An increase in various monooxygenase activities 
concomitant with an induction of cytochrome P-450 has been 
shown following administration of, or accidental exposure 
to, many agents (Conney, 1967; Remmer, 1972). The vast 
majority of these molecules are lipid soluble and 
cytochrome P-450 substrates. Such compounds include 
barbiturates, polycyclic aromatic hydrocarbons, steroids, 
insecticides, pesticides, ethanol and several environmental 
contaminants. There is increasing evidence to suggest 
that multiple forms of cytochrome P-450 exist and that 
different inducing substances increase the levels of 
different forms of cytochrome P-450.
The classical inducers of cytochrome P-450 
catalysed reactions are phenobarbitone. and 20-methyl- 
cholanthrene. Alvares et at. . (1967) produced evidence 
for the multiplicity of cytochrome P-450 following 
the observation of changes in the A .of the reduced- 
carbon monoxide absorbance spectrum after pretreatment 
with these compounds. The cytochromes induced by 
phenobarbitone and 20-methylcholanthrene have been called 
cytochrome P-450 and cytochrome P-448 (Pi-450, P-446) from 
the absorption maxima of the respective carboxy ferro- 
haemochromes. Three forms of cytochrome P-450 have been 
isolated from hepatic microsomes from untreated rats 
according to their affinity for cyanide (Comai and Gaylor,
1973) and these forms are preferentially induced by 
ethanol, phenobarbitone and 20-methylcholanthrene 
respectively. Jefcoate et at. (1970) have used n-octylamine 
and ethylisocyanide as haem ligands to differentiate 
between low-spin cytochrome P-450 (phenobarbitone-inducible) 
and high-spin cytochrome P-448 (inducible by 20-methyl­
cholanthrene) .
Major differences in the rates of metabolism 
and metabolic patterns obtained following treatment with 
phenobarbitone or 20-methylcholanthrene have been 
observed. Phenobarbitone is known to increase the 
metabolism of a wide variety of substrates whereas 20- 
methylcholanthrene is much more specific in its action, 
(Conney, 1967). The use of microsomes from rats treated 
with either of these two inducing agents often leads to 
the enzymic incorporation of the oxygen atom into
different positions in the substrate molecule compared 
with control rat hepatic microsomes. Cytochrome P-450 
substrates metabolized at multiple sites include 
biphenyl (Creaven and Parke, 1966; Burke and Bridges,
1975), testosterone (Conney et at.3 1969, 1973), chloro- 
benzene (Selander et at.3 1975) and warfarin (Pohl 
et at.3 1977).
Recent work on the induction of cytochrome 
P-450 has focussed on the increase in haemoproteins 
with differing molecular weights which can be separated 
by sodium dodecylsulphate (SDS)-polyacrylamide gel 
electrophoretic techniques. Microsomes from phenobarbitone- 
and 20-methylcholanthrene-pretreated rat (Alvares and 
Siekevitz, 1973; Welton and Aust, 1974), mouse (Haugen 
et at. j 1976) and rabbit (Haugen et at.3 1975) livers 
show preferentially-induced proteins in the 45,000-
60,000 molecular weight region. In general, the protein 
induced by 20-methylcholanthrene has a minimum molecular 
weight greater than that of the phenobarbitone-induced 
haemoprotein.
Following purification of the separate 
forms, antibodies raised to the different cytochrome 
species have been shown to inhibit preferentially reactions 
catalysed by either cytochrome P-450 or cytochrome P-448. 
Immunological techniques indicate that there are at 
least six immunochemically distinguishable forms of 
cytochrome P-450 in the rat (Thomas et at.3 1976a).
Moreover, it seems that the haemoprotein preferentially 
induced by a particular agent in different.species is 
not always the same. Gel electrophoretic and 
immunochemical evidence supports the idea that purified 
cytochrome P-448 from the rat and the rabbit are 
structurally different proteins, although their spectral 
properties are similar (Lu et at., 1976).
The mechanism of both phenobarbitone and 
20-methylcholanthrene induction is thought to involve 
de riovo protein synthesis (Gelboin, 1972; Parke, 1975).
Both barbiturates and polycyclic hydrocarbons have been 
shown to increase the incorporation of radiolabelled 
amino acids into microsomal preparations. In addition, 
enzyme induction by phenobarbitone and 20-methylcholanthrene 
can be inhibited by classical inhibitors of protein 
synthesis such as ethionine, puromycin, cycloheximide 
and actinomycin D. It is also possible that reduced 
degradation or stabilization of various components 
involved in,the enzyme synthetic process are brought 
about by cytochrome P-450 enzyme inducers (Seifert and 
Vacha, 1970; Louis-Ferdinand and Fuller, 1970, 1972;
Black et aZ., 1971; Pousada and Lechner, 1972).
Steroid hormones, including corticosteroids, 
androgens, and certain synthetic steroids have been 
shown to induce hepatic microsomal cytochrome P-450 
enzyme activities (Selye, 1970). Certain of these 
molecules actually inhibited or produced less induction
when microsomes from different organs or animals of 
different sexes were studied (Stripp et at. 3 1973). The 
most potent steroid inducer described is the catatoxic 
steroid pregnenelone-16a-carbonitrile (PCN). This 
compound induces a pattern of metabolism unlike either 
phenobarbitone or 20-methylcholanthrene and spectral 
(Lu et al.3 1976) and electrophoretic evidence (Birnbaum 
et al.3 1976) suggests that PCN may induce a novel 
haemoprotein.
A number of halogenated insecticides such 
as l,l,l-trichloro-2,2-bis(p-chlorophenylethane, DDT), 
dieldrin and aldrin were observed to be inducing agents 
following the spraying of animal rooms with insecticide 
(Hart and Fouts, 1963). The pattern of induced activity 
is similar to that of phenobarbitone and it is thought 
that chlorinated insecticides and barbiturates act 
through a common mechanism. No further induction of 
drug-metabolizing activity was observed following the 
simultaneous administration of chlordane and phenobarbitone 
(Hart and Fouts, 1965), unlike that observed for pheno­
barbitone and 20-methylcholanthrene dosed concomitantly 
(Gillette, 1963).
Other highly lipid-soluble halogenated 
residues are extremely resistant to degradation and as 
such are potent inducers of cytochrome P-450. Polychlorinated 
biphenyls (PCBs) are widespread environmental contaminants 
and induce spectral properties similar to those produced 
by 20-methylcholanthrene. However, using a range of 
cytochrome P-450 substrates, experiments (Alvares et al.3
1973) suggested that PCBs induced a metabolic pattern 
which resembled that of . both phenobarbitone and 20- 
methylcholanthrene administered together. This is 
probably because PCBs are mixtures of biphenyls containing 
different numbers of chlorine atoms. Separation of the 
pure polychlorinated biphenyl isomers into two types of 
inducers on the basis of induction of cytochrome P-450 
or cytochrome P-448 has been reported (Goldstein et at.s 
1977). More recently, Ryan et at. (1977) showed that a 
mixture of purified phenobarbitone and 20-methylcholanthrene- 
induced haemoproteins had identical electrophoretic 
properties to purified cytochrome P-450 from rats which 
received PCBsr indicating that PCBs induce two separate 
haemoproteins. In contrast, the extremely toxic herbicide 
contaminant, 2,3,7,8-tetrachlorodibenzo(—p—)dioxin (TCDD) 
induces cytochrome P-448 in rats and mice and the 
pattern of induced enzyme activity resembles that after 
20-methylcholanthrene administration (Poland and Glover,
1974; Haugen et at. 3 1976). However, TCDD is reputedly
30,000 times more potent than 20-methylcholanthrene as 
an inducer of cytochrome P-448-mediated aryl hydrocarbon 
hydroxylase (Poland and Glover, 1974).
Flavones are a group of compounds whose 
inducing properties were first described by Wattenberg 
et at. (1968). Many of these compounds are inducers of 
the 20-methylcholanthrene-type and are reputedly non- 
carcinogenic. The most potent inducer of this group 
is 5,6-benzoflavone (3-naphthoflavone, BNF) which induces
cytochrome P-448 to a similar degree as 20-methylcholanthrene, 
and the two compounds presumably act.y^a the same mechanism 
(Boobis et at.3 1977). The spectral, immunological and 
electrophoretic properties of purified cytochrome P-448 
from BNF-treated rabbits appear to be identical to those 
of the major form of haemoprotein isolated from TCDD- 
treated rabbits (Johnson and Muller-Eberhard, 1977).
Ethanol has been reported to induce some 
cytochrome P-450 catalysed reactions (Joly et at.3 1973). 
Recently, a form of haemoprotein preferentially induced 
by ethanol has been reported with specific spectral 
and catalytic properties (Joly et at. s 1977). Other 
monohydric alcohols have also been reported to have a 
mild inducing action (Powis, 1975).
In summary, numerous agents are capable of 
increasing hepatic drug metabolism. Many of these 
agents also, induce metabolism in other organs of the body 
where cytochrome P-450 is present. Different compounds 
may induce by different mechanisms and multiple forms 
of cytochrome P-450 have been shown to exist, one or 
more of which may be induced following exposure to 
inducing agents. The different forms may be 
distinguished by their spectral, catalytic, immunochemical 
and electrophoretic properties.
1.1.7. Purification of cytochrome P-450-dependent
hydroxylation system
Some years ago a soluble form of cytochrome 
P-450 was isolated from the bacterium Pseudomonas putida
(Katagiri et al.3 1968). This haemoprotein catalyses 
the hydroxylation of camphor and has been extensively 
purified and crystallized (Peterson, 1971).
Hepatic microsomal cytochrome P-450 is bound 
to the membrane of the endoplasmic reticulum and as such 
requires detergent solubilization for isolation (Lu 
and Levin, 1974) . Early attempts to purify the microsomal 
haemoprotein resulted in catalytically inactive preparations. 
However, in 1967, Ichikawa and Yamano reported that 
glycerol and other polyols stabilized detergent-treated 
cytochrome P-450. Glycerol was used by Lu and Coon (1968) 
in their initial solubilization of the components of the 
drug-metabolizing enzyme system, and is still widely 
used as a protective agent for cytochrome P-450. Mammalian 
cytochrome P-450 has been isolated and purified from a 
number of species including rat (Levin et al.3 1974;
Ryan et al.3 1975), mouse (Haugen et al.3 1976) and rabbit 
(Haugen and Coon, 1976) by the use of ionic and non-ionic 
detergents. Affinity chromatography, with a)-amino-n- 
octyl sepharose as a hydrophobic adsorbent, has been used 
by Imai and Sato (1974a,b) to purify rabbit microsomal 
cytochrome P-450.
Two other factors are essential for the 
cytochrome P-450-dependent hydroxylation system to 
function:- namely, the flavoprotein reductase, NADPH- 
dependent cytochrome P-450 reductase, which has recently 
been isolated and purified (Yasukochi and Masters,
1976; Dignam and Strobel, 1977) and a heat stable, organic 
solvent extractable factor (Lu and Coon, 1968) which 
was later identified as phosphatidylcholine (Strobel 
et at.3 1970).
A reconstituted system containing purified 
cytochrome P-450, NADPH-cytochrome P-450 reductase 
and phosphatidylcholine in the presence of oxygen is 
active in the hydroxylation of various drugs. In the 
last few years, extensive experiments by Lu and his 
associates have shown that many of the reactions catalysed 
by microsomal preparations are equally well mediated by 
the solubilized system. The catalytic specificity of 
microsomal preparations observed following treatment 
of animals with different inducing agents has also been 
found for the purified haemoproteins (Lu et at.3 1976).
1.1.8. Denaturation and destruction of cytochrome
P-450
A wide variety of substances and enzymes have 
been reported to bring about the conversion of microsomal 
cytochrome P-450 to its modified, inactive form, cytochrome 
P-420. These compounds include cholate (Klingenberg, 1958) , 
deoxycholate, snake-venom phospholipase A, and steapsin 
(Omura and Sato, 1964a,b), trypsin, urea and sulphydryl 
reagents such as p-chloromercuribenzoate (Mason et at.3 
1965) and high concentrations of neutral salts such as 
potassium thiocyanate, sodium iodide and guanidine (Imai 
and Sato, 1967a). It seems that the anomalous spectra
of cytochrome P-450 arise from its abnormal existence in 
the microsomal membrane and typical b-type haemoprotein 
spectra are elicited by cytochrome P-420.
A number of agents have been shown to bring 
about' the destruction of cytochrome P-450, usually by 
degradation of the haem moiety. NADPH-dependent lipid 
peroxidation has been demonstrated to be a powerful 
degrading agent of cytochrome P-450 haem using in vitro 
microsomal incubations (Levin et at. 3 1973a,b; Jacobson 
et at. 3 1973). Carbon disulphide (Bond and De Matteis,
1969), 2-allyl-2-isopropylacetamide (AIA) (De Matteis,
1970) allyl-substituted barbiturates (Levin et at.9 
1973a), and a volatile anaesthetic agent, fluoroxene 
(2,2,2-trifluoroethylvinylether) (Ivanetich et at.3 
1976), have all been reported to be active as destructive 
agents of cytochrome P-450.
Metals such as cobalt (Maines and Kappas,
1975) nickel and platinum (Maines and Kappas, 1977) are 
potent inducers of haem oxygenase activity and thus 
destroy cytochrome P-450. The degradatory effects of 
heavy metals were totally prevented by the administration 
of cysteine or glutathione (Maines and Kappas, 1977).
It seems that different species of cytochrome 
P-450 may be sensitive to different destructive agents. 
Cytochrome P-450 from phenobarbitone-induced animals is 
sensitive to degradation by AIA whereas 20-methylcholanthrene 
induced cytochrome P-448 is resistant (Levin et at.3
1973a). In contrast, it has recently been reported that 
fluoroxene destroys both cytochrome P-450 and cytochrome 
P-448 (Marsh et at.3 1977).
1.1.9. Inhibition of cytochrome P-450-mediated
metabolism
The most widely studied inhibitors of cytochrome 
P-450-catalysed reactions are those that interact at either 
the site of oxygen activation (the haem iron) or the 
binding of catalytic active sites of cytochrome P-450.
Carbon monoxide is the classical inhibitor of cytochrome 
P-450-dependent metabolism, binding reversibly to the 
reduced haemoprotein. The reduced haemoprotein-carbon 
monoxide complex is photodissociable, with the optimal 
wavelength for the reversal of the inhibition being about 
450 nm (Diehl et at.3 1969; Cooper et at.3 1977).
A widely used inhibitor of monooxygenase 
activity is 3-diethylaminoethyl diphenylpropylacetate 
(SKF-525A). This compound has been shown to bind to the 
Type I binding site and thus competes with cytochrome 
P-450 substrates for the active site. Further, SKF-525A 
itself is metabolized by cytochrome P-450, producing 
metabolites which bind to the haem of cytochrome P-450 
and thus compete with oxygen for the reduced haemoprotein 
(Hildebrandt, 1973). The primary amine metabolite has 
been shown to bind to sodium dithionite-reduced cytochrome 
P-450, eliciting an absorption maximum at 446 nm.
Schenkman et at. CL972b) have observed the generation of
a 455 nm absorbance peak following in vitro metabolism of 
SKF-525A. A 452 nm maximum has also been seen after in vivo 
administration of SKF-525A (Buening and Franklin, 1976).
Both competitive and non-competitive kinetics 
have been described for SKF-525A inhibition (Anders and 
Mannering, 1966; Ikeda et at.3 1968). Competitive inhibition 
probably results from the competition between SKF-525A 
and substrates for the active site of cytochrome P-450. 
Non-competitive inhibition is thought to be due to the 
binding of metabolite(s) of SKF-525A to the catalytic 
(haem) site with consequent formation of an inactive 
cytochrome P-450-metabolite complex.
In contrast to SKF-525A, 2-methyl-l,2- 
bis-(pyrid-3-yl)-propan-l-one (metyrapone) elicits a 
Type II binding spectrum when added to an oxidized 
microsomal suspension. In addition, metyrapone binds to 
the reduced haemoprotein producing a 446 nm absorbance 
maximum, similar to that observed with the primary 
amine metabolite of SKF-525A (Hildebrandt et at./ 1969).
Thus the major mode of inhibitory action of metyrapone 
is non-competitive, although recent evidence suggests 
that metyrapone may be oxidatively metabolized by cytochrome 
P-450 indicating that the compound could also inhibit in 
a competitive manner.
Metyrapone has been shown to bind preferentially 
to the phenobarbitone-induced haemoprotein (Ullrich et at.3 
1973). However, 7,8-benzoflavone (a-naphthoflavone, ANF)
has been shown to have a very high affinity for cytochrome 
P-448, induced by polycyclic hydrocarbons, and is thus 
a potent inhibitor of reactions catalysed by this form of 
haemoprotein (Gelboin et at. 3 1970). Such reactions include 
aryl hydrocarbon hydroxylation (E.C.l. 1.4.14".2) (Wiebel 
and Gelboin, 1975) and ethoxyresorufin O-deethylation 
(Burke et at.3 1977). Metyrapone and ANF have been used 
in conjunction to produce differential patterns of 
inhibition and so provide an indication of the species 
of haemoprotein present (Ullrich et at. 3 1975a; Burke 
et at. 3 1977) .
Alkyl- and aryl-substituted imidazoles have 
been widely used as inhibitors of bacterial (Lipscomb 
and Gunsalus, 1973) and insect (Wilkinson et at.3 1974a,b) 
cytochrome P-450-dependent metabolism, and have subsequently 
been shown to be potent inhibitors of mammalian mono­
oxygenation. These compounds elicit Type II binding 
spectra (Wilkinson et at.. 3 1972) and values of about
0.5 jiM have been reported for some hepatic microsomal 
reactions (Leibman and Ortiz, 1973).
Various sulphydryl reagents also inhibit 
cytochrome P-450-mediated reactions. Mersalyl (Franklin 
and Estabrook, 1971), p-chloromercuribenzoate (Orrenius, 
1965; Kampffmeyer and Kiese, 1963; 1964; Illing and 
Netter, 1975) and N-ethylmaleimide (Kampffmeyer and Kiese, 
1963; 1964) are examples of sulphydryl reagents which 
inhibit monooxygenase activity. Illing and Netter (1975)
have suggested that p-chloromercuribenzoate inhibits various 
steps in the cytochrome P-450 reaction cycle including 
NADPH-cytochrome P-450 reductase and the formation of the 
ternary oxycytochrome P-450 complex, although conversion 
of cytochrome P-450 to inactive cytochrome P-420 is 
probably a major inhibitory factor (Mason et al.3 1965).
Methylenedioxyphenyl compounds are another 
class of cytochrome P-450 inhibitors. These have been 
used as insecticide synergists and their mode(s) of 
action will be the subject of later discussion.
1.2. METHYLENEDIOXPHENYL. COMPOUNDS (1,3-BENZ0DI0X0LES)
1.2.1. Occurrence
A number of methylenedioxyphenyl (MDP) 
compounds (Fig. 1.1) are substituents of essential oils 
of certain spices. MDP compounds have been isolated from 
nutmeg, mace, ginger, cinnamon and black pepper (Bejnarowicz 
and Kirch, 1963; Weil, 1965; Furia and Bellanca, 1971).
Other natural sources of MDP molecules include sassafras 
oil, sesame oil and carrots (Fishbein and Falk, 19 69).
1.2.2. Metabolism of methylenedioxyphenyl compounds
MDP compounds are extensively metabolized
by mammals and insects and several major routes of metabolism 
have been reported. In particular oxidative cleavage of 
the methylene bridge (producing carbon dioxide and 
the corresponding catechol) together with epoxidation and
FIGURE 1.1.
Structure of the methylenedioxyphenyl nucleus
hydroxylation of the side-chain were observed for safrole 
(4-ally1-1,2-methylenedioxybenzene) metabolism in the rat 
(Stillwell et al.9 1974). Conjugation with UDP-glucuronate 
and sulphate is also thought to occur. The metabolism 
of piperonyl butoxide (a-[2-(2-butoxyethoxy)ethoxy]-4,5- 
methylenedioxy-2-propyltoluene) in the mouse has also been 
reported and Fisbein et at. (1969) found at least 26
urinary and biliary metabolites of this compound. However, 
different patterns of metabolism of MDP synergists are 
shown by insects (Casida et at. 9 1966) e.g. insect microsomes 
do not catalyse the oxidative cleavage of the methylene 
bridge as efficiently as mammals.
The metabolism of safrole in man has been 
reported by Benedetti et at. (1977). As for the majority 
of the experimental animals, the maj or metabolite was 
the catechol derivative.
1.2.3. Toxicity and carcinogenicity
Most MDP compounds have relatively low toxicity.
No evidence exists for the teratogenicity of MDP compounds, 
although some metabolites of safrole have been shown to 
be mutagenic (Wislocki et at.9 1976; 1977). The parent 
molecule, methylenedioxybenzene, is quite toxic, having an oral
LD50 of about 0.5 g/kg in the rat. The naturally Occurring 
MDP derivatives such as safrole appear to be more toxic
than the synthetic MDP analogues. Safrole and isosafrole
(4-propenyl-l,2-methylenedioxybenzene)7 were found to be
toxic at doses of 0.5 - 2.5 g/kg in the mouse and rat
(Hagan et al,3 1965; Fujii et al.3 1970). In contrast, 
piperonyl butoxide, a synthetic MDP derivative used 
commercially as an insecticide synergist, was acutely 
toxic at 0.6 - 11.5 g/kg in these species (Sarles et al.3 
1949). It appears that the longer the side-chain, 
the lower the toxicity of the compound as shown by the 
MDP insecticide synergists, all of which have a long 
oxygen-containing side-chain.
Many of the toxic effects of MDP compounds 
are due to their ability to inhibit cytochrome P-450- 
mediated metabolism. Piperonyl butoxide, which is itself 
relatively non-toxic to insects and mammals, produced 
synergistic acute toxicity of Freons (Epstein et al.3 
1967a) and enhanced toxicity was produced by a combination 
of piperonyl butoxide and benzo(a)pyrene or griseofulvin 
(Epstein et al.9 1967b).
Safrole, isosafrole and dihydrosafrole 
(4-propy1-1,2-methylenedioxybenzene) have all been 
shown to produce tumours in experimental animals (IARC,
1976). Safrole was shown to be a weak hepatocarcinogen 
in the rat (Long et al.3 1963). Recently, l'-hydroxy- 
safrole was proposed as the proximate carcinogenic 
metabolite of safrole (Borchert et al.3 1973a).
Isosafrole and dihydrosafrole were reported to induce 
hepatic and oesophageal tumours respectively, following 
long-term administration in the diet.
1.2.4. Methylenedioxyphenyl compounds as insecticide
synergists and inhibitors of monooxygenase
activity
A number of MDP compounds derived from the 
natural product safrole are widely used to synergize the 
action of a number of insecticides. The most widely 
used MDP synergist is piperonyl butoxide, but others in 
common use include sesamex (acetaldehyde-2-(2-ethoxy- 
ethoxy)ethyl-3,4-(methylenedioxy)phenyl acetal) and 
sulfoxide (1,2-(methylenedioxy)-4-[2-(octylsulfinyl)- 
propyl]benzene. The MDP synergists are characterized 
by a long oxygen containing substituent on the benzene 
ring. MDP derivatives were originally used in conjunction 
with pyrethroid insecticides (Eagleson, 1942) but have 
since been utilized with cyclodienes such as aldrin, 
rotenoids, organophosphates and carbamates. It is 
generally recognized that the synergists exert their 
activity by inhibiting the enzymes within the insect 
which are responsible for the detoxication of insecticides, 
thus potentiating the insecticidal action (Metcalf, 1967). 
The involvement of microsomal monooxygenase in synergistic 
action was the subject of a review (Casida, 1970).
In 1968, Jaffe et at. observed inhibition 
of mouse hepatic microsomal monooxygenase activity by 
MDP synergists. It was subsequently shown that MDP 
compounds elicited Type I binding spectra with cytochrome 
P-450 of mammalian (Matthews et at.3 1970) and insect 
(Philpot and Hodgson, 1970) origin, suggesting that the
MDP derivatives competed with substrates of cytochrome 
P-450. Indeed, competitive inhibition of naphthalene 
hydroxylation by sesamex was reported by Philleo et at.
(1965). However, various types of inhibition have been 
observed by various authors including competitive, partially 
competitive, curvilinear and non-competitive.
The apparently abnormal inhibitory characteristics 
were further investigated by Franklin (1971) and Philpot 
and Hodgson (1971a). These authors reported the 
generation of an unusual difference spectrum following 
the in vitro incubation of liver microsomes with NADPH 
and various MDP derivatives. The reduced minus oxidized 
spectrum had absorbance maxima at 427 and 455 nm, similar 
to the spectrum elicited following addition of ethyl- 
isocyanide to reduced cytochrome P-450. Metabolism was 
essential for the appearance of the spectrum and Franklin 
(1971) suggested that it was due to the formation of a 
MDP-metabolite complexed with cytochrome P-450. In 
support of this hypothesis, Philpot and Hodgson (1972) 
observed decreases in both carbon monoxide binding to 
the reduced haemoprotein and in Type II binding, following 
the in vitro metabolism of piperonyl butoxide.
Franklin (1972) and Philpot and Hodgson (1972) 
interpreted the inhibitory properties of MDP compounds 
in the following way; initially competitive inhibition 
was seen due to the competition between substrate and 
the MDP inhibitor for metabolism, followed by non-competitive 
inhibition, due to the formation of a stable complex
between reduced cytochrome P-450 and a MDP-metabolite. .
The stability of the complex was borne out.by experiments 
carried out- following administration of various MDP 
compounds to animals. Parke and Rahman (1971) and 
Elcombe et at. (1975a) reported an absorbance maximum 
at 455 nm following treatment of rats with safrole or 
isosafrole and Philpot and Hodgson (1971b) observed a 
similar peak when microsomes from piperonyl butoxide- 
treated mice were examined. The apparent decrease in 
cytochrome P-450 content observed by Matthews et at.
(1970) after treatment with piperonyl butoxide was 
explained by the presence of the inhibitory MDP-metabolite- 
cytochrome P-450 complex in vivo, rendering a portion of 
the cytochrome P-450 insensitive to carbon monoxide.
The MDP-metabolite-cytochrome P-450 complex 
is thought to be dependent upon the intact methylene­
dioxy grouping for binding to the haem iron of cytochrome 
P-450 (Franklin, 1976a). The exact mechanism of formation 
of the complex has yet to be resolved.
1.2.5. Induction of monooxygenase activity by MDP
•compounds
Treatment of animals with MDP derivatives 
has been shown initially to inhibit cytochrome P-450 
dependent metabolism. However, the inhibitory phase is 
followed by an-inductive process-“on continued treatment
v V
with MDP compounds, (Jaffe et at.s 1969; Skrinjaric-Spoijar 
et at.9 1971). The inductive phase of microsomal
monooxygenase activity by MDP compounds was also observed 
by other authors (Wagstaff and Short, 1971; Lake et al.3 
1973; Yu and Terriere, 1974).
The properties of the induced haemoprotein 
are not well documented. Lotlikar and Wasserman (1972) 
indicated that safrole and isosafrole, induced the 3- 
and 5-hydroxylation of 2-acetamidofluorene to a greater 
extent than the N-hydroxylation reaction. This is similar 
to the pattern of metabolism of acetamidofluorene induced 
by 20-methylcholanthrene. In addition Elcombe et at.
(1975a) observed a shift of the reduced-carbon monoxide 
absorbance maximum to 448 nm following safrole treatment 
of rats. However, Parke and Rahman (1970) observed induction 
of both biphenyl 2- and 4-hydroxylases by safrole and 
isosafrole and similar induction of cytochrome P-450 
and P-448-mediated activities by isosafrole has been 
reported (Wagstaff and Short, 1971; Lake et al.3 1973;
Vainio and Parkki, 1976).
1.3. BENZIMIDAZOLES
The MDP (Fig. 1.1) and benzimidazole (Fig. 1.2) 
nuclei are structurally very similar and for this reason 
it was decided to investigate further the interactions 
of these compounds with cytochrome P-450. Both MDP 
and benzimidazole derivatives have been reported to inhibit 
monooxygenase activity in vivo and in vitro.
FIGURE .1.2,
Structure of the benzimidazole nucleus
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Benzimidazole
Benzimidazoles (Fig. 1.2) serve an important 
role as constituents of mammalian compounds (5,6-dimethyl- 
benzimidazole is part of the vitamin Bi2 structure) and 
are used as anthelmintics and antifungal agents. Many 
of the pharmacologically active derivatives contain 
2-substituents, especially carbamate residues. A major 
metabolite of benzimidazole and related compounds is 
the 5-hydroxylated molecule, isolated following pretreatment 
of animals in vivo (Tocco et at. 3 1965; Tyler et at. 3
1976). It was recently reported (Arnett et at.3 1977) 
that benzimidazole itself was converted in vitro to
1-methylbenzimidazole, a W-methylation process catalysed 
by purified catechol-d-methyltransferase (E.C.2.1.1.6.).
Recently, a series of papers by Seiler have 
demonstrated the mutagenicity of benzimidazole and its 
derivatives. These compounds are thought to act as 
base analogues because of their structural resemblance 
to purines and mediate their mutagenic effects by this 
means (Seiler, 1972; 1973; 1976). Substituted benzimidazoles 
appear to be relatively non-toxic to mammals but several 
mechanisms have been proposed for their toxicity towards 
worms and fungi (Seiler, 1975).
Benzimidazole has been reported to elicit 
a Type II binding spectrum when added to hepatic microsomal 
preparations (Mailman et at.3 1974). In contrast the 
fungicidal benzimidazole derivative benomyl (methyl-1- 
butylcarbamoyl-2-benzimidazole carbamate) produced a
Type I binding spectrum (Mailman and Hodgson, 1972). 
Following the observation that a number of imidazole 
derivatives were potent inhibitors of some microsomal 
cytochrome P-450-mediated reactions (Wilkinson et at 
1974a,b), some substituted benzimidazoles were also found 
to inhibit drug metabolism in vivo and in vitro (Holder 
et at.3 1976).
It was decided to investigate further the 
interactions of various substituted benzimidazoles with 
cytochrome P-450. Since homologous series of substituted 
imidazoles are already known to bind tightly to cytochrome 
P-450, and inhibit cytochrome P-450-mediated metabolism, 
the type of binding and inhibitory properties of a series 
of substituted benzimidazoles were studied.
CHAPTER 2 
METHODS
2. METHODS
2.1. CHEMICALS
Isosafrole and dihydrcsafrole were purchased 
from Merck G.m.b.H, (Darmstadt, West Germany) and safrole 
was obtained from Hopkin and Williams Ltd. (Essex, England). 
All other methylenedioxy compounds were supplied by 
Aldrich Chemical Co, Ltd. (Middlesex, England), except 
for piperonyl butoxide which was kindly donated by Mr. G.
Poll (Wellcome Research Laboratories, Berkhamsted, England) 
and trans-methylenedioxycyclohexane, a gift of Dr. E.
Hodgson (Department of Entomology, North Carolina State 
University, U.S.A.).
[w-1^C]Isosafrole (5 mCi/mmol) and 5-amino[4- 
1^Gjlaevulinic acid hydrochloride (53 mCi/mmol) were 
purchased from the Radiochemical Centre (Amersham, 
Buckinghamshire, England)y both compounds were 99% 
radiochemically pure. [7-lkC]Styrene oxide was generously 
provided by Prof. F. Oesch (Institute of Pharmacology,
Mainz, West Germany).
NADH, NADPH, glucose-6-phosphate (disodium 
salt), glucose-6-phosphate dehydrogenase, glucose, 
glucose oxidase, catalase, a-oxoglutarate (monosodium 
salt), glutamate dehydrogenase, bovine serum albumin
T5
and Tris (Trizma base) were all purchased from Sigma 
Chemical Co, Ltd. (Surrey, England).
Cumene hydroperoxide was obtained from Peroxid 
Chemie (Munich, West Germany). Pregnenolone 16a~carbonitrile 
was a gift of Dr. H.G. Jonen (Institute of Pharmacology,
Mainz, West Germany). 20-Methylcholanthrene was purchased 
from Fluorochem Ltd. (Derbyshire, England), Homogeneous . 
epoxide hydratase was generously provided by Prof. F. Oesch 
(Institute of Pharmacology, Mainz, West Germany).
2-n-Methyl-, 2-propyl- and 2-nonylbenzimidazole 
were purchased from Aldrich Chemical Co, Ltd. The alkyl 
carbamates were a generous gift of Dr. D. Upshall of the 
Chemical Defence Establishment (Porton Down, Wiltshire, 
England).
iV'^-Dimethylformamide (puriss) , rc-octylamine 
(puriss) and Scintimix SMI scintillant mixture were 
obtained from Koch-Light Laboratories Ltd. (Buckinghamshire, 
England).
Carbon monoxide, nitrogen and oxygen were 
purchased from the British Oxygen Co. Ltd. (Surrey,
England). All other chemicals were purchased from British 
Drug Houses (Poole, Dorset, England) and were of the 
highest purity commercially available.
2.2. SYNTHESIS OF 2-n-ALKYLBENZIMIDAZOLES
The method of Pool et al. (1937) was used to 
synthesize the 2-n-alkyl derivatives of benzimidazole 
with o-phenylenediamine and the appropriate normal 
carboxylic acid as starting materials.
H
+ R.COOH
Method
A mixture of o-phenylenediamine (21.6 g) 
and a molecular equivalent of the acid was heated under 
constant reflux for 30 min. Ethanol (100 ml) was then 
added to dissolve the mixture and the unreacted acid 
was neutralized by the addition of KOH solution until 
the mixture was just alkaline to phenolphthalein (pH 10). 
The mixture was extracted with diethyl ether and the 
ether solution was washed with water. The ether extracts 
were dried over Na^Oi^, decolourizing charcoal was added 
and the ethereal solution was evaporated to dryness. The 
solids obtained were recrystallized from ethanol, ethanol- 
H20 or H20 and dried in an oven at 100°C.
Purity of the compounds was assessed by thin- 
layer chromatography using a chloroform/methanol (97:3, 
v/v) solvent system and by i.r. spectroscopy. The melting 
points of the derivatives obtained were in good agreement
with those of Pool et at. (1937).
2.3. ANIMALS
The rats used in this study were male albinos 
and were of one of two strains\ COBS (Caesarian-derived, 
barrier-sustained Wistar (Canterbury Ash) obtained from 
Charles River (Margate, Kent, England), or Sprague-Dawley 
purchased from the Zentralinstitut fur Versuchstiere 
(Hannover, West Germany), Animals of 150-200 g body weight
were used in the experiments. The mice used in this study
were male albinos of the CDl strain (purchased from
Charles River) or of the NMRI strain (obtained from the 
Hannover Institute as above).
All animals were housed in wire bottomed cages, 
over sawdust (sterilized, dust free) obtained from The 
Sawdust Marketing Co., Standon, Herts., England). The 
rodents were allowed food (Heygates 4IB rat pellets
T3
(Bugbrook Mills, Southampton, England) or Altromin rat 
pellets (Altromin G.m.b.H., Lage, Lippe, West Germany) 
and water ad libitum. A twelve hour light/dark cycle 
was in use (0700-1900 light); animals were always killed 
and dosed at the same time of day (0900-1000).
2.3.1. Pretreatment of animals
Controls
Control animals received either isotonic 
saline (0.9%, w/v), glass distilled water, corn oil or 
peanut oil (2.5 ml vehicle/kg body weight for rats and 
10 ml/kg for mice) by intraperitoneal (i.p.) injection 
on each of three consecutive days. Animals were killed 
24 h after the final injection.
MDP compounds
Isosafrole was routinely administered by
i.p. injection (at a dose level of 150 mg/kg) once daily 
for three consecutive days. The MDP compound was dissolved 
in corn oil or peanut oilj control animals received 
equivalent volumes of vehicle. Animals were killed 2 4 h 
after the last injection. Other MDP compounds were 
administered by the same route and at the same dose level 
unless otherwise specified in the text.
Pheriobarbitone
Phenobarbitone (sodium salt) was dissolved 
in 0.9% (w/v) saline or glass-distilled water. For 
induction purposes, rats received 80 mg/kg and mice 
100 mg/kg of the drug by i.p. injection once daily for 
three consecutive days. Animals were killed 24 h after 
the last injection.
20-Methylcholanthrene
20-Methylcholanthrene was administered to 
rats and mice as a solution in corn oil or peanut oil.
The dose level and route of administration used was 
20 mg/kg i.p. for both rats and mice^ the animals were 
treated once daily for three days and killed 24 h after 
the final injection.
Phenobarbitone-isosafrole, 20-methylcholanthrene-isosafrole, 
water-isosafrole, oil-isosafrole
Animals received either phenobarbitone, 
20-methylcholanthrene, water or oil once daily for three 
consecutive days at the dose levels described above.
On the fourth day, all animals received isosafrole (150 
mg/kg, i.p.) and were killed 24 h after the administration 
of isosafrole.
Pregnenolone 16a-carbonitrile (PCN)
PCN was administered as a solution in Tween 80/ 
water (one drop of Tween 80 in 10 ml of water) to rats 
at a dose level of 75 mg/kg i.p. The steroid was injected 
five times at 12 h intervals and animals were killed 2 4 h 
after the last injection.
2.4.1. Preparation of microsomes
Rats and mice were killed by cervical 
dislocation and the livers rapidly excised into ice-cold 
1.15% (w/v) KC1. (Gall bladders were removed from the 
mice in situ before the livers were dissected out). The 
livers were washed well, blotted dry and then weighed.
All subsequent operations were carried out at 0-4°C.
The livers were scissor-minced and washed three times 
with ice-cold 1.15% (w/v) KC1. The finely chopped livers 
were homogenized in three volumes (w/v) of ice-cold 1.15% 
(w/v) KC1 using a motor driven Potter-Elvehjem glass-Teflon 
homogenizer (4 complete strokes). The liver homogenate 
was centrifuged in 50 ml polycarbonate Oakridge bottles 
(M.S.E. Ltd.) at 15,000 g___ (13,500 rev/min) for 20 min
cLV
using an 8 x 35 ml aluminium angle head rotor in a 
M.S.E. "High-Speed 18" refrigerated centrifuge. The 
supernatant was carefully decanted and recentrifuged 
at 116,000 g___ (40,000 rev/min) for 50 min using an
3 V
8 x 35 ml aluminium angle head rotor in an M.S.E. "Super 
Speed 65" refrigerated centrifuge. The supernatant 
obtained was discarded and the top of the crude 
microsomal pellet rinsed with ice-cold 1.15% (w/v) KC1.
The pellet was resuspended in ice-cold 1.15% (w/v) KC1 
using a Potter-Elvehjem homogenizer (2 complete strokes) 
and the resultant suspension recentrifuged at 116,000 g„_
3 V
for 50 min. The washed microsomal pellet was finally
resuspended in 20 mM Tris-HCl buffer (pH 7.4) containing
250 mM sucrose and 5.4 mM EDTA (Netter, 1960) to a
concentration equivalent to 1 g of liver per ml
(approximately 20 mg microsomal protein per ml). The
microsomal suspension was stored in 2 ml aliquots in conical
polycarbonate sample cups (L.I.P. Equipment and Services
Ltd.) and stored at -20°. Microsomes prepared and stored
in this way showed no detectable loss of monooxygenase
activity or cytochrome P-450 relative to freshly prepared
microsomes, even when stored for up to two months.
When small volumes of homogenates were used
e.g. as for individual mouse liver microsomal preparations,
the post-15,000 gav centrifugations were carried out using
a 10 x 10 ml Titanium angle rotor at 300,000 g (65,000j a v .
rev/min) for 20 min in an M.S.E. "Super Speed 65" 
centrifuge.
2.4.2. Protein assay
Protein was determined by a modified method 
of Lowry et at. (1951), using bovine serum albumin as 
the standard.
Reagents
50 mM NaOH 
40 mM CuSOi*. 5H20
70.9 mM Sodium potassium tartrate
50 mM NaOH containing 190 mM anhydrous Na2C0 3
Folin-Ciocalteu phenol reagent, diluted with water 
1:3 (v/v)
Bovine serum albumin in 50 mM NaOH (50, 100, 150, 200, 
250 p,g/ml) .
Method
Homogenates or microsomal suspensions were 
diluted to appropriate concentrations using 50 mM NaOH.
The CuSO^, sodium potassium tartrate and Na2C03 solutions 
were mixed in the ratio 1;1:100 (by vol.) immediately 
before use. The mixed solution (5.0 ml) and diluted 
protein sample (0.5 ml) were mixed and allowed to stand 
for at least 10 min at room temperature. Diluted Folin- 
Ciocalteu phenol reagent (0.5 ml) was added and the solutions 
mixed immediately using a Vortex mixer. After at least 
30 min at room temperature, the absorbance at 700 nm was 
recorded using a Pye Unicam S.P.500 spectrophotometer.
Blanks (50 mM NaOH) and bovine serum albumin standards 
were run in parallel.
2.5. SPECTROPHOTOMETRY
All spectral measurements were made using 
either a Perkin-Elmer 356 dual beam dual wavelength 
spectrophotometer or an Aminco DW-2 UV-VIS spectrophotometer. 
Both instruments had thermostatted cuvette holders and 
unless otherwise stated, all spectral changes were 
recorded at 37°C. Measurements were made in either 
the split beam mode (using two cuvettes, Xj (sample 
wavelength) - X2 (reference wavelength) or the dual 
wavelength mode (using a single cuvette, Xi / X2).
The dual wavelength mode is advantageous for kinetic 
studies of monooxygenase activity since changes in
turbidity are automatically compensated for using a 
single cuvette.
2.5.1. Cytochrome P-450 determination 
Cytochrome P-450 was measured by the method
of Omura and Sato (1964a). A microsomal suspension
(1 mg microsomal protein/ml, 5 ml) was reduced with
sodium dithionite (1-2 mg) and divided equally between
two cuvettes. A baseline of equal light absorbance
between 400 and 500 nm was established. Carbon
monoxide was bubbled through the sample cuvette for
20 s and the difference spectrum was recorded. The
absorbance change of the absorbance maximum at about 450 nm
was measured relative to that at 490 nm and the cytochrome
P-450 content was calculated using an extinction coefficient
of 91 mM-1 cm*1. When the X  of the reduced-carbonmax
monoxide spectrum was determined a narrow slit width 
(1.0 nm), slow scan speed (0.1 nm/s) and slow response 
(2.5 s'), were used.
2.5.2. Substrate-induced binding spectra
Binding spectra were elicited as described by 
Schenkman et al. (1967). Microsomes (5 ml of a 1 mg
protein/ml suspension in 66 mM Tris-HCl (pH 7.4)) were 
divided equally between two cuvettes. The cuvettes were 
placed in the spectrophotometer and a base line of equal 
light absorbance was established between 350 and 500 nm. 
Substrate, in p.1 quantities of a solution in buffer or
dimethylformamide, was injected into the contents of
Rthe sample cuvette using a Terumo microlitre syringe 
(Shandon Southern Co. Ltd., Camberley, Surrey, England). 
An equal volume of solvent was added to the reference 
cuvette. The contents of both cuvettes were mixed by 
gentle inversion or by stirring with a plastic rod 
(Starstedt Ltd., Leicester, England), and the difference 
spectrum between 350 and 500 nm was recorded.
The addition of increasing amounts of 
substrate produced a corresponding increase in the 
magnitude (AEmax_min) the binding spectrum elicited. 
Measurement of the peak to trough absorbance changes at 
different substrate concentrations enabled apparent 
and apparent AEmnv values to be calculated from a
S IuciX
double reciprocal plot (Schenkman et al.s 1967).
2.5.3. Ethylisocyanide and n-octylamine spectra
Ethylisocyanide
The ethylisocyanide ligand spectrum with 
reduced cytochrome P-450 was elicited as described by 
Omura and Sato (1964a). A sodium dithionite-reduced 
microsomal suspension was prepared as in 2.5.1. and 
ethylisocyanide (10 jllM) was added to the sample cuvette. 
The absorbance of the maxima at 430 and 455 nm were 
measured (relative to an isosbestic point at 490 nm) 
and the results were expressed as a ratio of the 430:455 
absorptions.
n-Octylamine
The n-octylamine Type II binding spectrum was 
measured as described by Jefcoate et at. (1970). A 
microsomal suspension containing 1 mg microsomal protein/ 
ml in 100 mM Tris-HCl (pH 7,4) containing 50% (v/v) 
glycerol was divided equally between two cuvettes and 
a bseline was established between 350 and 500 nm. A 
solution of n-octylamine in the glycerol-containing 
buffer (1.0 mM) was added to the sample cuvette and 
buffer alone to the reference cuvette. The cuvette 
contents were mixed and the binding spectrum was 
recorded. The absorbance changes AE392.500 an(^  AEi+10_50o 
were measured and the respective amounts of high- and 
low-spin cytochrome P-450 were calculated using the 
following extinction coefficients} AE392-500/ £ = ■ 65 mM”1 
cm”1 and AE^iq-500/ e = 25 mM”1 cm”1. The calculated 
results were expressed as the high spin haemoprotein:low 
spin haemoprotein ratio.
2.6.1. Oxygen-depleting system
Some experiments in this study required the 
presence of anaerobic conditions within a hepatic 
microsomal suspension. The enzyme system used was that 
described by Staudt et at, (1974).
Reagents
250 mM Glucose in 66 mM Tris-HCl (pH 7.4)
Glucose oxidase (E.C.1.1.3.4) 1200 units/ml
Catalase (E.C.1,11.1.6), 15,300 units/ml in 66 mM 
Tris-HCl (pH 7.4)
6 6 mM Tris-HCl (pH 7,4).
Method
Spectrophotometric measurements were carried 
out in a total volume of 2.5 ml in an Aminco anaerobic 
cuvette (V.A. Howe and Co. Ltd., London, England) using 
the dual wavelength mode. Microsomal suspension (1 mg 
protein/ml), glucose (10 mM), glucose oxidase (12 units) 
and catalase (153 units) were added to the cuvette and 
the plunger assembly (usually containing NADPH) was placed 
in the top of the cuvette. The cuvette was flushed with 
oxygen-free nitrogen for 5 min and the cuvette was sealed 
by twisting the plunger assembly through 90°. The cuvette 
was placed in the cuvette holder of the spectrophotometer 
and allowed to equilibrate for 5 min.
Anaerobiosis was checked using an oxygen electrode 
within the cuvette. The glucose/glucose oxidase/catalase 
system produced anaerobiosis after about 3 min at room 
temperature (25°C).
2.6.2. NADPH-Dependent cytochrome P-450 reductase
(E.C.1.6.99.2) (Staudt et al.9 1974)
Method
The method for the estimation of this enzyme 
activity was carried out under anaerobic conditions as 
previously described (2.6.1.). The Aminco anaerobic 
cuvette contained microsomes (1 mg protein/ml), glucose 
(10 mM), glucose oxidase (12 units), catalase (153 units) 
and the substance under study. The plunger assembly 
contained NADPH (200 jliM) . The microsomal suspension was
mixed and gassed with carbon monoxide for 5 min. The 
cuvette was then sealed and placed in the cuvette holder. 
After equilibration at room temperature (25°C) for 5 min, 
the plunger was depressed and the progress curve of the 
NADPH-cytochrome P-450 reductase activity was recorded 
over a 10 second period. An Aminco DW-2 spectrophotometer 
was used in the dual wavelength mode with a sample wave­
length of 450 nm and a reference wavelength of 490 nm.
2.6.3. NADPH: Regeneration and oxidation
In enzyme assays or incubations lasting longer 
than 2-3 min a NADPH regenerating system was used. This 
consisted of 4.0 mM glucose-6-phosphate and 2 units/ml 
of glucose-6-phosphate dehydrogenase (E.C.1.1.1.49).
In the presence of 200-400 jaM NADPH, this system sufficed 
to keep a constant NADPH concentration over longer time 
periods (up to 30 min).
For certain studies in which NADPH alone 
rather than a regenerating system was used it was necessary 
to oxidize the NADPH rapidly and efficiently. . This was 
achieved by the addition of 2,5 mM sodium a-oxoglutarate,
5.0 mM NHifCl and 20 units/ml of glutamate dehydrogenase 
(E.C.1.4.1.2) to the microsomal suspension. This system 
completely oxidized 300 p,M NADPH within one minute.
2.7. ASSAYS OF MONO OXYGENASE ACTIVITY IN' 'VITRO
Ethylmorphine and aminopyrine N-deiriethyTation
Ethylmorphine and aminopyrine are metabolized 
in vitro to N-dealkylated products and formaldehyde.
The latter can be reacted with Nash reagent (Nash,
1953) and the intensity of the yellow colour produced may 
be measured at 405 nm.
Reagents
2 mM Ethylmorphine or aminopyrine in dimethyl- 
formamide
700 mM ZnSOi*
320 mM Ba(0H)2 (saturated solution)
2 M Ammonium acetate containing 0.2% (v/v) acetyl 
acetone
2.3 mM Formaldehyde
66 mM Tris-HCl (pH 7.4)
31.12 mM NADPH in 66 mM Tris-HCl (pH 7.4)
40 mM Glucose-6-phosphate (disodium salt) containing 
20 units/ml glucose-6-phosphate dehydrogenase 
in 66 mM Tris-HCl (pH 7.4)
Method
Microsomal suspension (1 mg microsomal protein/ 
ml), 66 mM Tris-HCl (pH 7.4), glucose-6-phosphate (4.0 mM) , 
glucose-6-phosphate dehydrogenase (2 units/ml) and substrate 
(2.0 mM) were placed in 10 ml Sovirel test tubes (V.A. Howe 
Ltd., London) giving a final incubation volume of 2.5 ml.
The tubes were placed in a shaking water bath (120 cycles/ 
min) and preincubated at 37°C for 5 min. The reaction 
was initiated with NADPH (250 p,M) and incubation was
continued for 10 min. ZnSOi* (0.5 ml) and Ba(0H)2 (0.5 ml) 
were added together in clean tubes and the reaction 
was terminated by pipetting incubation mixture (1.0 ml) 
into the mixtures of ZnSO^ and Ba(0H)2. The tubes were 
mixed and centrifuged at 2,000 rev/min for 10 min.
Aliquots (1.0 ml) of a freshly prepared mixture of acetyl 
acetone and ammonium acetate were pipetted into fresh 
tubes. To these were added aliquots (1.0 ml) of the 
supernatants from the centrifuged incubation mixtures.
These tubes were incubated at 37°C for 30 min, allowed to 
cool to room temperature and the absorbance at 405 nm 
was determined. Formaldehyde standards and appropriate 
blanks were run in parallel.
Biphenyl 2- and 4-hydroxylation
Biphenyl is metabolized to two major products, 
4- and 2-hydroxybiphenyl. . The formation of these molecules 
can be estimated fluorimetrically in the same incubation 
mixture due to the different fluorescent properties of 2- 
and 4-hydroxybiphenyl. The method used was a modification 
of that of Creaven et at, (1965).
Reagents
1.0 M Biphenyl in dimethylformamide 
4 M HC1 
100 mM NaOH
n-Heptane containing 1% (v/v) 3-methyl-l-butanol 
250 mM Succinic acid
353 ]liM 4-hydroxybiphenyl in 5% (v/v) ethanol
70.5 jiM 2-hydroxybiphenyl in 5% (v/v) ethanol
66 mM Tris-HCl (pH 7.4)
25 mM NADPH in 66 mM Tris-HCl (pH 7.4)
40 mM Glucose-6-phosphate containing 20 units/ml 
glucose-6-phosphate dehydrogenase in 66 mM 
Tris-HCl (pH 7.4)
Method
Microsomal suspension (1 mg microsomal protein/ 
ml), 66 mM Tris-HCl (pH 7.4) buffer, glucose-6-phosphate 
(4.0 mM), glucose-6-phosphate dehydrogenase (2 units/ml) 
and biphenyl (2.0 mM) were placed in 15 ml Sovirel tubes 
on ice and preincubated in a shaking water bath (120 cycles/ 
min) at 37°C for 5 min. The reaction was started with 
NADPH (250 jiM) and the incubation time was 10 min.
Metabolism was terminated by plunging the tubes into ice 
and adding 4 M HC1 (0.5 ml). The 2- and 4-hydroxybiphenyl 
standards (14.1 jj,M and 70.6 juM respectively) and biphenyl 
(2.0 mM) were added to the appropriate standard and blank 
tubes after the reaction was stopped. The tube contents 
were mixed with a Vortex mixer and to each was added n-heptane 
containing 1% (v/v) 3-methyl-T-butanol (7.0 ml). The tubes 
were capped and extracted using a tumble mixer for 10 min.
The caps were removed and the tubes were centrifuged at 
1,200 rev/min for 5 min at 4°C. Portions (2.0 ml) 
of the upper (n-heptane) layer were pipetted into clean 
10 ml Sovirel tubes and 100 mM NaOH (5.0 ml) was added 
to all the tubes. The tubes were capped and extracted 
as before. The caps were then removed and the tubes
were centrifuged at 2,000 rev/min for 15 min at 4°C. The 
upper (n-heptane) layer and the suspension at the interface 
of the two layers were aspirated off using a Pasteur pipette 
attached to a water pump. Aliquots (2.0 ml) of the aqueous 
layer were placed directly in the fluorimeter cuvette,
250 mM succinate (0.5 ml) was added and the cuvette contents 
were mixed well. The fluorescence of the cuvette contents 
was measured at the wavelengths indicated below.
Fluorophor Fluorescence characteristics
AExcitation AEmission
4-hydroxybiphenyl 275 nm 338 nm
2-hydroxyb ipheny1
(plus a small contribution
from the 4-hydroxybiphenyl) 295 nm 415 nm
4-Nitroanisole O-demethylation
4-Nitroanisole is converted to 4-nitrophenol 
by the hepatic microsomal monooxygenase system. The 
production of 4-nitrophenol is monitored directly in a 
spectrophotometer cuvette. The method used was a 
modification of that described by Netter and Seidel 
(1964) .
Reagents
500 mM 4-Nitroanisole in dimethylformamide 
66 mM Tris-HCl (pH 7,85)
31.12 mM NADPH in 66 mM Tris-HCl (pH 7.85)
Method
The reaction was carried out in the 
thermostatted cell compartment of either a Perkin-Elmer 
356 or an Aminco DW-2 dual beam dual wavelength 
spectrophotometer at 37°C. The instrument was used in 
the dual wavelength mode with a sample wavelength (Ai) 
of 420 nm and the reference wavelength (A2) of 490 nm.
Microsomal suspension (0.5 mg of microsomal 
protein/ml, 2.5 ml) was pipetted into a cuvette and 
4-nitroanisole (200 jiM) was added to the microsomes.
The cuvette contents were mixed and allowed to 
equilibrate at 37°C for 5 min. The reaction was 
initiated by NADPH (250 p.M) and the initial (linear) part 
of the progress curve was recorded. Values for the amount 
of 4-nitrophenol produced were calculated using an 
extinction coefficient of 18.5 mM"1 cm"1.
7-Ethoxycoumarin O-deethylation
7-Ethoxycoumarin is metabolized to a single 
fluorescent product, 7-hydroxycoumarin (umbelliferone) 
by microsomal monooxygenases. The rate of reaction may 
be measured continuously by recording the increase in 
fluorescence with time. The method used was that of 
Ullrich and Weber (1972).
Reagents
1.0 mM 7-Ethoxycoumarin in 66 mM Tris-HCl (pH 7.4)
1.0 mM 7-Hydroxycoumarin in 66 mM Tris-HCl (pH 7.4)
6.2 mM NADPH in 66 mM Tris-HCl (pH 7.4)
6 6 mM Tris-HCl (pH 7.4)
Method
Microsomes (2.5 ml of a 1 mg microsomal protein/ 
ml suspension) were placed in a fluorescence cuvette and 
7-ethoxycoumarin (100 jiM) was added. The contents were 
mixed by inverting the cuvette several times and were 
allowed to equilibrate at room temperature for 3 min in the 
cuvette holder of a Hitachi Perkin-Elmer MPF-2A spectro- 
photofluorimeter. NADPH (50 p,M) was added to the cuvette 
(with mixing) and the initial increase in fluorescence at 
450 nm was recorded using an excitation wavelength of 370 nm. 
Standards of 7-hydroxycoumarin (0.5 and 1.0 jliM) were added 
after the reaction.
7-Ethoxyresorufin O-deethylation
7-Ethoxyresorufin is metabolized to a single 
fluorescent molecule, resorufin, by hepatic microsomes.
The reaction may be measured continuously in a fluorescence 
cuvette. The method used was a modification of that 
described by Burke and Mayer (1975).
Reagents
1.0 mM 7-Ethoxyresorufin in dimethylformamide
10 mM Resorufin in dimethylformamide 
66 mM Tris-HCl (pH 7.4)
31.12 mM NADPH in 66 mM Tris-HCl (pH 7.4)
Method
An incubation mixture in a fluorescence 
cuvette typically contained microsomal protein (200 jig/ 
ml) 7-ethoxyresorufin (1.0 jiM) and 66 mM Tris-HCl (pH 7.4) 
in a final volume of 2.5 ml. The cuvette contents were
allowed to equilibrate at room temperature for 3 min, and 
the reaction was initiated with NADPH (250 jiM) . The time- 
dependent linear increase in fluorescence at 586 nm was 
monitored directly using an excitation wavelength of 
510 nm. Resorufin (50 nM) was added after the reaction 
to calibrate measurement of the metabolic process.
2.8.1. Epoxide hydratase (E.C.4.2.1.63)
Epoxide hydratase, located in hepatic 
microsomal fractions, converts epoxides to the 
corresponding trans-dihydrodiols. Epoxides are produced 
during the microsomal metabolism of a number of compounds 
and conversion to diols via epoxide hydratase is a major 
route of further metabolism. The method used was a 
modification of that pf Oesch et at, (1971) using [7-1IfC] 
styrene oxide as substrate.
Reagents
43.6 mM [7-14C] styrene oxide (70 jiCi/mmol)
500 mM Tris-HCl (pH 9.0)
Method
Microsomal suspension (about 3 mg microsomal 
protein/ml), water and 500 mM Tris-HCl (pH 9.0) in a 
final volume of 200 p,l were added to 10 ml Sovirel tubes 
placed on ice and preincubated in a shaking water bath 
(120 cycles/min) at 37°C for 5 min. 1^C-Styrene oxide 
(2.18 mM, 30.5 nCi) was added to the test reactions to 
initiate metabolism. The tubes were incubated for 15 min 
and the reaction was stopped with light petroleum
b.p. 30-60°C, 2.5 ml). 14C-Styrene oxide (2.18 mM,
30.5 nCi) and light petroleum (2.5 ml) were added to blank 
tubes. The contents of the tubes were extracted for 1 min 
using a Vortex mixer and the tubes were centrifuged at
2,000 rev/min for 1 min. The upper (light petroleum) 
layer was removed using a Pasteur' pipette attached to 
a water pump. Ethyl acetate (1.0 ml) was added to each 
tube, and the extraction and centrifugation procedures 
were repeated, each for 1 min. Portions (200 jliI) of 
the ethyl acetate phase were taken for radiometric assay. 
Standards of 14C-styrene oxide were prepared for 
scintillation counting by adding 1^C-styrene oxide (2.18 
mM, 30.5 nCi) to aliquots of ethyl acetate (200 jliI) in 
scintillation vials before the addition of the tT21 
scintillant (6.0 ml). The composition of the scintillant 
is described in 2.11.3.
2.8.2. Glutathione S-< • transferases(E.C.4.4.1.7)
Glutathione transferases, ore.- enzymes
found in hepatic cytosol, and catalysei the reaction of 
glutathione (GSH) with a wide range of epoxide substrates 
resulting in the formation of GSH conjugates. The 
method used was that described by James et at, (1976) .
Reagents
170 mM [7-14C] Styrene oxide (70 jiCi/mmol)
100 mM GSH in 100 mM Tris-HCl (pH 7,4)
100 mM Tris-HCl (pH 7.4)
Method
Soluble fraction (equivalent to 0.6 and 1.2 mg 
of 105,000 g supernatant protein, GSH (6.66 mM) and 100 mM
clV
Tris-HCl (pH 7.4) were added to 10 ml Sovirel tubes on ice 
to make a final incubation volume of 1.5 ml. The tubes 
were preincubated at 37°C in a shaking water bath for 5 
min and 14C-styrene oxide (1.13 mM, 119 nCi) was added 
to start the reaction. Incubation was continued for 10 
min and the reaction was stopped by the addition of 
ethyl acetate (1.5 ml)> the tubes were then mixed and 
placed on ice. The tubes were centrifuged (1,200 rev/min 
for 10 min) and the upper (ethyl acetate) layers were 
removed with a Pasteur pipette into clean 10 ml Sovirel 
tubes. The ethyl acetate extractions were repeated twice 
and the three 1.5 ml extracts from each tube were pooled.
The pooled extracts were mixed and samples (0.5 ml) of 
both aqueous and organic phases were placed in 
scintillation vials for radiometric assay (0.5 ml sample 
plus 0.5 ml water plus 10 ml tT21 scintillant).
Non-incubated tissue blanks were kept on ice 
and 1IfC-styrene oxide (1.13 mM, 119 nCi) and ethyl 
acetate (1.5 ml) were added. The ethyl acetate extractions 
were repeated as described and samples (0.5 ml) were 
taken for radioactive counting. Reagent blanks (which 
produce non-enzymic binding to GSH) were also prepared 
and carried through the extraction procedure.
2.9, SODIUM DODECYL SULPHATE-POLYACRYLAMIDE GEL
ELECTROPHORESIS
Sodium dodecyl sulphate (SDS)-polyacrylamide 
gel electrophoresis was used as a means of separating 
microsomal proteins following the solubilization of 
microsomes in buffer containing SDS. The method used 
was that of Laemmli (1970), which utilizes a discontinuous 
buffer system.
Reagents
Gel stock, 30% (w/v) Acrylamide containing 0.8%
(w/v) N9N 1-methylenebis-acrylamide(bis)
Buffer 1, 1.5 M Tris-HCl (pH 8.8) containing 
0.4% (w/v) SDS
Buffer 2, 500 mM Tris-HCl (pH 6.8) containing 
0.4% (w/v) SDS
Buffer 3, 25 mM Tris-HCl (pH 8.3) containing 
0.1% (w/v) SDS and 192 mM glycine
Buffer 4, 62.5 mM Tris-HCl (pH 6.8) containing 
2.3% (w/v) SDS, 15% (v/v) glycerol, 5%
(v/v) mercaptoethanol and 0.001% (w/v) 
bromophenol blue
Propan-2-ol/acetic acid/water (5:2:13, by vol.)
containing 0.05% (w/v) Coomassie Blue G-250
Propan-2-ol/acetic acid/water (1:1:8, by vol.)
2.9.1. General method
The apparatus used was a water-cooled vertical 
slab gel apparatus (Desaga G.m.b.H., Heidelberg, West 
Germany). The glass cuvette which contained the gel 
measured 100 mm x 85 mm x 3 mm and electrophoresis was 
carried out at 4°C.
The cuvette was sealed with adhesive tape 
and placed in a casting block (Desaga). The lower 
(separating) gel was prepared by mixing Buffer 1 (10 ml), 
gel stock (13.4 ml), water (16.6 ml), ammonium persulphate 
solution (freshly prepared, 10% (w/v), 240 p.1) and 
N9N9N l ,i!7’-tetramethylethylenediamine (TEMED, 20 p.1) .
The solutions were mixed thoroughly and pipetted into the 
glass cuvette using a Pasteur pipette to a height of about 
70 mm. A layer of water (about 3 mm) was introduced above 
the gel mixture to ensure a completely flat interface 
between the water and the separating gel after polymerization 
of the latter had occurred. When polymerization of the 
separating gel was complete, the water layer was removed 
and the upper (stacking) gel, consisting of a mixture 
of Buffer 2 (2.5 ml), gel stock (1 ml), water (6.5 ml), 
ammonium persulphate solution (10% (w/v) , 60 (il) and 
TEMED (20 jil) was added to the cuvette above the 
separating gel. A Teflon comb was introduced into the 
cuvette to form the sample wells within the stacking 
gel after polymerization had occurred. When the stacking 
gel had set, the comb was removed and a small volume of 
Buffer 3 was added to the cuvette to ensure separation 
of the sample wells. The cuvette was placed in the 
electrophoresis apparatus and suitable amounts of 
electrode buffer (Buffer 3) were added to the upper and 
lower buffer reservoirs.
Microsomal suspensions were diluted with 
sample buffer (Buffer 4) to a final concentration of 
3 mg microsomal protein/ml. Samples were placed in a 
boiling water bath (2-3 min) prior to application to 
the stacking gel. The amount of microsomal protein 
typically applied to the gel was 15-30 p.g. A constant 
current of 10-15 mA was used in the stacking gel and 
this was increased to 30 mA when the bromophenol blue 
tracking dye entered the separating gel. The electro­
phoresis was continued until the bromophenol blue 
tracking dye was within 3 mm of the end of the gel.
After the electrophoresis was complete, the cuvette was 
removed from the apparatus and the two halves separated. 
The stacking gel was cut away from the separating gel 
and the latter was immersed overnight in a solution which 
stained for protein (propan-2-ol/acetic acid/water, 
5:2:13, by vol., containing 0.05% (w/v) Coomassie Blue 
G-250). Destaining of the background gel was achieved 
in a Deska diffusion destaining bath containing a mixture 
of propan-2-ol/acetic acid/water (1:1:8, by vol.). Gels 
were stored in 3% (v/v) glycerol at 4°C prior to 
photography.
2.9,2. Methods used to detect haemoproteins after
SDS gel electrophoresis
Benzidine-hydrogen peroxide has been widely 
used as a reagent to determine the peroxidase activity 
of haem and haemoproteins. Treatment with SDS converts
cytochrome P-450 to cytochrome P-420 and the latter has 
considerable peroxidase activity (Hrycay and O'Brien,
1971a,b). A portion of the haem is not cleaved from 
the apoprotein using the mild conditions of electro­
phoresis described below and thus proteins may be 
identified as haemoproteins by this technique,
2.9.2.1. Benzidine stain (Welton and Aust, 1974)
Reagents
Buffer 5, 62.5 mM Tris-HCl (pH 6.8) containing 
1% (w/v) SDS, 15% (v/v) glycerol, and 
0.001% (w/v) bromophenol blue
Buffer 6, 20 mM Tris-HCl (pH 7.5) containing 
50% (v/v) methanol
Buffer 7, 250 mM Sodium acetate-HCl (pH 4.7) 
containing 25% (v/v) methanol, 0.25%
(w/v) benzidine and 0.75% (v/v) 30% 
hydrogen peroxide
Method
Preparation and setting up of the stacking 
and separating gels was as previously described in 2.9.1. 
The microsomal suspensions were diluted with ice-cold 
Buffer 5 (which contained a lower concentration of SDS 
than the normal sample buffer (Buffer 4) and which 
also lacked the sulphydryl reducing agent (mercaptoethanol)) 
to a final microsomal protein concentration of 6 mg/ml.
The diluted microsomes were immediately placed on ice 
and applied to the stacking gel (60 fig protein) . The 
electrophoresis was carried out in the dark at 4°C using 
the same current settings described in 2.9.1. until the
tracking dye was within 3 mm of - the end of the gel. The
separating gel was removed from the cuvette and immediately 
immersed in Buffer 6 to reduce the SDS concentration 
within the gel. The Buffer 6 solution was changed three
times to further reduce the SDS content of the gel. The
gel was immersed in the benzidine-hydrogen peroxide
staining buffer (Buffer 7) for about 15 min at room 
temperature. The staining procedure was carried out under 
strict protective conditions involving the use of plastic 
gloves, apron and face-mask, and using an absorbent 
plastic-backed paper on the bench (Benchkote, Whatman 
Co. Ltd., Maidstone, Kent, England).
2.9.2.2. 3,3*,5,5'-Tetramethylbenzidine stain (Thomas
et al.> 1976b)
Reagents
6.3 mM 3,31,5,51-Tetramethylbenzidine (TMBZ) 
in methanol
Buffer 8, 250 mM Sodium acetate-HCl (pH 5.0)
Buffer 9, 250 mM Sodium acetate-HCl (pH 5.0) 
containing 30% (v/v) propan-2-ol.
Method
The conditions of electrophoresis were 
exactly as described in 2.9.2.1., using the same amount 
of microsomal protein. The separating gel was removed 
and immersed in a mixture of freshly prepared 6.3 mM 
TMBZ in methanol and Buffer 8 (3:7, v/v) at room 
temperature in the dark. After one hour with occasional 
mixing (every 10 min), hydrogen peroxide was added to
the TMBZ-Buffer 8 mixture to a final concentration of 
30 mM. Staining was complete after about 20-30 min and 
the gel was placed in Buffer 9, which was replaced tv/ice 
with fresh solution to remove any precipitated TMBZ 
and to clear the gel background,
2.10. DETERMINATION OF THE EFFECTS OF SAFROLE AND 
ISOSAFROLE ON 1IfC LABELLED HAEM IN VITRO
2.10.1. Animal treatment and tissue preparation
Rats were treated with phenobarbitone (80 mg/kg)
for three days as described in 2.2.1. On the fourth day
the animals received 5-amino [4-14C] laevulinate (2 jiCi,
37 nmol) by i.p. injection and were killed (using a
guillotine) 2 h after the radioactive dose. The livers
were excised, washed in 1.15% (w/v) KC1, blotted dry
and weighed. A 20% (w/v) liver homogenate was prepared
in 1.15% (w/v) KC1 using a Potter-Elvehjem homogenizer
and the homogenate was centrifuged at 10,000 g (11,000av
rev/min) for 20 min at 4°C. The supernatant was carefully 
removed and used in the assay system for haem degradation 
in vitro.
2.10.2. Assay for haem degradation in vitro 
Reagents
600 mM Safrole in dimethylformamide
600 mM Isosafrole in dimethylformamide
160 mM Glucose-6-phosphate (disodium salt) containing 
60 units/ml glucose-6-phosphate dehydrogenase 
in 200 mM potassium phosphate-NaOH (pH 7.4)
200 mM Potassium phosphate-NaOH (pH 7.4) containing 
3 mM EDTA
13.4 mM NADPH in 200 mM potassium phosphate-NaOH- 
(pH 7.4)
Method
Post mitochondrial (10,000 9av) supernatant 
(2.0 ml), glucose-6-phosphate (5.3 mM), glucose-6- 
phosphate dehydrogenase (2 units/ml) 200 mM potassium
phosphate-NaOH (pH 7.4) containing 3 mM EDTA (2.0 ml)
safrole or isosafrole (1 mM), 1,15% (w/v) KC1 (1.4 ml) 
and NADPH (450 jj,M) in a total volume of 6.0 ml were
added to 25 ml conical flasks placed on ice. The
reaction was started by placing the flasks in a shaking 
water bath (100 cycles/min) at 37°C and the incubation 
was■continued for 15 min. The reaction was terminated 
by plunging -the flasks into ice. Control incubations 
were carried out in the absence of i) the NADPH 
regenerating system and ii) the MDP compound, and a 
non-incubated mixture was prepared at 4°C.
2.10.3. Preparation of crystalline haem (Labbe
and Nishida, 1957)
Reagents
75 mM SrCl2.6H20 in glacial acetic acid 
50% (v/v) glacial acetic acid
Method
Aliquots (2.0 ml) of the incubation mixture 
from 2.10,2., were transferred to tubes containing 
carrier haem (horse erythrocyte lysate, 3.0 ml). The 
contents of each tube were mixed and transferred (dropwise, 
with continuous swirling of the flask to form a fine 
precipitate), to a conical flask containing 60 ml of 
a mixture of 75 mM SrCl2.6H20 (in glacial acetic acid) 
and acetone (1:3, v/v). The mixture was filtered (3 times)
through Whatman No, 1 filter paper and collected in a 
beaker. The acetone in the filtrate was allowed to evaporate 
off in a fume cupboard at room temperature. When 
approximately 10 ml of solution remained, the contents 
of the beaker were decanted into a conical centrifuge 
tube and left overnight at room temperature.
The tubes were centrifuged at 1,000 rev /nin 
for 5 min in a bench centrifuge, the supernatants were 
decanted off and the crystals resuspended in 50% (v/V) 
glacial acetic acid (3.0 ml). The contents of the tubes 
were mixed (Vortex mixer) to obtain a homogeneous 
suspension. The centrifugation procedure was repeated 
and the crystals were washed with water (2 x 4.0 ml), 
ethanol (2.0 ml) and diethyl ether (4.0 ml). The crystals 
were dried at room temperature and the tubes were 
wrapped in foil and placed in a desiccator before analysis 
for haem content,
2.10.4. Estimation of haem
The haem content was determined by two 
methods i) combustion of a radioactive sample and ii) the 
pyridine haemochromagen method.
i) Determination of radioactive haem
The dried haem crystals were dissolved in pyridine 
and samples were taken for radiometric determination by 
spotting aliquots on folded strips of filter paper. These
T?were placed in small polycarbonate bottles ("Oxymat 
capsules) sealed and combusted for the determination of 
1LfC02.
ii) Determination of pyridine haemochrome (Paul et~ at. 3 1953)
A portion of the dried haem crystals (2-4 mg) 
was dissolved in pyridine (350 jil) and filtered through 
cotton wool in the neck of a Pasteur pipette. A sample of 
the filtrate (10 jil) was added to 10 ml of a mixture of 
pyridine and 0.2 M NaOH (1:3, vyV). A portion (6 ml) of 
the resultant mixture was divided equally between two 
cuvettes and the sample cuvette was reduced with sodium 
dithionite. The extinction at 557 nm was determined and 
the haem content was calculated using an extinction 
coefficient of 34,4 nM^1 cm”1,
2.H. COVALENT BINDING
The apparently irreversible binding (covalent 
binding) of 1^C-isosafrole-related material was determined 
in rat hepatic microsomes and tissues and mouse livers 
following the administration of 1^C-isosafrole in vivo.
The extraction procedure was that described by Kappus and 
Remmer (1975).
2.11.1. Pretreatment of animals
Rats and mice received either phenobarbitone, 
20-methylcholanthrene, isosafrole, oil or water for three 
days at the dose levels described in 2.3.1. On the 
fourth day rats received 1 ^ C-isosafrole (6.33 p.Ci,
185 pmol) and mice received 14C-isosafrole (460 nCi, 28 jimol) , 
by i.p. injection. All animals were killed 24 h after 
treatment with 1^C-isosafrole and hepatic microsomes were 
prepared as in the case of the rats.
2.11.2. Extraction of samples
Rat hepatic microsomal suspensions (1.0 ml,
equivalent to about 20-30 mg microsomal protein) were
pipetted into Sovirel tubes and absolute ethanol (7 ml)
was added. The contents of the tubes were mixed and the
i isro ^av
precipitate of denatured protein was spun down^(2,000 rev/min) 
for 10 min « The ethanolic supernatants were decanted off 
and saved.
The protein pellets were then extracted 
sequentially with 5 ml aliquots of the following solvents:
70% (v/v) ethanol, 250 mM Tris-HCl (pH 7.4) (twice),
70% (v/v) ethanol, 96% (v/v) boiling ethanol (twice), 
acetone/chloroform (4:1, v/v) (twice) and 70% (v/v) 
ethanol. The extractions were carried out using a 
tumble mixer for 10 min and centrifugation was effected with 
a bench centrifuge (2,000 rev/min for 10 min). The 
protein pellets obtained were finally stored under 
distilled water (5 ml).
Rat tissues were homogenized in 1.15% (w/v)
KC1 to give 50-300 mg wet weight of tissue/ml of homogenate. 
Mouse livers were homogenized in 1.15% (w/v) KC1 (5.0 ml).
In both cases portions of homogenate (1.0 ml) were taken 
and absolute ethanol (5.0 ml) was added as a protein 
precipitant and the extraction procedure was repeated as 
described.
2.11.3, Solubilization of protein and scintillation
counting (Dent and Johnson, 1974)
Preparation of samples
Reagents
SHT Solubilizer
NaOH 80 g
H20 600 ml
Methanol 300 ml
75% (v/v) Triton X-405 100 ml
tT21 Scintillarit
Toluene 1240 ml
Triton X-100 800 ml
Toluene SMI concentrate 360 ml
SMI concentrate consists of a mixture of toluene 
(2,400 ml) and Scintimix SMI (100 g). Scintimix SMI is 
composed of 91% 2,5-diphenyloxazole (PPO) and 9% bis-1,4- 
di (2-methylstyryl)benzene.
Method
SHT solubilizer (1.0 ml) was added to each 
of the protein pellets obtained and the tubes were heated 
at 60°C for 2 h. Duplicate samples of the solubilized 
protein (0.2 ml) excess 4,4 M HNO3 (0.1 ml) and water 
(0.7 ml) were added to scintillation vials followed by 
addition of the scintillant tT21 (10 ml). The vials 
were mixed thoroughly using a Vortex mixer to obtain a 
homogeneous solution.
Protein pellets obtained from the extraction 
of rat tissues and mouse livers were solubilized in SHT 
such that 1 ml of SHT contained up to 100 mg equivalent 
wet weight of tissue. Samples (0.2 or 1.0 ml) of the 
solubilized protein were transferred to scintillation 
vials neutralized with excess 4.4 HNO3 (0.1 or 0.5 ml) 
diluted with water as above and scintillant (10 ml) 
was added.
2.11.4, Covalent binding of 1^C-isosafrole to rat
hepatic microsomes in vitro
Reagents
1 ^ C-isosafrole, 34 jiCi/nmol
40 mM Glucose-6-phosphate containing 20 units/ml 
glucose-6-phosphate dehydrogenase in 66 mM 
Tris-HCl (pH 7.4)
31.12 mM NADPH in 66 mM Tris-HCl (pH 7.4)
66 mM Tris-HCl (pH 7.4)
Method
Phenobarbitone, 20-methylcholanthrene, 
isosafrole, oil or water microsomes (10 mg microsomal 
protein), glucose-6-phosphate (4.0 mM), glucose-6- 
phosphate dehydrogenase (2 units/ml) and 14C-isosafrole 
(50 juM - 1.0 mM, 17 - 340 nCi) were added to conical 
flasks placed on ice to give a final incubation volume 
of 10.0 ml. The flasks were preincubated at 37°C for 
5 min in a shaking water bath (100 cycles/min) and NADPH 
(312 jjM) was added to initiate the reaction. The 
incubation time was 7.5 minj after this time the flasks
were plunged into ice and absolute ethanol (10.0 ml) was 
added to terminate the reaction.
Extraction and solubilization of the 
microsomal pellets were carried out as described above 
and samples were taken for scintillation counting.
2.11.5. Scintillation counting
All samples were counted for 4 min with a 
2% error, using either a Nuclear Chicago Mk. II or an 
Intertechnique SL40 4K scintillation counter. 
Standardization was by an external standard channels 
ratio method. Counting efficiencies were calculated 
by an appropriately programmed computer, the pre-existing 
quench curve being verified for selected samples using 
1^C-hexadecane as a standard.
CHAPTER 3
THE BINDING OF SUBSTITUTED BENZIMIDAZOLES 
TO CYTOCHROME P-450 AND THE INHIBITION OF
MONOOXYGENATION
3. THE BINDING OF SUBSTITUTED BENZIMIDAZOLES TO
CYTOCHROME P-450 AND THE INHIBITION OF 
MONOOXYGENATION
3.1. INTRODUCTION
Various compounds containing nitrogen atoms 
have been shown to bind to cytochrome P-450 (Temple,
1971). The majority of these compounds elicit Type II 
binding spectra when added to microsomal preparations.
Such spectra are given by basic amines (aniline and 
n-alkylamines), and heterocyclic compounds containing 
an [-N=] grouping such as an imidazole ring. The addition 
of an alkyl chain to an amine grouping or imidazole 
nucleus (which might be expected to convey Type I character 
to a molecule) still produces Type II spectra (Jefcoate, 
et at, j 1969} Wilkinson et at,3 1972). Imidazole derivatives 
containing alkyl or aryl substituents have a very high 
affinity for cytochrome P-450 and are potent inhibitors 
of several cytochrome P-450-mediated reactions.
Certain compounds have been shown to induce Type 
RI binding spectra when added to hepatic microsomal 
suspensions. In recent years, characterization of ligands 
of cytochrome P-450 as Type II compounds has been 
complicated by the similarity of the Type RI difference 
spectrum. As a result, some Type RI molecules have been 
wrongly classified as Type II compounds (Anders, 1971).
Vore et at, (1974) suggested that the initial fast phase 
of the reaction catalysed by NADPH-dependent cytochrome 
P-450 reductase was not affected by Type RI compounds
whereas Type II molecules decreased this parameter. In 
contrast, Type I compounds are known to stimulate this 
enzyme activity. The effect on the initial rate of 
NADPH-cytochrome P-450 reductase was used as a means of 
distinguishing between Type II and Type RI molecules 
together with observations of the wavelength minima 
and maxima of microsomal difference spectra.
The present study utilized a series of 
substituted benzimidazoles. The nature of the binding 
to cytochrome P-450 was investigated using various 
derivatives containing substituents in either the benzene 
or imidazole ring. Special attention was focussed on a 
series of 2-n-alkylbenzimidazoles with regard to their 
binding to microsomes isolated from rats treated with 
phenobarbitone or 20-methylcholanthrene. These compounds 
were tested for their ability to inhibit cytochrome P-450- 
dependent monooxygenase activity.
3.2. RESULTS
,3.2.1. The binding of 2- and 5-substituted
benzimidazoles to phenobarbitone-
induced microsomal preparations
The compounds produced either Type II or 
Type RI binding spectra with phenobarbitone-induced 
microsomal preparations. In Table 3.1 are shown some 
of the substituted benzimidazoles which gave rise to 
Type II spectra. The complex formed with benzimidazole 
itself and four 5-substituted derivatives (5-dodecanoyl-
TABLE 3.1.
Substituted benzimidazoles which elicited Type II 
binding spectra with microsomes from 
phenobarbitone pretreated rats
Substituent Maximum
(nm)
Minimum
(nm)
Ks
(mM)
None 428 394 0.17
5-methyl 430 395 0.13, 0.06
5-dodecanoylamido 431 400 0.5
2-carboxylic acid 430 395 0.85
2-aminomethyl 428 392 0.65
Phenobarbitone microsomes (1 mg protein/ml) in 66 mM Tris- 
HCl (pH 7.4) were divided equally between two cuvettes and 
a baseline of equal light absorbance between 350 and 500 nm 
was established. Binding spectra were recorded in the split 
beam mode at 37°C.
amidobenzimidazole, 5-methylbenzimidazole, 5-amino- 
benzimidazole and 5-chlorobenzimidazole) had a minimum 
at 394-400 nm and a maximum at about 430 nm in the 
difference spectrum thus fulfilling the requirements 
for a Type II interaction. In addition, some 2-substituted 
benzimidazoles e.g. compounds containing either a 
carboxylic acid group or an aminomethyl group, produced 
Type II spectra. It was found that substitution in the 
benzene ring of the benzimidazole molecule consistently 
gave rise to Type II spectra. In contrast, substitution 
in the 2-position of the benzimidazole nucleus produced 
very few Type II-binding compounds and only derivatives 
with polar substituents in this position (e.g. 2-benz- 
imidazole acetic acid and 2-benzimidazole carboxylic acid) 
gave Type II spectra. The Ks values for binding to 
cytochrome P-450 were in the order of 0.1 - 1.0 mM 
(Table 3.1).
Many of the 2-substituted benzimidazoles 
gave rise to Type RI binding spectra with phenobarbitone- 
induced microsomes (Table 3.2). The minima and maxima 
observed in difference spectra generated with these 
compounds approximated to those observed with Type RI 
compounds such as ethanol and phenacetin. The peak and 
trough wavelengths were at shorter wavelengths than the 
derivatives listed in Table 3.1. The Ks values ranged 
from 0.1 - 38.0 mM.
TABLE 3.2.
2-Substituted benzimidazoles which elicited Type RI 
binding spectra with microsomes from 
phenobarbitone pretreated rats
Substituent Maximum
(nm)
Minimum
(nm)
Ks
(mM)
2-methyl 422 390 0.42, 0.18
2-ethyl 421 391 0.71
2-propyl 422 389 1.0
2-phenyl 420 390 0.23, 0.1
2-benzyl 425 391 0.26
2-hydroxy 419 390 0.17
2-trifluoromethyl 423 390 7.0
2-phenoxymethyl 418 383 38.0
2-p-hydroxybenzy1 417 384 7.0
2-carbamonitrile 422 390 10.0
2- (4 »-thiazolyl) 423 390 0.24
Conditions as in Table 3.1.
The effects of some substituted benzimidazoles 
on the NADPH-dependent cytochrome P-450 reductase 
activity are described in Tables 3.3 and 3.4. Two 
parameters were studied; the initial rate of the second 
fast phase of cytochrome P-450 reduction by exogenous 
NADPH and the final AE^gQ-itgo change indicating the 
quantity of cytochrome P-450 which was reduced. Each 
compound was tested at a final concentration of 1.0 mM. 
Initially, the effects of classical Type II compounds 
were observed; imidazole and n-octylamine (classical 
Type II compounds) and aniline (which elicits a Type II 
binding spectrum containing a Type I component). All three 
molecules decreased both the initial rate of reduction of 
cytochrome P-450 and the final AE^50-490 absorbance change. 
Aniline was much less effective in reducing these values than 
either imidazole or n-octylamine. Two compounds which 
produced the Type II spectral change, 5-methylbenzimidazole 
and 2-aminomethylbenzimidazole were equally effective in 
decreasing the initial rate of reduction and the final 
absorbance change and the observed results were very 
similar to the decreases elicited by imidazole itself.
Typical Type RI compounds (phenacetin and ethanol), 
although reducing both the initial rate of reduction and 
the final absorbance change, were less efficient in 
decreasing these quantities (Table 3.4 and Fig. 3.1). 
Substituted benzimidazoles which were designated as
Type RI compounds (by virtue of their and A .J c J max min
TABLE 3.3.
Effect of some Type II compounds on NADPH-dependent 
cytochrome P-450 reductase activity of hepatic 
microsomes from phenobarbitone pretreated rats
Type II Compound Percentage of control Cyt. 
P-450 reductase activity (%)
Initial rate *AE4 50-it90
Imidazole 29 59
Aniline 46 88
Octylamine 9 47
5-methylbenzimidazole 23 53
2-aminomethylbenzimidazole 28 65
The Type II compound (1.0 mM) was added to a phenobarbitone- 
induced microsomal suspension (1 mg protein/ml) in 66 mM Tris- 
HCl (pH 7.4) in the presence of a deoxygenating system; 
glucose (10 mM), glucose oxidase (5 units/ml) and catalase 
(60 units/ml). The NADPH-dependent cytochrome P-450 
reductase was recorded as described in Methods at 20°C in the 
dual wavelength mode (X^  = 450 nm, X2 = 490 nm).
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TABLE 3.4.
Effect of some Type RI compounds on NADPH-dependent 
cytochrome P-450 reductase activity of hepatic 
microsomes from phenobarbitone pretreated rats
Reverse Type I Compound Percentage of control Cyt. 
P-450 reductase activity (%)
Initial Rate AEij. 5 0 —  ^g o
Phenacetin 73 89
Ethanol 94 91
SUBSTITUTED BENZIMIDAZOLES 
2-methyl 100 94
2-propyl 50 92
2-phenyl 55 • 93
2-benzyl 55 90
2-hydroxy 82 90
2-trifluoromethyl 70 90
Conditions as in Table 3.3., except that Type RI compounds 
(1.0 mM) were added to the microsomal suspension.
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FIGURE 3.1.
Effect of substituted benzimidazoles on NADPH- 
dependent cytochrome P-450 reductase activity 
of hepatic microsomes from phenobarbitone- 
pretreated rats
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Conditions as in Table 3.3. The traces
shown were (1) ----  , Control;----,
+ 2-methyibenzimidazole (1.0 mM).
(2) ---- , + 5-methylbenzimidazole (1.0 mM)
wavelengths in difference spectra) produced similar 
results to ethanol and phenacetin. The results obtained 
from the NADPH-cytochrome P-450 reductase studies were 
in good agreement with the preliminary classification 
of the substituted benzimidazoles into Type II or Type 
RI compounds based solely on the location of maxima and 
minima from binding spectra.
3.2.2. The binding of 2-re-alkylbenzimidazoles to
control, phenobarbitone and 20-methyl- 
cholanthrene-induced microsomes
A detailed investigation on the binding of
2-n-alkylbenzimidazoles to cytochrome P-450 was carried
out using hepatic microsomal preparations from rats
treated with phenobarbitone, 20-methylcholanthrene and
vehicles (saline and corn oil) alone. It was noted from
earlier experiments (3.2.1.) that substitution of the
2-position of benzimidazole produced a Type RI spectrum,
the only exceptions being derivatives containing relatively
polar moieties.
2-Methyl-, 2-ethyl-, 2-propyl- and 2-butyl-
benzimidazole all produced typical Type RI spectra with
control microsomes (Table 3.5). 2-MethyIbenzimidaJzole-
had the lowest Ks value (1.54 mM) and 2-propylbenzimidazole
the highest Ks (15.0 mM),.
Derivatives containing 2-substituents with
longer alkyl chains i.e. 2-pentyl- and 2-hexylbenz-
imidazole, produced mixed Type I/Type RI spectra. Type I
spectra were observed at low substrate concentrations;
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as the concentration was increased mixed Type I and 
Type RI spectral interactions were noted, whereas 
at high concentrations only Type RI spectra were 
apparent (Fig. 3.2). As the alkyl chain length was 
increased, the degree of Type I character also increased. 
This was deduced from the concentration of compound which 
could be added before the observed spectrum became 
intermediate between Types I and RI. 2-Pentylbenzimidazole 
gave rise to Type I spectra at concentrations up to 0.1 fiM. 
The elicited spectral change was too small for a Ks value 
for the Type I component to be determined in the usual 
manner. The Ks for the Type RI component was found to 
be 0.18 mM. 2-Hexylbenzimidazole produced Type I binding 
spectra up to a concentration of 200 jiM. However, this 
compound produced additive Type I .spectra up to a final 
concentration of 150 JJ.M. Concentrations greater than 
200 jliM of 2-hexylbenzimidazole gave rise to a decreased 
Type I spectrum indicative of a Type I spectrum containing 
a Type RI component, resulting in a decreased Type I 
spectrum. A high affinity Type I binding constant was 
calculated for 2-hexylbenzimidazole of 0.77 p.M.
Turbidity effects due to insolubility of the compound 
in aqueous microsomal suspensions prevented the titration 
of concentrations necessary to produce Type RI spectral 
changes.
2-Heptyl-, 2-octyl- and 2-nonylbenzimidazole 
all elicited Type I binding spectra with control microsomal
FIGURE 3.2.
Effect of concentration on the binding spectrum 
elicited on the addition of 2-hexyl- 
benzimidazole to phenobarbitone- 
induced rat hepatic microsomes
O-OOSE
370 3 9 0 410 4 3 0 450 470 4 9 0
Phenobarbitone-induced microsomes (1 mg protein/ml) 
in 66 mM Tris-HCl (pH 7.4) were divided equally 
between two cuvettes and a baseline of equal light 
absorbance was established between 350 and 500 nm 
(0-0). Various concentrations of 2-hexylbenzimidazole 
were added to the sample cuvette and the binding 
spectra were recorded. Spectrum 1, 0.8 yM; 2, 2.8 yM? 
3, 6.8 yM? 4, 150 yM? 5, 400 yM.
cytochrome P-450 (Table 3.5). The K_ values for these 
compounds were 0.29 jllM, 0.17 JiM and 0.48 jiM 
respectively. These three derivatives did not produce 
Type RI spectra at any concentration tested up to 500 ]iM. 
From these results, it appeared that the 2-heptyl and 
2-octyl derivatives (containing C7 and C3 alkyl chains) 
bound most avidly to the Type I binding site.
As stated previously, the 2-methyl-, 2-ethyl-, 
2-propyl- and 2-butylbenzimidazoles produced Type RI 
binding spectra when added to phenobarbitone-induced 
microsomes (Table 3.5). K values for the Type RIO
spectra elicited by these compounds showed a similar
pattern to those observed for the same compounds when
added to control microsomes. However, the K values ofs
these four compounds observed with phenobarbitone microsomes 
were considerably lower than the Kg values established 
for control microsomes. The 2-propyl and 2-methyl 
derivatives had the highest and lowest Kg values 
respectively. 2-Pentylbenzimidazole produced Type 
I spectra up to a final concentration of 0.6 jiM ,  but 
intermediate Type I/Type RI spectra were observed at 
higher concentrations. Type RI spectra only were 
observed at concentrations above 50 jiM.  A Kg value of 
0.38 jllM  was calculated for the Type RI component of the 
binding spectrum. As the length of the alkyl side-chain 
was increased, the degree of Type I character increased.
Type I spectra only were noted for 2-hexylbenzimidazole
(up to 2.4 jiM  final concentration) ; 2-heptylbenzimidazole 
(up to 4.0 jliM) and 2-octylbenzimidazole (up to 10.0 fiM) .
At concentrations above these values, mixed Type I/Type 
RI spectra were apparent. The 2-nonyl derivative 
produced Type I spectra up to a final concentration of 
150 jiM  and intermediate binding spectra were not observed. 
The Ks values for the Type I components of the 2-hexyl, 
2-heptyl, 2-octyl and 2-nonyl derivatives were all very 
similar (between 0.3 and 0.4 p,M) in contrast to the 
affinity constants calculated for the interactions of 
these compounds with control microsomes. The 2-heptyl 
and 2-octyl derivatives had the highest affinity for 
cytochrome P-450.
With 20-methylcholanthrene-induced microsomal 
preparations, the 2-methyl, 2-ethyl, 2-propyl and 2-butyl 
derivatives gave rise to Type RI spectra only with Ks 
values similar to those obtained with control microsomes 
(Table 3.5). The Ks for 2-methylbenzimidazole was similar 
to the Kg value observed with phenobarbitone microsomes.
In contrast to both phenobarbitone an d control microsomes, 
the remaining five derivatives all produced Type I 
binding spectra only. The Ks values observed for these 
five substituted benzimidazoles were in the range 0.3 - 
1.1 jiM, with the 2-octyl and 2-pentyl derivatives having 
the lowest and highest respective Ks values. 2-Hexyl-, 
2-octyl- and 2-nonylbenzimidazole binding to 20-methyl- 
cholanthrene-induced and control microsomes showed a 
similar pattern of affinity for cytochrome P-450, but
2-heptylbenzimidazole had a somewhat higher Ks value with 
20-methylcholanthrene microsomes.
The Ks values for the Type RI spectral binding 
of 2-methyl-, 2-ethyl-, 2-propyl- and 2-butylbenzimidazole 
showed a similar pattern for microsomes from control, 
phenobarbitone or 20-methylcholanthrene pretreated animals 
(Table 3.5). 2-Propylbenzimidazole had the highest Ks 
of these four compounds and 2-methylbenzimidazole had 
the lowest Ks value, regardless of the type of microsomes 
used. However, phenobarbitone microsomes showed a higher 
affinity for all four compounds than either control or 
20-methylcholanthrene stimulated microsomes. The Type I 
binding compounds (2-hexyl-, 2-heptyl-, 2-octyl- and 
2-nonylbenzimidazole) showed distinct differences in their 
Ks values for either 20-methylcholanthrene-induced or 
control microsomal cytochrome P-450, but the Type I 
binding spectra elicited with phenobarbitone microsomes 
produced very similar binding constants for the compounds 
studied.
Since the magnitude of the spectral change 
resulting from substrate interaction is dependent on 
the concentration of cytochrome P-450 present (Estabrook 
et at, j 1972b) the theoretical maximal AE values were 
calculated (Table 3.6). The results showed that the 
maximal Type I spectral changes observed were for 20-methyl- 
cholanthrene-stimulated microsomes, showing that the 
cytochrome P-450 of these microsomes bound more of the
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benzimidazole derivatives than either.phenobarbitone or 
control microsomes.
3.3.3. The inhibition of cytochrome P-450-dependent
monooxygenation by 2-re-alkylbenzimidazoles
2-n-Alkylbenzimidazoles were found to inhibit 
the cytochrome P-450 dependent 0-dealkylation of 
7-ethoxycoumarin and 7-ethoxyresorufin (Tables 3.7 and 
3.8). These substrates were used because linear initial 
rates of metabolism are readily obtained in the presence 
of microsomes and NADPH. The inhibition constants (Ki 
values) of the benzimidazoles showed a similar pattern 
to the binding constants (Ks values) of the spectral 
interactions with cytochrome P-450 (Table 3.5). Maximal 
inhibition of both reactions was elicited by 2-heptyl- 
benzimidazole and the type of inhibition of both 7-ethoxy­
coumarin and 7-ethoxyresorufin 0-deethylation was found 
to be competitive. values were calculated from Dixon
plots (Dixon and Webb, 1958) of reciprocal initial 
velocity versus inhibitor concentration, knowing the Vmax 
value of the appropriate enzyme activity. Increase or 
decrease of the substitutent chain length above or below 
the C 7 (heptyl) moiety produced progressively weaker 
inhibition (Tables 3.7 and 3.8).
The inhibition of 7-ethoxycoumarin 0-deethylation 
was studied with both phenobarbitone- and 20-methylcholanthrene- 
stimulated microsomes and the latter preparation was used 
for 7-ethoxyresorufin metabolism. No correlation between
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TABLE 3.8.
Inhibition of 7-ethoxyresorufin metabolism 
by 2 -n-alkylbenzimidazoles
Substituent 20-Methylcholanthrene
Ki (JiM) I50 (*UM)
2-methyl 108.0 170.0
2-ethyl 51.0 103.0
2-propyl 20.8 35.8
2-butyl 8.2 17.4
2-pentyl 0.25 0.60
2-hexyl 0.17 0.15
2-heptyl 0.03 0.37
2-octyl 0.06 0.38
2-nonyl 0.12 0.54
20-Methylcholanthrene refers to 
microsomes from rats pretreated 
with 20-methylcholanthrene.
the I50 (inhibitor concentration producing 50% inhibition) 
or values and the log P values of the inhibitors was 
observed. However, inhibition was shown to decrease 
sharply when the degree of Type RI character of the 
inhibitor was increased, i.e. 2-methyl-, 2-ethyl-,
2-propyl- and 2-butylbenzimidazole were comparatively 
weak inhibitors. Further, substituted benzimidazoles 
with low binding constants had correspondingly low 
inhibitory constants. This transition was particularly 
marked when 20-methylcholanthrene microsomes were used, 
(Table 3.7). 2-Butylbenzimidazole (a Type RI compound)
had a Ks value of 3.3 mM and a value for the 
inhibition of 7-ethoxycoumarin metabolism of 20.0 JiM. 
However, the next member of the series, 2-pentyl- 
benzimidazole (a Type I compound) had Ks and values 
of 1.1 jiM  and 3.8 JiM respectively. A similar sharp 
break was seen for these two derivatives for the 
d-deethylation of 7-ethoxyresorufin catalysed by 20- 
methylcholanthrene microsomes (Table 3.8).
3.4. DISCUSSION
Substituted benzimidazole derivatives have 
been shown to produce all three types of binding spectra 
with rat hepatic microsomal cytochrome P-450.
Benzimidazole itself and other derivatives with an 
unsubstituted imidazole moiety all produced typical Type II 
binding spectra. Wilkinson, studying a series of
substituted imidazoles, has shown that some 4(5)- and
1-substituted imidazoles all bound to cytochrome P-450 
giving a Type II spectrum. In addition, imidazoles 
containing 4(5)- and 1-substituents had a very high 
affinity for the haemoprotein with Ks values ranging 
from 2.8 fiM to 7.5 p,M (Wilkinson et at.3 1974b) whereas 
imidazole itself bound much more'weakly (K = 210 jiM) , If 
imidazole was substituted in the 2-position, the Ks was 
also about 2 orders of magnitude greater than 4(5)-. or
1-substituted derivatives. However only Type II spectra 
were observed.
The 5-substituted benzimidazoles studied all 
produced Type II binding spectra with Ks values of 
- 100 jiM. The addition of a long alkyl chain (a dode.canoy.l- 
amido substituent) which imparts a large degree of lipo- 
philicity to the molecule did not alter the type of binding 
spectrum obtained. This is in agreement with the results 
of Wilkinson et at. (1972), who found that n-alkyl- 
imidazoles all produced Type II spectra regardless of 
the length of the substituent alkyl chain. Similarly, 
a number of n-alkylamines were all found to elicit Type II 
binding spectra (Jefcoate et at.3 1969). The addition of 
a carboxylic acid or amino grouping to the 2-position 
of the benzimidazole nucleus also gave rise to Type II 
spectral changes.
However the introduction of various other 
substituents into the 2-position elicited Type RI binding.
It has been suggested that Type RI compounds bind to a 
more hydrophobic site than Type II substances, which 
probably ligand to haem iron in a hydrophilic region 
(Al-Gailany et at.3 1974). Measurement of the lipo- 
philicity of the Type II and Type RI binding benzimidazoles 
supported this hypothesis, in that log P values were in 
general greater for Type RI binding substrates than the 
Type II benzimidazoles. No correlation was found between 
these log P values and the K values of the compounds.O
The log P values did not seem to be related to the nature 
(Type II or Type RI) of the binding of cytochrome P-450, 
e.g. both 5-methyl- (Type II) and 2-methylbenzimidazole 
(Type RI) had the same log P (1.96), although in general 
the Type RI compounds had greater log P values than the 
Type II compounds.
An explanation for these findings has been 
suggested by Mailman et at. (1974) . These authors stated 
that the steric and basic feature of nitrogen are of 
primary importance in determining whether or not a 
particular ligand will give rise to a Type II binding 
spectrum. Experiments using a wide range of nitrogenous 
ligands showed that the Type II spectrum was associated 
with ligands containing nitrogen atom(s) with sterically 
accessible non-bonded sp2 or sp3 electrons, e.g. 
pyridine or n-octylamine respectively. It seems that 
the introduction of even a sterically small grouping 
such as a methyl group into the 2-position of a
benzimidazole nucleus effectively alters the type of 
binding elicited by benzimidazole itself from Type II 
to Type RI. If such a grouping was bound to either 
the 1- or to the 3- position, leaving one nitrogen atom 
free, Type II- binding would result.
A basic difference between the binding of
2-substituted imidazoles and the majority of 2-substituted 
benzimidazoles studied is that the former elicit Type II 
binding and the latter Type RI binding. The presence 
of the benzene ring in the benzimidazole nucleus presumably 
hinders access to the Type II binding site for steric 
reasons. Further, the addition of the benzenoid moiety 
to the imidazole ring renders the parent benzimidazole 
molecule less basic than imidazole. Consequently, derivatives 
of benzimidazole are more likely to interact at the Type 
RI site than imidazole derivatives which are more basic 
and hence prefer the hydrophilic environment of the Type 
II binding site.
The introduction of a lipophilic side-chain 
into the 5-position of the benzimidazole nucleus produced 
no qualitative change in the Type II binding spectrum 
obtained with benzimidazole alone. Since Type RI 
spectra were persistently observed when relatively 
hydrophilic moieties were present in the 2-position, the 
binding characteristics of a series of 2-n-alkyl- 
substituted derivatives of benzimidazole. were investigated.
A small number of nitrogenous compounds 
produce composite or mixed binding spectra with microsomal 
cytochrome P-450. These spectra contain both Type I and 
Type RI binding components. Heterocyclic derivatives 
such as allyl-substituted barbiturates produce Type I 
spectra at low substrate concentrations but Type RI 
spectra are observed at higher concentrations (Jansson 
et at. s 1972). Similar changes from Type I to Type RI 
binding has been reported for phenacetin (Schenkman 
et at. j 1973), lysergic acid diethylamide (Niwaguchi 
and Inoue, 1975) and agroclavine (Wilson and Orrenius,
1972).
The 2-alkylbenzimidazoles were shown to 
possess both Type I and Type RI binding character. Clear 
differences were observed in the binding of the 
derivatives to microsomes obtained from differently 
pretreated animals. The critical chain length for the 
initial observation of Type I binding was five carbon 
atoms (the 2-pentyl derivative). The binding of
2-pentylbenzimidazole to 20-methylcholanthrene microsomes 
was exclusively Type I. Higher analogues also elicited 
Type I spectra only with 20-methylcholanthrene microsomes. 
However, 2-pentylbenzimidazole showed almost exclusive 
Type RI character with both control and phenobarbitone 
microsomes, Type I spectra being only apparent at very 
low concentrations of substrate. Derivatives with longer 
alkyl chains produced Type I spectra at progressively
higher substrate concentrations, but the reversion to a 
Type RI spectrum was noted at much lower concentrations 
using phenobarbitone microsomes than control microsomes.
It seems that the Type I character associated with the 
various microsomal, preparations tested increased in the 
order phenobarbitone< control< 20-methylcholanthrene.
Type RI character increased in the opposite manner i.e. 
20-methylcholanthrene < control< phenobarbitone.
Pretreatment with phenobarbitone or 20-methyl- 
cholanthrene produced changes in the spectral binding 
constants of 2-alkylbenzimidazoles to the cytochrome P-450 
species present in the respective microsomal preparations 
(Table 3.5). In general, the pattern of affinity of the 
derivatives for cytochrome P-450 was similar for control 
and 20-methylcholanthrene-induced microsomes. In 
addition, the Ks values for both the Type I and Type RI 
spectral components were very similar. In contrast, the 
observed affinity constants for both Type I and Type RI 
spectral changes obtained with phenobarbitone microsomes 
were different from those observed with either 20-methyl- 
cholanthrene microsomes or control microsomes.
These results indicate that the 2-alkyl- 
benzimidazoles bind to separate binding sites of 
microsomal cytochrome P-450 or to different species of 
cytochrome P-450.
Various 1- and 4(5)-substituted imidazoles 
have been shown to be potent inhibitors of microsomal
drug oxidation in vitro and in vivo (Wilkinson et at.3 
1972, 1974a, b; Leibman and Ortiz, 1973;. Palmer and 
Cawthorne, 1974). The inhibitory activity of these 
derivatives was found to be closely related to their 
capacity to bind to cytochrome P-450 as measured by 
their Ks values. Wilkinson et at. 3 (1974b) showed that
in a homologous series of 1-alkylimidazoles, both 
inhibitory activity and Ks values were closely correlated 
with lipophilic character and were optimum for compounds 
containing an 8-10 carbon chain. However, 2-substituted 
imidazoles have been shown to be weak inhibitors of 
cytochrome P-450-catalysed monooxygenation (Wilkinson 
et at.3 1974b).
Holder et at. (1976) reported the inhibitory 
properties of a series of 2-n-alkylbenzimidazoles during 
the course of my study. Their results suggested a similar 
dependence on the lipophilicity of these compounds for 
maximal inhibition of aminopyrine il/-demethylation and 
aniline hydroxylation. They showed that log P values 
of the substituted benzimidazoles could be correlated 
with the I50 values for the inhibition of these 
monooxygenase activities.
The work reported here largely confirms and 
extends the results of Holder et at. (1976). Since the 
I5Q values calculated by Holder et at. (1976) are dependent 
on the concentration of substrate utilized in the enzyme 
assays, quantitative inhibition could not be directly
compared with the results presented in.this chapter. 
However, a similar, overall pattern of inhibition was 
obtained, with 2-heptylbenzimidazole being the best 
displacer of the series. In all cases, the type of 
inhibition was competitive, indicative of the inhibitor 
competing with the substrate for the active site of 
cytochrome P-450 (in the case of the higher benzimidazoles 
which elicited Type I spectra at low concentrations) or 
possibly by the inhibitor modifying or competing more 
weakly for the binding site (Type RI spectra).
In contrast to the results of Holder et at. 
(1976) no correlation was found between the I50 inhibition 
constants and the log P values of the substituted 
benzimidazoles. The results obtained suggested a much 
closer agreement between the K values (together withO
the spectral types of binding to cytochrome P-450 
(Type I or Type RI) and the observed values. However, ' 
increasing the lipophilicity of the inhibitor by the 
introduction of longer alkyl substituents (up to a C7 
derivative) produced more effective inhibition. The 
lipophilicity of the inhibitor is thus also important 
in determining the potency of the 2-alkylbenzimidazoles 
as inhibitors.
CHAPTER 4
CYTOCHROME P-450-METABOLITE COMPLEXES 
" FORMED BY THE METABOLISM OF METHYLENE- 
DTOXYPHENYL COMPOUNDS
4. CYTOCHROME.P-450-METABOLITE COMPLEXES FORMED
BY THE METABOLISM OF METHYLENEDIOXYPHENYL
COMPOUNDS
4.1. INTRODUCTION
A number of compounds such as the amphetamines 
(Franklin, 1974a,b,c,d), SKF-525A and related compounds 
(Schenkman et al.j 1972b; Buening and Franklin, 1976), 
carbon tetrachloride (Uehleke et at.3 1973), 2-nitroso-l- 
phenylpropane (Jonsson and Lindeke, 1976) and other 
nitrogenous compounds (Franklin, 1976b) have all been 
shown to produce spectrally manifested complexes with 
cytochrome P-450 while undergoing in vitro hepatic 
microsomal metabolism. These compounds produce absorption 
maxima in the range 448-456 .nm following incubation with 
microsomes in the presence of NADPH and oxygen, indicative 
of a product complex formed between a metabolite and 
reduced cytochrome P-450. Under similar metabolizing 
conditions, MDP compounds also produce spectrally manifested 
cytochrome P-450 complexes in vitro, typically with dual 
absorption maxima at about 427 and 455 nm (Franklin 1971; 
Philpot and Hodgson, 1971a,b).
Following the in vivo administration of certain 
MDP compounds, these complexes may be detected in isolated 
hepatic microsomes, indicating the stability of these 
complexes. The reduced form of the haemoprotein complex 
has been shown to be spectrally identical to that 
generated by NADPH in vitro, and may be visualized by
the addition of various reducing agents such as sodium 
dithionite (Philpot and Hodgson, 1971b). The oxidized 
form of the in vivo MDP metabolite-cytochrome P-450 
complex has a single absorbance maximum at 437-438 nm, 
and this too may be produced in vitro following removal 
of the reducing conditions from microsomes containing 
the reduced MDP metabolite complex (Elcombe et al.s 
1975b).
It was recently shown that organic hydro­
peroxides (e.g. cumene hydroperoxide) could catalyse a 
number of cytochrome P-450 dependent reactions such as 
steroid hydroxylation and 4-nitroanisole <9-demethylation 
in the absence of NADPH and oxygen (Rahimtula and O'Brien, 
1974a,b; Hrycay et 1975a,b). Elcombe et al. (1975b)
reported that cumene hydroperoxide could also bring about 
the formation of a spectrally apparent complex with a 
maximum at. 438 nm when hepatic microsomes were incubated 
with safrole and cumene hydroperoxide; peaks at 427 and 455 nm 
were observed following reduction with sodium dithionite 
(Fig. 4.1).
Several theories have been postulated for 
the nature of the MDP product giving the unusual maxima 
in the Soret region when MDP compounds are metabolized 
by hepatic microsomes. The methylenedioxy group is an 
absolute requirement for production of these absorbance 
maxima. Various workers have suggested that the methylene­
dioxy compounds ligand to the haem of cytochrome P-450
FIGURE 4.1.
Cumene hydroperoxide-mediated formation of 
spectral changes attributed to an oxidized 
safrole metabolite-cytochrome P-450 
complex in phenobarbitone-induced rat 
hepatic microsomes
0-01E
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Phenobarbitone-induced microsomes (1 mg protein/ 
ml) in 66 mM Tris-HCl (pH 7.4) were divided 
equally between two cuvettes and a baseline of 
equal light absorbance between 350 and 500 nm 
was established. Safrole (400 pM) was added to 
the sample cuvette and the binding spectrum was 
recorded (0-0). Cumene hydroperoxide (200 pM) 
was added to both sample and reference cuvettes 
and the increase in absorbance at 438 nm was 
recorded every 15 s. After the maximal formation 
of the 438 nm absorbance, sodium dithionite (1-2 
mg) was added to both cuvettes and the spectrum 
was recorded (©-©).
through a modification of this group. Replacement of 
both hydrogen atoms of the methylene group- by oxygen 
or methyl groups destroyed the synergistic activity 
of MDP compounds. Replacement of hydrogen by deuterium 
reduced activity.
a) Benzodioxolium ion theory
Hennessy (1965) has proposed that the loss 
of a hydride ion from the methylene bridge could lead to 
the formation of an electrophilic benzodioxolium ion:-
Rl 
r2
This ion could react with the iron atom of 
the haem of cytochrome P-450 by means of a pi-bonded 
complex.
b) Free radical theory
Hansch (1968), using a structure-activity 
relationship to equate synergistic activity with homolytic 
steric and hydrophobic constants, suggested that the 
methylene bridge may undergo homolytic cleavage resulting 
in the loss of a hydrogen atom:-
•H
The reactive metabolite produced would be 
a free radical, capable of interacting with haem iron.
c) Carbanion theory
Ullrich and Schnabel (1973) have suggested 
that the MDP metabolite liganding to cytochrome P-450 
may be a carbanion:-
This theory was based on the aerobic microsomal 
metabolism of fluorene, which resulted in an absorbance 
maximum at 446 nm in the presence of NADPH and phenobarbitone 
microsomes. Ullrich and Schnabel (1973) showed that the 
anion formed by abstraction of a proton from the methylene 
bridge of the fluorene molecule has an absorbance peak at 
about 374 nm. This maximum was also observed under 
anaerobic conditions following fluorene metabolism. It 
was suggested that the fluorenyl carbanion liganded to the 
haem of cytochrome P-450 and that a similar derivative 
of MDP compounds was the active species which bound to 
cytochrome P-450.
d) Carbene theory
Various halogenated hydrocarbons (Uehleke
et aZ.j 1973) elicit maxima at about 455 nm in the 
presence of NADPH. More recently, Wolf et at. (1977) 
investigated a number of halogenated methanes which 
gave rise to metabolic intermediate complexes either 
enzymically in the presence of NADPH or chemically under 
anaerobic, sodium dithionite reduced conditions. Wolf 
et at. (1977) showed that carbon monoxide was produced 
following metabolism of the halogenated compounds and 
proposed that the active metabolite was a carbene, formed 
by abstraction of two halogen atoms from the substrate 
molecule. A similar mechanism was proposed by Mansuy 
et at. (1974) to explain the maximum at 470 nm generated 
by halothane (1 ,1 ,1-trifluoro-2-chloro-2--bromo-ethane) 
in the presence of metabolizing conditions with low oxygen 
tension. The trifluoromethyl carbene species was produced 
chemically and shown to have almost identical spectral 
characteristics to those induced by halothane under 
reduced anaerobic conditions. Formation of a carbene 
at the methylene bridge of MDP compounds was recently 
postulated as the active MDP metabolite (Ullrich et at.>
.1975a).
e) Carbon monoxide release theory
The MDP derivative, (E)-4- [ (6 ,7-epoxy-3,7- 
dimethyl-2-nonenyl)oxyl]-1 ,2- (methylenedioxy)benzene, 
(R0-203600) has been shown to produce carbon monoxide 
following aerobic metabolism (Mayer and Burke, 1976;
Mayer and Prough, 1976). This was manifested by a 
hypsochromic shift of the 455 nm maximum to about 
452-453 nm accompanied by a rapid increase in absorbance. 
However, the carbon monoxide formed was considered to 
derive from haem catabolism as a result of NADPH-mediated 
lipid peroxidation (Mayer and Burke, 1976), the peak shift 
only being evident under anaerobic conditions. Subsequent 
gassing of the cuvette with oxygen caused the spectrum to 
revert to the 455 nm form. This effect was also seen 
following incubation with other MDP compounds. It is 
possible that the carbon monoxide may be derived from 
breakdown of the MDP metabolite formed during metabolism.
The carbon monoxide so produced could then bind to 
cytochrome P-450 when the haemoprotein was in the reduced, 
anaerobic state.
The following experiments report an investigation 
of the metabolic intermediate spectra produced with several 
MDP compounds and variously induced microsomes, using 
either NADPH or cumene hydroperoxide to generate the 
respective reduced and oxidized metabolite complexes with 
cytochrome P-450.
4.2. RESULTS
4.2.1. Methylenedioxycyclohexane
Methylenedioxycyclohexane elicited Type I 
binding spectra with control rat hepatic microsomes in 
agreement with the binding of methylenedioxycyclohexane 
to control hepatic mouse microsomes (Hodgson et at.*
1973). However, Type RI spectra were consistently observed 
with this compound at a range of substrate concentrations 
when added to phenobarbitone of 20-methylcholanthrene 
microsomes prepared from Wistar rats. In contrast, 
microsomes from rats of the Sprague-Dawley strain elicited 
Type I binding spectra with methylenedioxycyclohexane 
regardless of the state of induction.
When NADPH was added to oxidized microsomes 
containing methylenedioxycyclohexane, a single absorbance 
maximum at about 427 nm was observed with each of the 
differently induced microsomal preparations (Table 4.1).
No increase in absorbance at 455 nm was recorded at any 
methylenedioxycyclohexane concentration or with any of 
the different microsomal preparations. Phenobarbitone 
microsomes produced a rapid formation of the 427 nm 
peak (Fig. 4.2) whereas control microsomes catalysed 
the reaction at a much slower rate, but at a greater 
rate than 20-methylcholanthrene microsomes.
When cumene hydroperoxide was used as the 
oxygen donor, a maximum at 438 nm was generated with 
methylenedioxycyclohexane and phenobarbitone microsomes.
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FIGURE 4.2.
NADPH-mediated formation of an absorption 
maximum at 427 nm during the metabolism 
of methylenedioxycyclohexane by 
phenobarbitone-induced rat hepatic 
microsomes
0-005E
450 nm 490470
.Phenobarbitone-induced microsomes (1 mg protein/ 
ml) in 66 mM Tris-HCl (pH 7.4) were divided 
between two cuvettes and a baseline was established. 
Methylenedioxycyclohexane (1.5 mM) was added to the 
sample cuvette and the binding spectrum was 
recorded (0-0). NADPH (250 yM) was added to both 
sample and reference cuvettes and the increase in 
absorbance at 427 nm was recorded every 15 s.
As with NADPH, the greatest rate of formation of the 
oxidized complex was given by phenobarbitone microsomes, 
control microsomes producing a much slower rate and 
20-methylcholanthrene microsomes producing a barely 
detectable absorbance change. Upon reduction of the 
cumene hydroperoxide treated microsomes (by addition of 
sodium dithionite to both cuvettes) a single absorbance 
peak was produced at 427 nm and this was proportional to 
the maximal absorbance observed at 438 nm with cumene 
hydroperoxide as the source of active oxygen. As with 
NADPH, the magnitude of the 427 nm maximum obtained by 
metabolism with cumene hydroperoxide followed by sodium 
dithionite reduction of the differently induced microsomes 
was of a similar order (phenobarbitone>>control>20-methyl- 
cholanthrene). Similar metabolic intermediate spectra 
were observed with animals from both the Wistar and the 
Sprague-Dawley strains, irrespective of the state of 
induction of the animals, and thus the differences in 
binding of methylenedioxycyclohexane to different forms 
of cytochrome P-450 do not appear to affect the metabolism 
of this compound.
4.2.2. Methylenedioxybenzene
Methylenedioxybenzene elicited Type I binding 
spectra with all three types of microsomes, binding most 
avidly (as evidenced by the magnitudes -of the spectra) in the 
order phenobarbitone>control>20-methylcholanthrene microsomes. 
However, major differences were observed in the metabolism
of methylenedioxybenzene by different microsomal 
preparations using NADPH as. cofactor. Both phenobarbitone 
and control microsomes catalysed the production of absorption 
peaks at 427 and 455 nm, with a 427/455 ratio of - 2.0 
using a final concentration of 400 jllM methylenedioxybenzene 
(Fig. 4.3). In contrast, 20-methylcholanthrene microsomes 
produced a single maximum at 455 nm with methylenedioxy­
benzene and NADPH (Fig. 4.4)> only a small absorbance 
change at 427 nm with time was observed.
Phenobarbitone microsomes produced a 
maximum at 438 nm when methylenedioxybenzene (400 jiM) and 
cumene hydroperoxide were added to the cuvette. Control 
and 20-methylcholanthrene microsomes elicited a large 
absorbance change at about 414 nm under these conditions, 
but in both cases a distinct shoulder at about 438 nm on 
the side of the major 414 nm maximum was seen to increase 
with time relative to an isosbestic point at 490 nm.
Reduction of the cumene hydroperoxide-catalysed spectral 
intermediate following maximal absorbance change at 
438 nm produced peaks at 427 and 455 nm. However, the 
427/455 ratios were markedly different for the respective 
microsomal preparations from rats treated with phenobarbitone 
(427/455 = 8.3), oil (control) (1.3) and 20-methylcholanthrene
FIGURE 4,3.
NADPH-mediated formation of absorption maxima 
at 427 and 455 nm during the metabolism of 
methylenedioxybenzene by phenobarbitone- 
induced rat hepatic microsomes
0-01E
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Conditions as in Fig. 4.2, except that methylene­
dioxybenzene (400 yM) was used as the substrate.
NADPH (250 yM) was added to both cuvettes and 
spectra were recorded every 30 s. 0-0, binding 
spectrum; 1,3,5 were the spectra obtained 0.5,
1.5 and 2.5 min respectively after the addition 
of NADPH. ©-©, spectrum obtained by the addition 
of an NADPH depleting system (a-oxoglutarate, 
glutamate dehydrogenase and NH^Cl) to both cuvettes 
after maximal absorbance changes at 427 and 455 nm 
had occurred.
FIGURE 4.4
NADPH-mediated formation of an absorption 
maximum at 455 nm during the metabolism 
of methylenedioxybenzene by 20-methyl- 
cholanthrene-induced rat hepatic microsomes
0-01E
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20-Methylcholanthrene-induced microsomes (1 mg 
protein/ml) in 66 mM Tris-HCl (pH 7.4) were 
divided between two cuvettes and a baseline 
was established. Methylenedioxybenzene (400 pM) 
was added to the sample cuvette, the binding 
spectrum recorded (0-0), and NADPH (250 pM) was 
added to both sample and reference cuvettes.
The increase in the absorbance of 455 nm was 
recorded every 30 s j 1,3,5 were the spectra 
obtained 0.5, 1.5 and 2.5 min after the 
addition of NADPH.
4.2.3. Isosafrole
Isosafrole bound to all the different 
microsomal preparations, producing Type I binding spectra 
in all cases. At the concentration employed (400 pM), 
the size of the binding spectrum decreased in the order 
phenobarbitone>20-methylcholanthrene>control. NADPH, 
isosafrole and phenobarbitone microsomes produced a 
427/455 ratio of 1.6 whereas control microsomes produced 
peaks with a greater 455 nm absorption (427/455 = 0.5). As 
for methylenedioxybenzene, 20-methylcholanthrene microsomes 
catalysed the formation of a 455 nm maximum with only 
a small time dependent change at 427 nm similar to that 
shown in Fig.4.4.
Cumene hydroperoxide produced 438 nm maxima 
with control or phenobarbitone microsomes, and a prominent 
shoulder at 438 nm with 20-methylcholanthrene microsomes. 
Sodium dithionite reduction produced the dual maxima 
at 427 and 455 nm, the respective 427/455 ratios being 
phenobarbitone (3.3), control (4.5) and 20-methylcholanthrene 
(1.0).
4.2.4. Dihydrosafrole
Dihydrosafrole elicited a similar binding 
spectral pattern to isosafrole, except that the magnitudes 
of the binding spectra were greater for each set of 
microsomes. Corresponding metabolic spectra with NADPH 
and dihydrosafrole (400 jiM) were observed with 427/455 ratios 
similar to those recorded for isosafrole, the ratios for
phenobarbitone and control microsomes being 2.1 and 0.3 
respectively. A single peak at 455 nm was observed with 
20-methylcholanthrene microsomes and NADPH with a small 
change at 427 nm (cf. Fig. 4.4).
All the microsomal preparations produced 
prominent absorbance maxima at 438 nm with cumene 
hydroperoxide and dihydrosafrole. When reduced with 
sodium dithionite, the major absorption peak for 
phenobarbitone and control microsomes was the 427 nm 
absorbance (427/455 ratios of 6.0 and 9.1 respectively), 
whereas the 455 nm peak was the more prominent with 
20-methylcholanthrene microsomes (427/455 =0.8) (Fig. 4.5).
4.2.5. Piperonyl butoxide
Piperonyl butoxide produced Type I binding 
spectra with phenobarbitone, 20-methylcholanthrene and 
control microsomes. The AE peak-trough values recorded 
for piperonyl butoxide were similar to those noted for 
methylenedioxybenzene. When NADPH and piperonyl butpxide 
(400 fiM) were incubated together with phenobarbitone 
microsomes, a small absorbance at 427 nm was produced 
together with a larger 455 nm peak. 20-Methylcholanthrene 
microsomes catalysed the formation of both 427 and 455 nm 
maxima (427/455 ratio = 0.6) but control microsomes produced 
the 427 nm peak as the dominant absorbance species (427/
455 = 1.6).
Cumene hydroperoxide elicited the formation 
of maxima at 438 nm with both phenobarbitone and control
FIGURE 4.5.
Cumene hydroperoxide-mediated formation of an 
absorption maximum at 438 nm during the 
metabolism of dihydrosafrole by 20-methyl­
cholanthrene rat hepatic microsomes
0-01E
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20-Methylcholanthrene microsomes (1 mg protein/ 
ml) in 66 mM Tris-HCl (pH 7.4) were divided 
between two cuvettes and a baseline was established. 
Dihydrosafrole (400 yM) was added to the sample 
cuvette, the binding spectrum recorded and cumene 
hydroperoxide (200 yM) was added to both sample and 
reference cuvettes. The increase in the absorbance 
at 438 nm was recorded every 15 s m, 1,3 and 5 were 
the spectra obtained 0.25, 0.75 and 1.25 min after 
the addition of cumene hydroperoxide. ®-©, spectrum 
obtained 2 min after the addition of cumene hydro­
peroxide, following the addition of sodium dithionite 
(1-2 mg) to both cuvettes.
microsomes together with piperonyl butoxide. No definite 
absorbance change with time at 438 nm could be detected 
with 20-methylcholanthrene microsomes. However, 
reduction of all three microsomal incubations elicited 
427 and 455 nm peaks. The respective ratios of the 427 
to the 455 nm absorbance were: phenobarbitone (7.0),
control (6.2) and 20-methylcholanthrene (3.0).
4.2.6. Stability of the MDP-metabolite complexes
formed in the presence of NADPH or cumene 
hydroperoxide
The reduced MDP metabolite-cytochrome P-450 
complex formed with phenobarbitone microsomes, safrole 
and NADPH has been found to be very stable (Elcombe,
1976). Similar stabilities were found for the reduced 
intermediates formed by other MDP compounds and variously 
induced microsomes. The 427 and 455 nm maxima, generated 
in vitro with MDP compounds, phenobarbitone microsomes 
and NADPH, were stable at 37°C for several hours and 
could not be displaced by ligands with high affinity for 
reduced cytochrome P-450 such as carbon monoxide. No 
decrease in the 427 and 455 nm peak heights were 
observed when carbon monoxide was bubbled through 
sodium dithionite-reduced microsomes containing the 
complex. The oxidized form of the complex observed after 
exhaustion of NADPH eliciting a maximum at 438 nm (Fig.
4.3) was detected with isosafrole and phenobarbitone 
microsomes and was found to slowly decay with time (Fig. 
4.6). No 438 nm maximum was noted under similar conditions 
using 20-methylcholanthrene microsomes and isosafrole.
FIGURE 4.6,
Degradation of the 438 nm absorbance maximum 
observed after the maximal formation of 
absorption peaks- at - 427' and - 455 nm due to 
the reduced isosafrole metabolite-cytochrome 
P-^450 complex - and the enzymic removal of NADPH
a E438-490(x10 3)
T im e (m in )
Conditions as in Fig. 4.3. except that isosafrole 
(400 pM) was used as substrate. The time- 
dependent decrease at 438 nm was plotted versus 
time (min).
Elcombe et at. (1975b) also reported a
similar stability for the oxidized (438 nm) complex 
formed by safrole, phenobarbitone microsomes and cumene 
hydroperoxide. My results show the same stability for 
complexes of other MDP compounds formed in the presence 
of phenobarbitone microsomes. Control microsomes also 
elicited the formation of stable complexes with cumene 
hydroperoxide. However, if 20-methylcholanthrene 
microsomes were used as the enzyme source, the oxidized 
MDP metabolite-cytochrome P-450 complex formed was much 
less stable and could not be detected five minutes after 
the addition of cumene hydroperoxide (200 fiM) . However, 
if sodium dithionite was added 1-2 min after the cumene 
hydroperoxide, the complex could be converted to its 
stable, reduced state with maxima at 427 and 455 nm.
4.3. DISCUSSION
It is well established that the natural 
source of the first electron (which converts oxidized 
mammalian cytochrome P-450 to its reduced state) is 
from NADPH via the flavoprotein NADPH-dependent cytochrome 
P-450 reductase. A similar requirement for NADPH and 
molecular oxygen has been found for reactions catalysed 
by both hepatic microsomal (i.e. membrane-bound) and 
purified forms of cytochrome P-450. Substrates of 
cytochrome P-450 are thus metabolized following the 
insertion of active oxygen which is produced by the 
cytochrome P-450 mechanism.
In 1971, Hrycay and O'Brien showed that 
cytochrome P-450 could act as a peroxidase, using 
linoleic acid hydroperoxide as a substrate. Subsequently, 
Kadlubar et at. (1973) showed that the addition of
organic hydroperoxides to rat hepatic microsomes resulted 
in the C-oxidation of several amine substrates. Rahimtula 
and O'Brien (1974a,b) later observed 0-dealkylation and 
aromatic hydroxylation of typical cytochrome P-450 
substrates; following their incubation with cumene 
hydroperoxide and microsomal or purified cytochrome P-450. 
More recently various peracids and hydroperoxides (Hrycay 
et at.3 1975a,b> 1976) and iodosobenzene (Lichtenberger 
et at,3 1976) have been used as oxygen donors to cytochrome 
P-450 to hydroxylate various substrates. NADPH, NADPH- 
cytochrome P-450 reductase and oxygen were not required 
for these reactions.
The specificity of the cumene hydroperoxide- 
supported reaction in general appears to agree well with 
NADPH-dependent hydroxylation. Thus Burke and Mayer
(1975) found that the 2-hydroxylation of biphenyl was 
catalysed by both NADPH and cumene hydroperoxide to a 
much greater extent by 20-methylcholanthrene microsomes 
or purified cytochrome P-448 than by phenobarbitone 
microsomes or purified cytochrome P-450. It has also 
been reported that the 'NIH' shift phenomenon (seen 
following hydroxylation of tritiated aromatic substrates) 
occurs to a similar degree with both NADPH and cumene 
hydroperoxide (Rahimtula and O'Brien, 1977).
The generation, of MDP metabolite complexes 
with reduced cytochrome P-450 following in vitro incubation 
of microsomes, NADPH and various MDP compounds is well 
documented (Franklin, 1971 > Hodgson et at,y 1973). 
Typically, maxima at 427 and 455 nm are observed and 
represent the spectral manifestation of a complex formed 
between reduced cytochrome P-450 and a MDP metabolite. 
Philpot and Hodgson (1971b) and Elcombe et at. (1975a) 
reported the formation of a single absorbance maximum 
at 437-438 nm which they attributed to an oxidized 
form of a MDP metabolite-cytochrome P-450 complex. Mayer 
and Prough (1976) noted the formation of maxima at 427 nm 
and 455 nm in the reduced state and a single maximum 
at 442 nm in the oxidized state following the metabolism 
of the MDP-juvenile hormone analogue, R0-203600. The 
438-442 maximum was readily converted to peaks at 427 and 
455 nm after sodium dithionite reduction, indicating 
that the spectra observed represented different redox 
states of the same complex. Elcombe et at. (1975b) 
also showed that the 438 nm peak could be formed directly 
from safrole in the presence of the organic hydroperoxide, 
cumene hydroperoxide. Subsequent reduction with sodium 
dithionite converted the complex to its reduced state 
with maxima at 427 and 455 nm.
My experiments further suggest that both 
NADPH and molecular oxygen or cumene hydroperoxide 
catalyse the formation of similar MDP metabolite-cytochrome
P-450 complexes which differ only in their redox state. 
Generation of an absorbance change at 438 nm with cumene 
hydroperoxide relative to an isosbestic point was always 
accompanied by the observation of typical 427 and 455 nm 
maxima upon reduction of the microsomes. In agreement 
with other workers (Burke and Mayer, 1975; Rahimtula 
and O ’Brien, 1977) the specificity of the reaction 
catalysed either by NADPH and oxygen or by cumene hydro­
peroxide was in reasonably good agreement. However, 
the 427/455 ratios observed after sodium dithionite 
reduction of cumene hydroperoxide-generated MDP 
metabolite-cytochrome P-450 complexes were consistently 
greater than those of NADPH-generated spectral maxima. 
This may have been due to differences in the magnitude 
of the maxima formed by NADPH or cumene hydroperoxide 
fpllowed by sodium dithionite, or to a change in the pH 
of the microsomal suspension following sodium dithionite 
addition.
Neither the 427 nm nor the 455 nm maxima 
observed in the reduced state seem to be exclusively 
related to the 438 nm oxidized spectrum. However, a 
compound which elicited the formation of 427 nm maxima 
only (methylenedioxycyclohexane) produced a marked 
absorption at 438 nm with cumere hydroperoxide and
phenobarbitone microsomes. This indicates that the
/
formation of the 427 nm maximum (in the absence of any 
detectable 455 nm peak) is related to the 438 nm maximum.
That the 455 nm maximum is also related to the 438 nm 
peak is seen following administration of isosafrole 
in vivo to rats, where the magnitude of the 455 nm peak 
could be directly related to a 438 nm absorbance minimum 
following dissociation of the oxidized metabolite 
cytochrome P-450 complex. This is discussed in more 
detail in Chapter 7. Furthermore, Elcombe (1976) has 
shown that the magnitude of both 427 nm and 455 nm 
maxima generated by NADPH, isosafrole and phenobarbitone 
microsomes are linearly related to the size of the,438 nm 
peak generated by cumene hydroperoxide and identical 
affinity constants (17 pM) were calculated for the 455 nm 
and 438 nm complexes of cytochrome P-450. Mayer and Prough
(1976) calculated similar Km values for the loss of carbon 
monoxide-reactive cytochrome P-450 and the maximal absorbance 
at,455 nm relative to 490 nm, indicating that both the 
455 nm absorbing species and carbon monoxide interacted 
at the same site.
The degree to which the various MDP compounds 
bind initially to the differently induced microsomal 
preparations does not seem to influence greatly their 
metabolism. For example, methylenedioxybenzene and 
piperonyl butoxide elicited very small binding spectral 
changes with 20-methylcholanthrene microsomes.
In contrast, the short chain derivatives (safrole, 
isosafrole and dihydrosafrole) produced binding spectra 
of similar magnitude with both phenobarbitone and
20-methylcholanthrene microsomes, possibly indicating 
that more of the enzyme-substrate complex was formed when 
these compounds were added to 20-methylcholanthrene 
microsomes.
Methylenedioxycyclohexane was found to produce 
only a 427 nm maximum under metabolizing conditions and 
this compound has been reported to be the best inhibitor 
of carbon monoxide binding to reduced cytochrome P-450 
of any methylenedioxy compound tested using hepatic 
mouse microsomes (Hodgson et aZ.3 1973). In contrast, 
the other MDP compounds tested produced different proportions 
of maxima at 427 and 455 nm. A particularly marked 
change was evident when an unsaturated ring system (benzene) 
instead of the saturated cyclohexyl ring was attached 
to the methylenedioxy group. Thus the unsaturated 
nature or the planarity of the benzene ring may be 
important for the formation of the 455 nm maximum of the 
metabolic intermediate spectrum, since the absence of 
the 455 nm component in the methylenedioxycyclohexane 
spectrum was not due simply to a shift of the pH 
equilibrium point. The MDP derivatives without exception 
produced 455 nm maxima following metabolism using either 
NADPH or cumere hydroperoxide together with any of the 
differently induced microsomes as the enzyme source.
Another observation that ought to be 
considered is that the reduced metabolite spectra formed 
by 20-methylcholanthrene microsomes and MDP compounds
show a much greater amount of the 455 nm absorbance 
relative to phenobarbitone or control microsomes. This 
may be due to a shift in the pH equilibrium point for 
20-methylcholanthrene microsomes, a change which is 
known to occur for the interaction of ethylisocyanide 
with reduced cytochrome P-450. Alternatively, the 455 nm 
absorbing species may bind preferentially to cytochrome 
P-448, the haemoprotein preferentially induced by 
20-methylcholanthrene and the 427 nm species may bind 
to cytochrome P-450. An exception to this latter 
hypothesis is shown by the metabolism of piperonyl 
butoxide by phenobarbitone microsomes and NADPH, 
where the 427 nm peak is smaller than the 455 nm 
absorbance at all the substrate concentrations tested.
A further unexpected observation was that the metabolism 
of piperonyl butoxide by NADPH and 20-methylcholanthrene 
microsomes elicited the formation of a prominent 427 nm 
maximum (Table 4.1), in contrast to the metabolism of 
safrole, isosafrole and dihydrosafrole under these 
conditions. Thus piperonyl butoxide appears to be 
metabolized in a somewhat different manner to other 
substituted MDP compounds.
Several reports have been published which 
refer to the stability of metabolic intermediate 
complexes.
Many compounds which elicit spectra which 
are stable in the reduced state such as amphetamines 
and SKF-525A are unstable in the oxidized state
(Werringloer and Estabrook, 1975; Buening and Franklin, 
1976). Furthermore, phenobarbitone microsomes form 
metabolite—-cytochrome P-450 complexes at a greater rate 
and to a greater extent than either 20-methylcholanthrene 
or control microsomes (Franklin, 1976b; Mayer and Prough, 
1976; Wolf et at.3 1977). Intermediate complexes formed 
from polyhalogenated methanes have also been shown to 
be more stable with phenobarbitone microsomes than with 
3,4-benzo(a)pyrene microsomes (Wolf et at. 3 1977).
The results reported in this chapter are 
in agreement with the published data on the stability 
of metabolic intermediate complexes. The reduced 
metabolite spectra obtained with NADPH or cumene 
hydroperoxide followed by sodium dithionite have been 
shown to be remarkably stable complexes. The oxidized 
complex generated by phenobarbitone microsomes in the 
presence of MDP compounds and cumene hydroperoxide 
has also been shown to be very stable (Elcombe, 1975b,
1976). This is in contrast to complexes formed by 
amphetamines and SKF-525A which are discharged in the 
presence of potassium ferricyanide, a chemical oxidizing 
agent. The oxidized MDP metabolite-cytochrome P-450 
complex has been reported not to be dissociated by 
potassium ferricyanide (Buening and Franklin, 1976;
Mayer and Prough, 1976) . However, if 20-methylcholanthrene 
microsomes are used as the enzyme source, the oxidized 
MDP metabolic intermediate complex is much less stable
but the complex can be stabilized by the addition of 
sodium dithionite, converting the complex to its reduced 
state.
Of the various proposed mechanisms for the 
formation of an MDP metabolite which could then bind 
to the haem iron of cytochrome P-450, perhaps the carbene 
intermediate is most likely. Elcombe (1976) showed 
that the free radical scavenger, dithiothreitol, had 
no effect on the formation of the metabolite complex.
The formation of a carbanion is also unlikely since 
the fluorenyl carbanion generated under anaerobic 
conditions is unstable in the presence of oxygen, 
resulting in a loss of the ligand spectrum. The MDP 
metabolite complexes are stable in the presence of 
oxygen. In contrast, the proposed carbene complexes 
derived from polyhalogenated methanes and halothane 
may be formed under conditions of low oxygen tension, 
although the metabolite-complexes are far more readily 
visualized in the anaerobic state. The carbene would 
be stabilized by the same type of iron-carbon bond with 
pi-back bonding as in the carbon monoxide or ethyliso- 
cyanide complexes of reduced cytochrome P-450 and other 
ferroporphyrin proteins. Although the hypsochromic 
shift of the 455 nm maximum accompanied by a rapid 
increase in absorbance was observed on two or three 
occasions, this was not a common phenomenon. The vast 
majority of experiments showed no blue shift of the 
peak from 455 nm. In all cases any blue shift together
with an increased absorbance could be attributed to 
conditions of anaerobiosis and the 455 nm maximum 
was restored to its former magnitude by gassing with 
oxygen as found by Mayer and Burke (1976). Thus any 
carbon monoxide formed during metabolism was from a 
source other than the MDP metabolite.
Thus, on the basis of the available data, 
the carbene intermediate appears to be the most likely 
MDP metabolite. Further evidence was provided by 
Ullrich et at. (1975a) who have demonstrated the 
ligand nature of the MDP metabolite-cytochrome P-450 
complex by an experiment similar to that of Estabrook 
et at. (1963) who observed the photodissociation of 
the reduced-carbon monoxide complex of cytochrome P-450.
A photochemical action spectrum similar to that obtained 
by Estabrook et at. (1963) was noted by Ullrich et at. 
(1975a) with light at about 450 nm wavelength being 
optimal for destruction of the 455 nm complex. Carbon 
monoxide may be considered analogous to the putative 
MDP metabolite in that both can exist in a carbene form.
The structures of the compounds which elicit 
427 and 455 nm spectra during metabolism are of interest. 
Methylenedioxycyclohexane and compounds of the structure:-
produce a 427 nm maximum only, whereas other compounds 
such as amphetamines (Werringloer and Estabrook, 1973,
1975; Franklin, 1974a,b) and compounds related to SKF-525A 
(Franklin, 1974c; Buening and Franklin, 1976) elicit 
maxima in the 455 nm region only. In contrast, MDP
compounds produce maxima at both 427 and 455 nm in the
presence of NADPH. A comparison of the various groups 
of compounds producing metabolite-cytochrome P-450 
spectral intermediates are described in Table 4.2.
In contrast to both the amphetamine and SKF-525A 
complexes which are unstable in the ferric state,
MDP complexes are stable in the oxidized state and are 
resistant to potassium ferricyanide oxidation. Possibly the 
427 nm form or component of the observed MDP ligand spectrum
confers a greater degree of stability to the metabolic
intermediate complex. Evidence for the ligand nature 
of the complexes is shown by the apparent decrease in 
haemoprotein content as judged by carbon monoxide 
binding to the reduced cytochrome P-450 and the inhibition 
of monooxygenation. Further evidence was obtained when 
examples of MDP compounds (Franklin, 1976a) and amphetamines 
(Werringloer and Estabrook, 1975) were shown to decrease 
the low-spin EPR signal of cytochrome P-450.following metabolism.
Both SKF-525A and MDP derivatives have been 
shown to produce metabolite spectra in vivo which are 
sufficiently stable to survive the microsomal isolation 
procedure. However, SKF-525A traps the haemoprotein 
in the reduced state whereas the in vivo .MDP. metabolic 
intermediate complex is isolated in the oxidized form
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and requires the addition of a reductant (NADPH, NADH 
or sodium.dithionite) before the 427 and 455 nm maxima 
are observed. The degradation of the oxidized in vivo 
isosafrole metabolite-cytochrome P-450 complex in the 
presence of some Type I substrates is described in 
the following chapter.
CHAPTER 5
THE DISSOCIATION OF THE ISOSAFROLE 
METABOLITE-CYTOCHROME P-450 COMPLEX
5. THE DISSOCIATION OF THE ISOSAFROLE METABOLITE- 
CYTOCHROME P-450 COMPLEX
5.1. INTRODUCTION
Several authors have reported the presence of 
an in vivo MDP metabolite-cytochrome P-450 complex in 
hepatic microsomes following the administration of MDP 
compounds (Philpot and Hodgson, 1971b; Lake and Parke, 
1972; Elcombe et at. > 1975a, 1976a; Franklin, 1976a;
Mayer and Prough, 1976). Such complexes have been shown 
to be stable to dialysis and to prevent the binding of 
carbon monoxide to a portion of the reduced cytochrome 
P-450 (Elcombe et at.3 1976a).
On the addition of certain substrates of 
the monooxygenase system to oxidized isosafrole microsomes 
(i.e. microsomes from animals which were pretreated with 
isosafrole), a time-dependent intensification of that 
substrate's Type I binding spectrum (Gray and Parke,
1973) and a red shift in the absorption minimum (from 
420 to 438 nm) were observed (Elcombe et at.3 1975a).
This increase in the magnitude of the binding spectrum 
is accompanied by the expulsion of an isosafrole-related 
material from the microsomes and the binding of more 
substrate to the cytochrome P-450 (Elcombe et al.3 1976a). 
This phenomenon has been termed displacement and 
compounds eliciting these changes are called displacers 
(Gray and Parke, 1973; Elcombe et al.3 1975a).
Preliminary studies by Gray (1972) described 
a number of compounds which were capable of eliciting 
the displacement process. Elcombe et al. (1975a) showed 
that the phenomenon was concentration dependent and that 
the intensification of the displacer's binding spectrum 
could be related to a loss of the in vivo metabolic 
intermediate complex. The present study was designed to 
investigate the displacement process further, with 
particular emphasis on the binding to cytochrome P-450, 
lipophilicity and the dimensions of substrates which 
dissociated the complex.
5.2. RESULTS
5.2.1. Measurement of the displacement process
Fig.,5.1. illustrates the spectral changes 
observed on the addition of 7-ethoxycoumarin to oxidized 
isosafrole microsomes. The absorption maximum and minimum 
of the binding spectrum were seen to increase with time. 
Furthermore, a characteristic red shift of the trough 
was observed, from the typical Type I wavelength (about 
420 nm) to 438 nm. Isosbestic points were observed 
at about 420 nm and also in the region 475-490 nm 
(depending on the compound examined). The spectral changes 
described above are typical of those which occurred 
following the addition of a displacing agent to isosafrole 
microsomes.
FIGURE Syl.
Dissociation of the isosafrole metabolite 
cytochrome P~450 complex by 
  .... 7.^ .ethoxyco.umar.in........... ^
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Isosafrole microsomes (1 mg protein/ml) were 
suspended in 66 mM Tris^HCl (pH 7.4) divided 
equally between two cuvettes and allowed to 
equilibrate at 37°C for 5 min. A baseline of 
equal light absorbance between 350 and 500 nm 
was established and 7^ethoxycoumarin (250 jiM) 
was added to the sample cuvette. Spectra were 
recorded every minute between 350 and 500 nm,
The results presented in this chapter were 
calculated using the time-dependent decrease in 
absorbance at 438 nm (relative to an isosbestic point 
in the 475-490 nm region) as a measure of the rate 
of dissociation of the isosafrole metabolite-cytochrome 
P-450 complex. The validity of this measurement is 
supported by the following evidence. Using different 
concentrations of safrole as a displacer, the rate of 
change of absorbance at 438 nm was determined. Fig. 5.2. 
demonstrates that the rate of dissociation of the complex 
was dependent upon the concentration of the displacer 
utilized. By replotting these data as a double reciprocal 
plot (Fig. 5.3.), the maximal size of the 438 nm trough 
at an infinitely high concentration of displacer was 
obtained from the reciprocal of the intercept on the 
ordinate axis. It may be seen from Fig. 5.3. that the 
maximal change of absorbance at 438 nm was constant 
irrespective of the concentration of the displacer. 
Further, the maximal AE 1*33-4 7 5 (1*90) absorbance change was 
constant for a given preparation of isosafrole microsomes, 
regardless of the displacing agent used to effect 
dissociation of the complex. Thus, it was deemed valid 
to utilize the absorbance changes at 438 nm as an estimate 
of the displacement process.
5.2.2. Carboxylic acids as displacers
A series of carboxylic acids was used to 
dissociate the isosafrole metabolite-cytochrome P-450
FIGURE 5.2.
Effect of displacer concentration on the rate of 
dissociation of the isosafrole metabolite- 
cytochrome P-450 complex
2 A 
Time (min)
Isosafrole microsomes (1 mg protein/ml) in 66 mM Tris- 
HC1 (pH 7.4) were divided equally between two cuvettes 
and allowed to equilibrate at 37°C for 5 min. Various 
displacer (safrole) concentrations were added to the 
sample cuvette and the spectrum between 350 and 500 nm 
was recorded every minute. AEi*38-475 was then measured 
and plotted as ordinate versus time as the abscissa. 
Safrole (displacer) concentrations: o , 41.7 jiM?
83.3 jiM; A, 125 jiM; ♦ , 417 jiM* ▼, 833 jiM.
FIGURE 5.3.
Double reciprocal plot of the rate of dissociation 
of the isosafrole metabolite-cytochrome P-450 
complex versus the displacer concentration
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Conditions as in Fig. 5.2.
complex. Butyric acid (C3)* produced detectable displacing 
ability at a concentration of 1.0 mM and higher analogues 
were increasingly active up to undecanoic (C10) acid 
(log P = 4.65), the optimal displacer of this series 
(Fig. 5.4.). Carboxylic acids with longer alkyl chains 
than this compound elicited progressively slower rates 
of displacement . All the fatty acids tested between 
hexanoic (C5) acid and myristic (C13) acid produced Type I 
binding spectra with cytochrome P-450. The Ks values 
for the binding of the various carboxylic acids to 
microsomes from untreated animals showed a progressive 
decline as the length of the substituent alkyl chain was 
increased, with the Cxo^ Cxx and Cx3 derivatives having 
the lowest Kg values and hence the greatest apparent 
affinity for cytochrome -P-450 (Table 5.1.).
[*C3 etc. refers to the number of carbon atoms 
in the alkyl chain, R, in the general formula for 
carboxylic acids, R-COOH].
5.2.3. n-Alkylcarbamates as displacers
A number of n-alkylcarbamates were tested for 
activity as displacing agents and the results are shown 
in Fig. 5.5. The rate of dissociation of the complex 
at a fixed displacer concentration (1.0 mM) increased 
with increasing length of the alkyl chain up to decyl- 
carbamate (log P = 3.74). Higher analogues possessed 
lesser displacing ability. The addition of methyl- or
FIGURE 5.4.
Dissociation of the isosafrole metabolite 
cytochrome P—450 complex by a series of 
normal carboxylic acids
■10 ■17
o
o
c
1 -
0 31 2 4 5 7 86
Log p
Isosafrole microsomes (2 mg protein/ml) in 66 mM 
Tris-HCl (pH 7.4) were added to a cuvette and 
allowed to equilibrate at 37°C for 5 min. The 
carboxylic acid (1 mM) was added to the cuvette 
and the initial rate of dissociation of the iso­
safrole metabolite-cytochrome P-450 complex 
(expressed as A E ^ 38-^9o/min/2 mg protein) was 
recorded. These values were plotted against log P 
(log octanol/water partition coefficient) values 
(abscissa). The spectra were recorded in the dual 
wavelength mode (X-i = 438 nm, A2 = 490 nm) . Points 
represent the mean of two or more determinations. 
C 3 , Ciif C 5 etc. represent the number of carbon 
atoms in the n-alkyl substituent of the molecule.
TABLE 5.1. Ks values for the binding of 2-n-alkyl- 
benzimidazoles, n-alkylcarbamates and 
carboxylic acids to cytochrome P-450 and 
the log P values of these .compounds.
H
R = Spectrum Ks (JIM)* Log P
methyl RI 420 1.96
ethyl RI 710 2.48
propyl RI 1000 2.96
butyl RI 2500 3.48
pentyl RI 380 3.96
hexyl I 0.40 4.48
heptyl I 0.33 4.96
octyl I 0.37 5.48
nonyl I 0.48 5.96
R--o-co-nh2 n-alkylcarbamates
R = Type of Spectrum Ks (jiM) Lo g P
butyl I 1900 0.74
pentyl I 930 1.29
hexyl I 500 1.74
heptyl I 170 2.29
octyl I 71 2.74
decyl I 35 3.74
dodecyl I N.A.I 4.74
tetradecyl RI - N.A. 5.74
TABLE 5.1. (cont.)
R-COOH Carboxylic acids
R = Type of Spectrum Ks (jiM)* Log P
propyl N.A. if N.A. 0.79
butyl N. A. N.A. 1.35
pentyl I 500 1.90
hexyl I 2100 2.45
heptyl I 345 3.00
octyl I 161 3.55
nonyl I 128 4.09
decyl I 78 4.65
undecyl I 79 5.20
tridecyl I 67 6.30
pentadecyl N.A. N.A. N.A.
heptadecyl N.A. N.A. N.A.
Ks values are the apparent spectral dissociation constants 
of compounds binding to cytochrome P-450.
+
log P values are the logi0 ■°f the octanol/water partition 
coefficients.
In .A. = not available.
FIGURE 5.5.
Dissociation of the isosafrole metabolite- 
cytochrome P-450 complex by a series of 
n-alkylcarbamates
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Conditions as in Fig. 5.4., except that 
n-alkylcarbamates (1 mM) were used to 
elicit displacement.
ethylcarbamate to isosafrole microsomes resulted in a 
very weak Type RI binding spectrum, with no time-dependent 
decrease in absorbance at 438 nm. However, butyl-, pentyl-, 
hexyl-, heptyl-, octyl- and decylcarbamate showed progressively 
greater activity as displacers (Fig. 5r. 5.) accompanied by 
a corresponding increase in affinity for cytochrome P-450 
as shown by their K values with control microsomesb
(Table 5.1.) .
5.2.4. 2-n-Alkylbenzimidazoles as displacers
2-n-Alkylbenzimidazoles have been shown 
(Dickins et 1975, 1976) to interact with cytochrome
P-450 in a variety of modes. Types I, RI or mixed Type 
I/RI spectra were obtained following the addition of 
these compounds to microsomal suspensions (Table 5.1. and 
Chapter 3). The type of binding spectrum obtained was 
dependent on the state of induction of the microsomes 
(i.e. either control, phenobarbitone- or 20-methylcholanthrene- 
induced microsomes), the specific 2-alkyIbenzimidazole 
tested and the substrate concentration. The results are 
described more fully in Chapter 3.
The type of spectrum observed on the addition 
of 2-alkylbenzimidazoles to isosafrole microsomes was 
dependent upon the length of the alkyl substituent.
The short chain analogues (2-methyl- and 2-ethyIbenzimidazole) 
produced atypical displacement spectra as shown in Figs. 5.6a,b. 
Fig. 5.6a shows the time-dependent spectral changes elicited
FIGURE 5.6(a)
, 2-MethyIbenzimidazole as a displacer
0-002 A
430
wavelength, nm
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Conditions as in Fig. 5.1., except that 2-methy1- 
benzimidazole (250 jiM) was used as a displacing agent. 
0-0, baseliney •-©, initial binding spectrum. The 
other spectra were recorded 5(T~?) and 10(*-a) min 
after the addition of 2-methyIbenzimidazole.
FIGURE 5.6(b) 
2-E.thylbenzimidazole as a displacer
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Conditions as in Fig. 5.1., except that 
2-ethyIbenzimidazole (1 mM) was used as 
a displacing agent. 0-0, baseline? 
spectrum 1 was the initial binding spectrum. 
Spectra 2-9 were recorded at successive 
2.5 min intervals after the addition of 
2-ethyIbenzimidazole.
following 'the addition of 2-methylbenzimidazole to 
isosafrole microsomes, and Fig. 5.6b illustrates 
displacement by 2-ethyIbenzimidazole. Initially, both 
compounds elicited a Type RI spectrum with isosafrole 
microsomes which became progressively modified with time. 
The minimum at 390 nm was decreased and shifted to about 
380 nm (Fig. 5.6b) and the maximum at 420 nm was 
increased and also underwent a hypsochromic shift.
However, in both cases an entity with an absorbance minimum 
at 438 nm was formed which increased with time, indicative 
of the dissociation of the isosafrole metabolite-cytochrome 
P-450 complex.
2-Propyl- and 2-butylbenzimidazole produced 
a mixed Type RI/I spectrum with isosafrole microsomes 
which showed a time-dependent increase in absorbance at 
395 nm. This produced a prominent shoulder on the 
difference spectral peak which intensified and underwent 
a hypsochromic shift as shown in Fig. 5.6c. The 
AEij.33 — i+9o absorbance change also increased with time.
2-PentyIbenzimidazole and higher analogues 
produced typical displacement spectra with isosafrole 
microsomes i.e. a Type I binding spectrum which 
intensified and became modified with time, showing 
an enhanced absorbance maximum at 395 nm and an enhanced 
minimum at 438 nm (Fig. 5.6d).
As the length of the 2-alkyl substituent 
was increased the rate of displacement was also increased.
FIGURE 5.6(c)
2-PropyIbenzimidazole as a disp.lac.er
Conditions as in Fig. 5.1., except that 
2-propyIbenzimidazole (1 mM) was used as 
a displacing agent. Spectrum 1 was the 
initial binding spectrum, and the spectrum 
was scanned repetitively every minute 
(scans are numbered in sequence).
FIGURE 5.6(d)
2-HeptyIbenzimidazole as a displacer
0-01E
360 380 400 440420 nm 400
Conditions as in Fig. 5.1., except that 
2-hepty Ibenzimidazole (200 jiM) was used 
as a displacing agent. The spectrum was 
scanned repetitively every 15 s.
The optimal displacing compound was the C7 derivative, 
2-heptyIbenzimidazole (log P = 4.96) (Fig. 5.7.); as for 
the carbamate and carboxylic acid series, displacing 
ability decreased with compounds possessing longer or 
shorter chains than the optimal compounjd (Fig. 5.7.).
Table 5.1. shows the Ks values for the binding of 
2-alkylbenzimidazoles to phenobarbitone-induced microsomes. 
The compounds with the lowest Kg values (the C6-C9 
derivatives) showed considerably greater activity as 
displacing agents than the lower analogues (Fig. 5.7.).
5.2.5. Other compounds as displacers
A number of other compounds were found to be 
capable of dissociating the isosafrole metabolite-cytochrome 
P-450 complex (Table 5.2.). Several groups of compounds 
including well-established model substrates of cytochrome 
P-450, MDP compounds, alkanes, alcohols and steroids 
dissociated the complex at varying rates. Table 5.2 (i) 
shows certain groups of compounds which elicited 
displacement at a substrate concentration of 200 jliM .  The 
rates of displacement given by 2-heptyIbenzimidazole and 
decylcarbamate are included for comparison. Typical 
substrates of cytochrome P-450-mediated reactions, 
biphenyl, 7-ethoxycoumarin, cyclohexane and 4-nitroanisole 
all produced similar rates of displacement. MDP compounds 
showed greater activity than other cytochrome P-450 
substrates as displacers, but methylenedioxybenzene, 
which lacks the 4-substituent group, possessed about 
half the displacing ability of most of the other MDP
FIGURE 5.7.
Dissociation of the isosafrole metabolite* 
cytochrome P-450 complex by a series of 
2-n-alkylbenzimidazoles
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Conditions as in Fig. 5.4., except that 
2-n-alkylbenzimidazoles (200 p.M) were 
used as displacers and the microsomal 
protein concentration was 1 mg/ml. The 
initial rate (of displacement) is 
expressed as AEi*33-1+ 9o/min/mg protein.
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compounds. The straight-chain alkanes, hexane and heptane 
and the endogenous steroid molecules, progesterone and 
testosterone all possessed displacing activity and initially 
produced Type I binding spectra with isosafrole microsomes.
Table 5.2(ii) illustrates a number of 
displacers which exert an effect only at higher substrate 
and complex concentrations (1.0 mM and 2 mg/ml microsomal 
protein respectively). The MDP compound, piperonyl 
butoxide is a much weaker displacer than the other MDP 
derivatives in Table 5.2 (i). Pentane was found to possess 
appreciable displacing activity. A group of alcohols 
(which produced mixed Type RI/I initial binding spectra 
with isosafrole microsomes) were fairly weak displacers, 
with decan-l-ol being comparable to undecanoic acid and 
decylcarbamate in its displacing activity.- Cortisol 
(a Type RI compound) and oestradiol~17g produced 
detectable dissociation of the metabolic intermediate 
complex, but these compounds were much weaker than 
testosterone and progesterone as displacing agents.
5.2.6. Compounds inactive as. displacing agents
The investigation of the displacing activity 
of a large number of compounds which bind to cytochrome 
P-450 revealed that the vast majority of displacers 
produced a Type I binding spectrum with hepatic microsomal 
suspensions from untreated animals. The short-chain 
2-alkylbenzimidazoles which produced Type RI (Table 5.1.)
and the higher alcohols which elicited mixed Type RI/I 
spectral changes (Table 5.2 (ii)) were the only examples 
of compounds which did not produce solely Type I spectra 
and yet were displacing agents. Typical Type RI compounds 
such as ethanol were inactive. None of the compounds 
which produce Type II binding spectra (such as metyrapone, 
imidazole, benzimidazole, aniline and n-octylamine) 
elicited the displacement phenomenon.
Thus, it appeared that, with few exceptions, 
Type I substrate binding was essential for a compound to 
be a potential displacing agent. However, not all 
substrates of cytochrome P-450 brought about dissociation 
of the isosafrole metabolite-cytochrome P-450 complex. 
SKF-525A, ethylmorphine and aminopyrine which are 
metabolized principally by phenobarbitone-inducible 
cytochrome P-450 were all inactive as displacers and 
benzo(a)pyrene, a cytochrome P-448 substrate, was also 
unable to dissociate the complex. Hence, displacement 
is not a necessary consequence of Type I binding.
5.2.7. Effects of oxygen and temperature on the
displacement process
Oxygen was not essential for the displacement 
process to occur. Using 2-heptyIbenzimidazole as a 
displacing agent, the initial rate of dissociation of 
the complex was identical under aerobic and anaerobic 
conditions^ anaerobiosis was established as described in 
Chapter 2. However, the displacement reaction was
found to be sensitive to changes in the temperature of 
the reaction medium. Fig. 5.8. illustrates the effect 
of temperature changes on the rate of displacement 
elicited by 2-heptyIbenzimidazole. Two temperature 
ranges (11-28°C and 17-36°C) were utilized with saturating 
concentrations of displacing agent. The slopes of the 
Arrhenius plots for the two experiments were identical 
and an activation energy of 34.5 kcal/mol was calculated 
for the displacement process. No break or discontinuity 
in the line was detected in either experiment.
5.2.8. Dissociation of the isosafrole metabolite-
cytochrome P-450 complex formed vitro
A number of MDP compounds (including isosafrole) 
have been shown to be potent displacers (Table 5.2(i)). 
Following the addition of isosafrole (200 jllM )  to 
oxidized microsomes from rats pretreated with isosafrole, 
a typical displacement spectrum (cf. Figs. 5.1. and 5.6d) was 
observed and complete dissociation of the isosafrole 
metabolite-cytochrome P-450 complex was facilitated after 
30 min at 37°C. Displacement was considered to be 
complete when the sodium dithionite-reduced difference 
spectrum did not show an absorbance maximum at 455 nm.
In contrast, when isosafrole was added to oxidized control, 
phenobarbitone- or 20-methylcholanthrene-induced 
microsomes, a typical Type I binding spectrum was observed 
which did not show the time-dependent increase or spectral 
shift described in 5.2.1.
FIGURE 5.8.
Effect of temperature on the dissociation 
of the isosafrole metabolite-cytochrome 
P-450 complex
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Isosafrole microsomes were suspended in 
66 mM Tris-HCl (pH 7.4) and allowed to 
equilibrate at different temperatures in 
a range of 11-36°C. 2-HeptyIbenzimidazole 
was added to the cuvette and the initial 
rate of displacement was recorded. The 
log initial rate of displacement (ordinate) 
was plotted against the reciprocal of the 
absolute temperature (abscissa). Specific 
conditions (upper graph), isosafrole 
microsomes (1 mg protein/ml) and 2-hepty1- 
benzimidazole (250 p.M) over a temperature 
range of 17-36°C (290-309 K); lower graph, 
isosafrole microsomes (2 mg protein/ml) and 
2-hepty Ibenzimidazole (400 jj,M) over a 
temperature range of 11-28°C (284-301 K).
When NADPH was added to the various oxidized 
microsomal preparations containing isosafrole (which had 
been incubated at 37°C for 30 min in the presence of the 
MDP compound), maxima at 427 and 455 nm developed with 
time. Incubation was continued for 30 min and the 
microsomes were subjected to AmberliteR XAD-2 (polystyrene) 
chromatography and dialysis for 12 h {versus 66 mM Tris- 
HC1 (pH 7.4) containing 5.4 mM EDTA and 0.5% (w/v) bovine 
serum albumin). When the sodium dithionite-reduced 
difference spectrum of the dialysed isosafrole microsomes 
was recorded, a maximum at' 455 nm was observed, indicative 
of the presence of the isosafrole metabolite complex 
generated in vitro. The addition of 2-heptylbenzimidazole 
(200 jj.M) to a portion of the oxidized dialysed suspension 
of isosafrole-induced microsomes elicited a typical 
displacement spectrum. The addition of 2-heptylbenzimidazole 
to the oxidized dialysed microsomes from control, 
phenobarbitone- or 20-methylcholanthrene-induced animals 
after formation of the in vitro isosafrole-metabolite 
complex did not elicit displacement spectra.
5.3. DISCUSSION
Various series of compounds were tested for 
their ability to dissociate the in vivo generated rat 
hepatic microsomal isosafrole metabolite-cytochrome P-450 
complex. The alkylcarbamates, carboxylic acids and 
alcohols tested all displaced the metabolite from cytochrome 
P-450 (Table 5.2.). Alkylcarbamates and carboxylic 
acids produce Type I binding spectra with cytochrome P-450
(Al-Gailany, 1975) whereas lower alcohols elicit Type RI 
spectra and higher alcohols i.e. pentan-l-ol, hexan-l-ol, 
etc., produce additive Type RI/I binding spectra (Yoshida 
and Kumaoka, 1975).
The lowest effective log P necessary for 
displacement to occur was about 1.0 and the optimal log P . 
was between 3.0 and 5.0. The Ks values for the carbamates 
and fatty acids used in this study supported the hypothesis 
that lipophilicity was important for displacement. A 
correlation has been obtained between the log P and log Ks 
values for the substrate-cytochrome P-450 interaction for 
these two series of compounds (Al-Gailany, 1975). As 
the alkyl chain length was increased (and consequently 
the lipophilicity), the corresponding Kg value decreased 
and the initial rate of displacement of the isosafrole 
metabolite increased. For each series an optimal carbon 
chain length existed; this compound produced the greatest 
rate of displacement at a fixed displacer concentration. 
Further increase in chain length beyond this optimum 
produced a decrease in the displacement rate despite 
the fact that the Ks value for the higher members of 
each series did not change appreciably.
An optimal chain length of ten carbon atoms 
was obtained for the alkylcarbamates, carboxylic acids 
and alcohols tested. This C10 chain seemed to be 
independent of the properties of the respective functional 
group (-O.CO.NH2; -C00H; or -OH). The Ciq carbamate
(log P = 3.74), fatty acid (log P = 4.65) and alcohol 
(log P = 4.03) showed very comparable displacement rates.
It is noteworthy that the straight-chain alkanes, pentane, 
hexane and heptane were even better displacers than the 
Cio carbamate, alcohol and carboxylic acid. Thus the 
presence of a functional group capable of binding through 
an ionic interaction or through hydrogen bonding is not 
an essential characteristic of displacers, and such 
groupings may even retard the rate of dissociation of 
the cytochrome P-450-isosafrole metabolite complex. The 
difference in displacer activity between alkanes and 
compounds containing polar groups may be linked to the fact 
that alkanes have a higher affinity for cytochrome P-450.
Among the series of 2-alkylbenzimidazoles are 
the compounds which gave the greatest initial rates of 
displacement of the isosafrole metabolite-cytochrome 
P-450 complex. These compounds were tested as displacers 
following the observation that the higher members of 
the series had an extremely high affinity for cytochrome 
P-450 (Kg. <1.0 jiM, Table 5.1.) and elicited Type I binding 
spectra when added to hepatic microsomes (Chapter 3). 
Further, the benzimidazole nucleus is very similar in 
dimensions to the methylenedioxyphenyl grouping and the 
two nuclei are thus sterically analogous. The optimal 
displacing compound was 2-heptylbenzimidazole (log P =
4.»96) and a slower rate of dissociation of the metabolic 
intermediate complex was given by 2-alkylbenzimidazoles
with longer or shorter side-chains. 2-Heptylbenzimidazole 
had a very low Ks value for Type I binding to cytochrome 
P-450 (0.3 p.M) , (cf. decylcarbamate (35 jj.M) and undecanoic 
acid (78 jllM) .
A small number of compounds which produced 
Type RI spectra also elicited displacement of the isosafrole 
metabolite. A possible explanation for this finding is 
that the Type RI spectrum elicited by these compounds 
conceals a Type I component, and hence Type I and Type 
RI interactions with cytochrome P-450 may occur 
simultaneously. A number of compounds which have been 
shown to be metabolized by a cytochrome P-450-dependent 
enzyme elicit Type RI or mixed Type RI/I spectral changes 
with rat hepatic microsomes e.g. phenacetin (Schenkman 
et at.j 1972a), agroclavine (Orrenius et at.3 1972), 
lysergic acid diethylamide (Niwaguchi and Inoue, 1975) and 
acetanilide (Dickins, unpublished observations).
Thus, the displacers which initially elicited 
Type RI binding spectra with isosafrole microsomes, 
produced time-dependent spectral changes which included 
a progressively decreased absorbance at 438 nm. The 
other spectral shifts which were observed (described in 
5.2.4.) presumably represented a composite spectrum 
manifested by the dissociation of the isosafrole metabolite- 
haemoprotein complex together with binding of the compound 
to both the cytochrome P-450 released (presumably Type I) 
and uncomplexed or "free" haemoprotein (Type RI). The
form of-spectral change was probably determined by whether 
the displacing agent was a Type I or a Type RI substrate. 
Thus 2-methyl- and 2-ethylbenzimidazole merely showed a 
blue shift of both the 390 nm minimum and 420 nm maximum 
observed immediately after the addition of these compounds 
to isosafrole microsomal suspensions (Figs. 5.6a,b). 
2-Propyl- and 2-butylbenzimidazole which are more lipo­
philic and have lower affinity for the Type RI binding 
site (and hence probably greater affinity for the Type 
I site) produced slightly greater rates of displacement 
than the lower analogues, and manifested greater Type I 
character in the spectra observed when the propyl and 
butyl derivatives were added to isosafrole microsomes 
i.e. a shoulder at 395 nm was seen (Fig. 5.6c). The 
higher 2-alkylbenzimidazoles (all of which produced 
exclusively Type I initial binding spectra with isosafrole 
microsomes) showed markedly enhanced displacing ability 
(Figs. 5.6d and 5.7).
However, the majority of compounds which 
elicited.Type RI spectra with undisplaced isosafrole 
microsomes did not displace the isosafrole metabolite.
Thus classical Type RI compounds such as the lower 
alcohols (ethanol, propan-l-ol, butan-l-ol, log P - 
-0.32 - +0.88) were inactive, whereas the more lipophilic 
long chain alcohols (octan-l-ol, decan-l-ol and undecan-l-ol 
log P = 3.03 - 4.53) were active, presumably because of 
their increased Type I character (Yoshida and Kumaoka, 1975)
None of the Type II compounds tested elicited
\
displacement. Relatively polar Type II molecules such 
as imidazole (log P = 0.08) and benzimidazole (log P =
1.46) failed to dissociate the complex, but the addition 
of a methyl group in the 2-position of the benzimidazole 
nucleus produced a compound (log P = 1.96) which elicited 
a Type RI spectrum and also had displacing ability. Even 
the addition of an n-alkyl chain to a molecule which 
conferred lipophilicity to a Type II compound 
e.g. n-octylamine (log P = 2.90) did not facilitate 
displacement.
In summary, various factors seem to be important 
for effective dissociation of the isosafrole metabolite- 
cytochrome P-450 complex to occur. (1) The overall 
dimensions of the displacing molecule determines the 
potency of that compound as a displacer. In the series 
of compounds examined, an optimal physical size was noted. 
From molecular models of the best displacers of each series 
of compounds tested (i.e. decan-l-ol, undecanoic acid, 
decylcarbamate and 2-heptylbenzimidazole), it could be 
seen that all were of similar size. (2) A certain degree 
of lipophilicity was essential. In general, lipophilic 
molecules were good displacers whereas hydrophilic molecules 
were not. Furthermore, by conferring an increased degree 
of lipophilic character to a grouping, a corresponding 
increase was noted in displacing ability resulting in an 
optimal displacer for each series. However, since
further addition to the alkyl chain elicited decreased 
displacing activity, steric factors are possibly more 
important. (3) The affinity of the displacer for cytochrome 
P-450 and the type of binding spectrum elicited with 
oxidized microsomes.. In general, the compounds which 
had the greatest affinity for cytochrome P-450 were the 
best displacers. However, other factors are also important 
e.g. piperonyl butoxide (log P = 5.20) which has a K_O
value of 5 jiM, was a weak displacer. This is possibly 
due to the physical dimensions of the piperonyl butoxide 
molecule since other smaller MDPs tested were potent 
displacing agents. Only substrates which produced Type I 
binding spectra were active displacers. Some Type RI 
compounds were weak displacers but Type II molecules 
were inactive, thus illustrating that the nature of the 
binding of a compound to cytochrome P-450 is important.
Hence a combination of appropriate size, lipophilicity 
and affinity for the Type I binding site of cytochrome 
P-450 made it possible to predict whether or not a 
molecule would be an active displacer.
How does one envisage the displacement reactions 
The isosafrole metabolite appears to be bound to the haem 
moiety of cytochrome P-450 and Type I compounds are 
displacers whereas Type II compounds are not (Gray, 1973 > 
Elcombe et aZ., 1975a).
It seems improbable that the displacement 
mechanism is one of simple competition for binding sites
since the proposed carbene group of the isosafrole metabolite 
(Chapter 4) is almost certainly bound to the iron of the 
haem i.e. the Type II site (Ullrich et at. 3 1975a).
However, it is plausible that the isosafrole metabolite 
is a bidentate ligand, binding to both the Type I site 
(protein) and the Type II site. In the Fe2+ state a 
highly stable Fe-carbene (iron-carbon) bond would be 
produced which would be further stabilized by pi back- 
bonding (a donation of electrons from the iron atom to 
the carbon) and would be very difficult to displace.
In the Fe3+ state the complex would be less stable since 
the pi back-bonding would not be a preferred configurational 
state. Hence, dissociation of the Fe-C bond and concomitant 
displacement of the metabolite could occur. It is proposed 
that the methylene carbene of the isosafrole may interact 
with the haem moiety while the propenyl side-chain is 
embedded in the hydrophobic Type I binding site of tlie 
cytochrome P-450. Although many lipophilic substances 
are capable of dissociating the isosafrole metabolite- 
oxidized cytochrome P-450 complex, access to the displacer 
site may be limited as evidenced by the lack of, or 
decreased displacing ability of large lipophilic molecules.
As no typical Type II compounds elicited displacement, it 
appears that the initiating reaction for displacement is 
the breaking of a link between the metabolite and the 
apoprotein portion of cytochrome P-450.
An explanation of the spectral changes observed 
during the displacement process is shown in Fig. 5.9. 
Initially (A) the difference spectrum is a flat baseline 
since the oxidized isosafrole metabolite-cytochrome P-450 
complex (manifested by a minimum at 420 nm and a maximum 
at 438 nm) is present at the same concentration in both 
sample and reference cuvettes. On addition of a Type I 
displacing agent to the sample cuvette (B),. the Type I 
binding spectrum is initially observed as the difference 
spectrum (due to an increase in absorbance at 390 nm and 
a decrease at 420 nm). With increasing time, the MDP 
metabolite complex is dissociated in the sample cuvette 
but not in the reference cuvette (C). Hence the difference 
spectrum undergoes a time-dependent increase in absorbance 
at 390 nm (due to more substrate binding, eliciting an 
increased Type I spectrum) and a decrease in absorbance 
at 438 nm (due to the dissociation of the 438 nm absorbing 
species in the sample cuvette but not in the reference).
In the difference spectrum an isosbestic point was typically 
observed at about 420 nm because dissociation of the 
complex produced an increase in absorbance at this 
wavelength whereas the increased Type I (substrate) binding 
caused a decrease in absorbance at 420 nm. These two 
phenomena appeared to be mutually cancelling. An 
isosbestic point at 420 nm was not observed for the 
Type RI displacement spectra, presumably due to the 
enhanced binding spectrum containing both Type I and 
Type RI components.
FIGURE 5.9.
Diagrammatic explanation of the spectral changes 
observed during the displacement process
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Although oxygen has been shown to be essential 
for the formation of the MDP metabolite-cytochrome P-450 
complex in vitro (Franklin, 1971) the dissociation of the 
in vivo MDP metabolite complex did not require oxygen.
The displacement process is not therefore due to metabolism 
of the MDP compound and this is further substantiated by 
the fact that displacement was unable to occur in the 
presence of NADPH (or other reducing agents) (Elcombe 
et at.j 1975a). However, dissociation of the complex 
was found to be extremely sensitive to changes in 
temperature, and the initial rate of displacement was 
found to increase linearly over a temperature range of 
11°-36°C. The activation energy of the displacement 
process (calculated from an Arrhenius plot (Fig. 5.8.) 
as 34.5 kcal/mol) was somewhat higher than the values 
obtained for cytochrome P-450~dependent monooxygenations 
(Duppel and Ullrich, 1976* Yang et al.3 1977).
Unlike the Arrhenius plots constructed for 
various monooxygenase reactions (Duppel and Ullrich,
1976; Birkett, 1977; Yang et 1977) no break in the
curve at temperatures of about 20-25°C was detected
for the displacement process. This temperature range corresponds
to the temperature (23°C) at which a change in membrane
fluidity, as detected by EPR, has been demonstrated
(Raison, 1972) and this has been thought to affect the
lipid environment of cytochrome P-450 (Stier, 19 76). This
again illustrates a major difference between metabolism and
the displacement process, suggesting that the fluidity- 
state of the lipid environment does not influence 
displacement over the temperature range examined.
Although MDP metabolite-cytochrome P-450 
complexes are readily generated in vitro (Franklin,
1971; Philpot and Hodgson, 1971a), the dissociation of 
an in vitro generated complex has not been observed 
using control, phenobarbitone- or 20-methylcholanthrene- 
induced microsomes as the enzyme source (Elcombe et 
1975a; Elcombe, 1976 and this chapter). However, following 
the complete dissociation of the in vivo metabolite complex 
from isosafrole microsomes, an in vitro isosafrole 
metabolite-cytochrome P-450 complex was formed and spectral 
displacement was observed in a similar fashion to the 
in vivo complex. This suggests that the species of 
haemoprotein which binds the isosafrole metabolite in a 
form which may be dissociated by the addition of a Type I 
substrate is present only in isosafrole-induced microsomes. 
Thus it may be hypothesized that the administration of 
isosafrole induces the formation of a novel haemoproteih 
or alters the properties of existing haemoprotein by a 
conformational change which enables a stable MDP-metabolite 
complex to be formed in vivo. Since other MDP compounds 
are known to form similar in vivo complexes (Parke and 
Rahman, 1971; Elcombe et at,a 1975a; Franklin, 1976a) 
this may be a feature common to MDP compounds. Evidence 
which supports the hypothesis that isosafrole induces a 
novel haemoprotein to which isosafrole-related material 
is bound in vivo is presented in the following chapter.
CHAPTER 6
CHARACTERIZATION OF MICROSOMAL HAEMOPROTEINS 
USING SODIUM DODECYL SULPHATE-POLYACRYLAMIDE 
GEL ELECTROPHORESIS
6. CHARACTERIZATION OF MICROSOMAL HAEMOPRQTEINS
USING SODIUM DODECYL SULPHATE-POLYACRYLAMIDE 
GEL ELECTROPHORESIS
6.1. INTRODUCTION
Recently, much evidence has accumulated for 
the existence of multiple forms of cytochrome P-450.
Sodium dodecyl sulphate (SDS)-polyacrylamide gel 
electrophoresis has proved to be a useful means of 
separating various cytochrome P-450 species by virtue 
of their differing molecular weights (Alvares and 
Siekevitz, 1973; Welton and Aust, 1974). Hepatic 
microsomal proteins of molecular weight about 50,000 
were initially thought to be cytochrome P-450 apoproteins 
(Siekevitz, 1973) and this was subsequently confirmed 
by the use of a peroxidase staining technique to detect 
haem on SDS-polyacrylamide gels (Welton and Aust, 1974). 
SDS-gel electrophoresis is now used routinely to determine 
the molecular weight of purified cytochrome P-450 species 
(Haugen and Coon, 1976; Ryan et at. 3 1977).
Phenobarbitone and 20-methylcholanthrene 
are inducers of cytochrome P-450 and associated mono­
oxygenase activity. These compounds have been shown to 
induce haemoproteins with different characteristics, 
including different molecular weights. Thus phenobarbitone- 
and 20-methylcholanthrene-inducible apoproteins are 
readily separated by SDS-gel electrophoresis (Welton 
and Aust, 1974).
Isosafrole has also been shown to be a potent 
inducer of hepatic drug metabolism (Parke and Rahman,
1970; Lake et 1973) and cytochrome P-450 (Lake and
Parke, 1972). Experiments were designed to study the 
induction of microsomal haemoprotein brought about by 
isosafrole and several other MDP compounds using SDS-gel 
electrophoresis. The effects of co-administration of 
isosafrole and either phenobarbitone or 20-methylchol- 
anthrene were also observed.
6.2. RESULTS
6.2.1. Comparison of the induction of microsomal
haemoproteins by phenobarbitone, 20-methyl- 
cholanthrene, isosafrole and pregnenolone 
16a-carbonitrile
Hepatic microsomal suspensions from rats 
treated with phenobarbitone, 20-methylcholanthrene, 
isosafrole, and oil and water vehicles, were solubilized 
and subjected to SDS-gel electrophoresis. One faint 
and four distinct bands in the 50,000-60,000 mol. wt. 
region were observed for control (oil or water) 
microsomes after staining for protein with Coomassie blue 
(Fig. 6.1.). These bands are numbered 1-5 on the basis 
of increasing molecular weight. The mol. wts. were 
obtained by comparison with a number of standard molecular 
weight proteins run in parallel (Fig. 6.2.). Band 1 
(49,000 mol. wt.) was found to have the same electro­
phoretic mobility as homogeneous purified epoxide hydratase. 
Band 2 (50,000 mol. wt.) was the most intense band
FIGURE 6.1.
SDS-Polyacrylamide gel electrophoresis of 
rat hepatic microsomes from animals 
treated with phenobarbitone, 20-methyl- 
cholanthrene, isosafrole, oil or water
Rat hepatic microsomes were solubilized and 
subjected to gel electrophoresis as described 
in Methods. After electrophoresis, the gel 
was stained for protein with Coomassie Blue 
G-250, Samples were microsomes from rats 
treated with the following:- Wells 1 and 2, 
phenobarbitone (15 and 30 yg protein); 3 and 4, 
20-methylcholanthrene (15 and 30 yg); 5 and 6, 
isosafrole (15 and 30 yg); 7 and 8, oil (15 and 
30 yg); 9 and 10, water (15 and 30 yg). The 
arrows on the left denote the positions of 
proteins 1,2,3,4 and 5; origin is at the top 
of the gel.
FIGURE 6.2.
SDS-Polyacrylamide gel electrophoresis of 
standard molecular weight proteins
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Standard molecular weight proteins were dissolved 
in 62.5 mM Tris-HCl (pH 6.8) containing 2.3% (w/v) 
SDS, 15% (v/v) glycerol, 5% (v/v) mercaptoethanol, 
and 0.001% (w/v) bromophenol blue. 2 yg of each 
protein was applied to the gel in parallel with the 
solubilized microsomal samples. The proteins used 
were chymotrypsinogen A (mol. wt. = 25,000), aldolase 
(40,000), hen egg albumin (45,000), catalase (60,000) 
and bovine serum albumin (67,000). Determination of 
the molecular weight of microsomal proteins was 
carried out by comparing their mobilities with those 
of the standard mol. wt. proteins from a graph of 
log mol. wt. versus mobility.
observed in control microsomes after staining for protein. 
Band 3 (54,000 mol. wt.) was hardly visible whereas 
bands 4 and 5 (58,000 and 60,000 mol. wt. respectively) 
were relatively prominent. In phenobarbitone microsomes 
band 2 was markedly increased, band 3 was increased 
slightly, and bands 4 and 5 remained at the same intensity 
when compared with control microsomes (Table 6.1.). 
20-Methylcholanthrene microsomes showed no increase in
«ST y
bands 2^ a small increase in band 3 and a large increase 
in band 4 compared with control microsomes. In contrast, 
isosafrole microsomes showed a major increase in band 3, 
but no increases in the other bands relative to control 
microsomes with the exception of band 2 where a slight 
increase was noted.
Thus, phenobarbitone and 20-methylcholanthrene 
treatment preferentially induced cytochrome P-450 apoproteins 
of 50,000 and 58,000 mol. wt. respectively, whereas 
isosafrole induced a protein with a molecular weight of
54,000. The 54,000 mol. wt. band was barely visible 
in control microsomes. Both phenobarbitone and 20-methyl- 
cholanthrene treatment slightly increased the band of
54,000 mol. wt. as well as their own major bands (50,000 
and 58,000 mol. wt. respectively)..
Fig. 6.3. shows densitometric scans of slices 
taken from a gel prepared under identical conditions 
to the gel in Fig. 6.1. Each scan represents the total 
microsomal protein sample applied to each sample well
TABLE 6.1.
Changes in the concentration of the 50,000, 54,000 and
58,000 molecular weight bands following pretreatment 
with phenobarbitone, 20-methylcholanthrene or isosafrole
Pretreatment 50,000 54,000 58,000
Phenobarbitone ++ ± -
20-Methylcholanthrene - + ++
Isosafrole ± ++
Signs represent changes in extinction (compared with controls) 
of the Coomassie Blue-stained gels measured using a Gilford 
spectrophotometer 2400 at 560 nm (slit width = 2 mm, scanning 
speed = 2 cm/min).
+ indicates an increase of between 20 - 50% 
++ indicates an increase of >50%.
FIGURE 6.3.
Densitometrie scans of the electropherogram 
of rat hepatic microsomes from animals 
treated with phenobarbitone, 20-methyl- 
cholanthrene, isosafrole, oil or water
Segments of a Coomassie Blue-stained gel prepared 
under identical conditions to that shown in Fig.
6.1. were scanned using a Gilford 2400 spectro­
photometer at 560 nm (slit width = 2 mm, scan 
speed = 2 cm/min). The mol. wt. region 60,000-
45,000 is marked j | } origin is at the left (pKgh f'nob 
each scan.
of the polyacrylamide gel. The major differences in 
the scans were noted in the peaks which were given by 
the stained proteins in the mol. wt. region 45,000 -
60,000. Only the two sets of control microsomes showed 
an identical pattern in this region. Microsomal samples 
from animals treated with 20-methylcholanthrene or 
isosafrole showed evidence of a peak at 54,000 mol. wt. , 
but the peak elicited by isosafrole was far more prominent. 
No peak at 58,000 mol. wt. was observed for the isosafrole- 
induced microsomes.
Pregnenolone 16a-carbonitrile (PCN) has 
recently been shown to induce a specific form of 
cytochrome P-450 in both the rat (Birnbaum et at, ^ 1976) 
and the mouse (Haugen et at,3 1976). Microsomes obtained 
from PCN-treated rats showed that PCN induced a protein 
of similar electrophoretic mobility to the phenobarbitone- 
inducible protein, and hence was of a lower molecular 
weight (about 50,000) than the protein induced by 
isosafrole (54,000) (Fig. 6.4.).
6.2.2. Effect of other MDP compounds on the novel
54,000 molecular weight protein
Various other MDP compounds were tested for 
their ability to induce a protein of 54,000 mol. wt.
The compounds used were safrole, dihydrosafrole, methylene- 
dioxybenzene and piperonyl butoxide. Microsomes isolated 
from animals treated with the MDP compounds were 
solubilized and subjected to SDS-gel electrophoresis and
FIGURE 6.4.
SDS-Polyacrylamide gel electrophoresis of 
hepatic microsomes from rats treated with 
  pregnenolone 16a-carbonitrile
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Conditions as in Fig. 6,1. Samples were 
microsomes from animals treated with the 
following:- Well 1, phenobarbitone (30 yg 
protein); 2, 20-methylcholanthrene (30 yg); 
3, isosafrole (30 yg); 4, oil (30 yg); 5 
and 6 , PCN (15 and 30 yg); 7 and 8, Tween 
80 in water (15 and 30 yg). Wells 9 and 10 
contained standard mol. wt. proteins (1 and 
2 yg of each protein). Origin is at the 
top of the gel.
the results are shown in Fig. 6.5. Safrole and dihydro- 
safrole clearly induced a protein with a molecular 
weight of 54,000 similar to that induced by isosafrole.
In contrast, methylenedioxybenzene produced only a very 
small increase in this protein band and no visible 
increase could be detected with piperonyl butoxide 
microsomes.
The presence of the 54,000 mol. wt. protein 
seemed to correspond to the presence of a spectral change 
observed in the respective microsomal preparations.
In common with isosafrole microsomes, a maximum at 455 nm 
was observed in the sodium dithionite-reduced minus 
oxidized difference spectrum with both safrole and dihydro- 
safrole microsomal preparations. Methylenedioxybenzene 
microsomes gave rise to a shoulder at 455 nm but piperonyl 
butoxide microsomes produced no detectable 455 nm absorbing 
species.
Further evidence for the presence of a 
MDP metabolite complexed with cytochrome P-450 was obtained 
using "off-balance" difference spectroscopy. Microsomes 
from animals treated with isosafrole, safrole, or dihydro- 
safrole (when compared to oil control microsomes in the 
reference cuvette) produced a peak at 438 nm in the 
oxidized state and maxima at 427 and 455 nm in the 
reduced state (Fig. 6 .6 .). Microsomes from animals 
treated with methylenedioxybenzene or piperonyl butoxide 
did not produce the 438 nm (oxidized) or the 455 nm 
(reduced) maxima in similar experiments.
FIGURE 6.5.
SDS-Polyacrylamide gel electrophoresis of 
hepatic microsomes from rats treated with 
different MDP compounds
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Conditions as in Fig, 6.1. Samples were 
microsomes from animals treated with the 
following:- Wells 2 and 12, piperonyl 
butoxide (5 and 10 yg protein)? 3 and 13, 
dihydrosafrole (5 and 10 yg)? 4 and 14, 
20-methylcholanthrene-isosafrole (5 and 
10 yg) •, 5 and 15, phenobarbitone-iso- 
safrole (5 and 10 yg)? 6 and 16, oil-iso- 
safrole (5 and 10 yg)? 8 , phenobarbitone 
(5 yg) •, 9, saline (5 yg) ? 10, oil (5 yg) ? 
11, 20-methylcholanthrene (5 yg). Wells 
1,7 and 17 contained standard mol. wt. 
proteins (1 yg of each protein). Origin 
is at the top of the gel.
FIGURE 6.6.
"Off balance" difference spectrum to demonstrate 
the presence of the oxidized isosafrole 
metabolite-cytochrome P-450 complex in 
. . microsomes from rats treated with isosafrole
430 450 nm 470 490
Microsomes from animals treated with isosafrole 
or oil were resuspended in 66 mM Tris-HCl (pH 7.4) 
to a protein concentration of 1 mg/ml. Isosafrole 
microsomes were added to the sample cuvette and oil 
microsomes to the reference cuvette. The absorbance 
difference at 500 nm in the split beam mode was 
carefully balanced by the addition of small volumes 
of buffer to the cuvettes, and the spectrum was 
scanned between 410 and 500 nm (Spectrum 1). A few 
crystals of sodium dithionite were added to both 
cuvettes and the spectrum was rescanned (Spectrum 2).
6.2.3. Dependence on de novo protein synthesis for 
appearance of the 54,000 molecular weight 
protein
The proteins of 54,000 mol. wt. induced 
following administration of certain MDP compounds do not 
appear to arise from the presence of MDP metabolite being 
bound to the apoprotein of one of the other forms of 
cytochrome P-450. This is deduced from the fact that 
when the MDP metabolite-cytochrome P-450 complex was 
dissociated (by incubation of isosafrole microsomes 
with 2-heptylbenzimidazole for 20 min at 37°C prior to 
solubilization and application to the gel) the 54,000 mol. 
wt. band remained at a similar intensity to undisplaced 
isosafrole microsomes. Furthermore, when -the 427 and;455 nm 
maxima were generated V'itvo using phenobarbitone 
microsomes, isosafrole and NADPH and the microsomes 
applied to a gel, a protein band of 54,000 mol. wt. was not 
observed.
6.2.4. Identification of the 50,000, 54,000 and
58,000 molecular weight proteins as 
haemoproteins
Bands 2, 3 and 4 were identified as haemoproteins 
using the peroxidase staining methods of Welton and Aust 
(1974) and Thomas et al. (1976b). Initially, the method 
of Welton and Aust using a benzidine-hydrogen peroxide 
staining mixture was employed. The microsomes were 
solubilized in a modified sample buffer which contained 
SDS (1% w/v) but did not contain mercaptoethanol. When 
the gel was immersed in the staining solution, the relevant 
bands produced a blue colouration which rapidly turned
brown. The method of Thomas et at. (1976b) was used in 
subsequent experiments to detect the haem associated 
with particular proteins. The staining mixture 
contained 3,31,5,51-tetramethylbenzidine (TMBZ) and 
hydrogen peroxide as the active principles. An intense 
blue colouration was obtained for proteins in the 50,000 
- 60,000 mol. wt. region using this stain (Fig. 6.7.).
Only one other band stained for peroxidase 
activity using either of the haem staining techniques.
This protein had an apparent molecular weight of about
15,000 and was presumed to be cytochrome b5, the other 
major haemoprotein present in microsomes apart from the 
various species of cytochrome P-450.
Several major advantages of the TMBZ stain 
were observed during the course of the haem-staining 
experiments: (i) The gel remained clear with very little
diffusion of the stained bands resulting in greater 
separation and resolution of the bands. If the 
benzidine stain was used, the gel became opaque (making 
photography difficult) and the stained bands diffused.
(ii) The stained bands were stable for several days using 
the TMBZ stain whereas they became very faint only a few 
hours after staining with benzidine and hydrogen peroxide.
(iii) Gels stained with TMBZ and hydrogen peroxide could 
be easily destained and subsequently stained for protein 
using Coomassie blue although the microsomal proteins 
were poorly resolved. Thus gels could be stained for
-FIGURE 6.7.
3,31,5,51-Tetramethylbenzidine (TMBZ)-stained 
SDS-polyacrylamide gel electropherogram of 
rat hepatic microsomes
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Samples were solubilized and subject to 
electrophoresis as described in Methods 
(2.9.2.). The gel was stained for peroxidase 
activity in 250 mM sodium acetate (pH 5.0) 
containing 1.9 mM TMBZ, 30 mM hydrogen 
peroxide and 30% (v/v) methanol. Samples 
were microsomes from rats treated with the 
following:- Wells 1 and 6 , phenobarbitone 
(30 and 45 yg protein)? 2 and 7, saline (30 
and 45 yg)j 3 and 8 , oil (30 and 45 yg) ?
4 and 9, 20-methylcholanthrene (30 and 45 yg) 
isosafrole (30 and 45 yg). Stained bands are 
in the 50,000-60,000 mol. wt. region. Origin 
is at the top of the gel.
peroxidase activity and then for protein. (iv) TMBZ 
has been shown to be non-carcinogenic in animal tests 
in contrast to benzidine (Holland et at., 1974) which is 
well documented as a potent human bladder carcinogen 
(Spitz et at., 1950; Wendel et at., 1974).
Further experiments to identify the proteins 
derived from cytochrome P-450 were carried out using 
microsomes prepared from animals which had received 
isosafrole (26 h before death) and 5-amino [4-14C]- 
laevulinate (i^c-ALA) (2 h before death). The preparation 
of samples for these experiments was similar to that 
described for the samples which were stained for 
peroxidase activity. The radioactivity associated with 
the microsomal proteins in a typical experiment is depicted 
in Fig. 6 .8 . Most of the major radioactivity was 
contained in two regions of the gel corresponding to 
molecular weights of about 50,000 - 60,000 and about 
15,000. These results were in good agreement with the 
results derived from the TMBZ-haem staining experiment 
and identified the proteins in the 50,000 - 60,000 mol. 
wt. regions as haemoproteins. Some of the activity at 
the 15,000 mol. wt. region of the gel may well have been 
due to free haem which had migrated to the bottom of 
the gel, but it is possible that part of the radioactivity 
was associated with a particular protein, i.e. cytochrome
FIGURE 6.8«
Radioactivity associated with microsomal 
proteins following the administration of 
5-amino-[4-14C]laevulinate in vivo .
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Animals were pretreated with isosafrole and 
then received an i.p. injection of 5-amino- 
[4-1^C]laevulinate (470 nmol, 25 yCi) 2 h 
before death. Microsomes were solubilized 
in a similar manner to that described for 
samples stained for peroxidase activity. 
Microsomal protein (120 yg) was applied to 
the gel and electrophoresis was carried out 
as described for samples stained for peroxidase 
activity. Segments of gel containing the 
separated microsomal proteins were cut from 
the gel and placed in scintillation vials. 30% 
Hydrogen peroxide (0.2 ml) was added to each 
vial and the vials were stored overnight. SHT 
solubilizer (1.0 ml), 4.4 M HN03 (0.5 ml) and 
tT21 scintillant (10.0 ml) were added to each 
vial and the vials were taken for radiometric 
assay as described in Methods. The positions of 
proteins of molecular weight 60,000, 50,000 and
15,000 are marked 60K, 50K and 15K respectively.
6.2.5. Comparison of the induction of microsomal
haemoproteins by phenobarbitone-isosafrole,
20-methylcholanthrene-isosafrole and isosafrole
The pattern of induced microsomal cytochrome 
P-450 produced by administration of isosafrole in combination 
with phenobarbitone or 20-methylcholanthrene is shown in 
Fig. 6.9. Microsomes from animals treated with isosafrole 
alone, and isosafrole together with phenobarbitone or 
20-methylcholanthrene all showed the characteristic 
increase in band 3 (54,000 mol. wt.) observed with 
isosafrole microsomes in Fig. 6.1. This increase in 
band 3 was particularly marked in samples from rats 
treated with 20-methylcholanthrene-isosafrole. In 
addition, band 2 was less prominent in microsomes from 
rats treated with phenobarbitone-isosafrole when compared 
with the same band from phenobarbitone-stimulated microsomes. 
However, band 2 was more prominent in phenobarbitone- 
isosafrole microsomes than in isosafrole microsomes, 
indicating that induction of the 50,000 mol. wt. protein 
by phenobarbitone had occurred. Band 4, preferentially 
increased by treatment with 20-methylcholanthrene (Fig.
6 .1 .) seemed to be of similar intensity when 20-methyl- 
cholanthrene microsomes and 20-methylcholanthrene- 
isosafrole microsomes were compared. Bands 1 and 5 
showed similar intensities to the equivalent proteins 
in Fig. 6.1.
Fig. 6.10. shows the densitometric scans of 
the Coomassie blue-stained gel depicted in Fig. 6.9.
FIGURE 6.9.
SDS-polyacrylamide gel electrophoresis of rat 
hepatic microsomes from animals treated with 
phenobarbitone-isosafrole, 20-methy1- 
cholanthrene-isosafrole or isosafrole alone
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Conditions as in Fig. 6.1. Samples were from 
rats treated with the following:- Wells 1,2 
and 3, phenobarbitone-isosafrole (15 yg protein) 
and 5, 20-methylcholanthrene-isosafrole (15 yg)? 
6 and 7, oil-isosafrole (15 yg) ? 8 and 9, water- 
isosafrole (15 yg) and 10, water-isosafrole 
(30 yg). The arrows on the left denote the 
positions of proteins 1,2,3,4 and 5? origin is 
at the top of the gel.
FIGURE 6.10.
Densitometrie scans of the electropherogram 
of rat hepatic microsomes from animals 
treated with phenobarbitone-isosafrole, 
20-methylcholanthrene-isosafrole or 
isosafrole alone
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Conditions as in Fig. 6.3. The mol. wt. 
region 60,000-45,000 is marked ] |?
origin is at the left of each scan.
Large differences were observed only in the 45,000 -
60,000 mol. wt. region. A large peak at 54,000 mol. wt. 
was observed with 20-methylcholanthrene-isosafrole 
microsomes, accompanied.by a smaller peak at 58,000 mol. 
wt. Phenobarbitone-isosafrole microsomes showed prominent 
maxima for the 49,000 and 50,000 mol. wt. proteins, but 
no increase was observed for the 54,000 mol. wt. protein 
compared with controls receiving vehicles plus isosafrole 
alone. The water-isosafrole and oil-isosafrole 
combinations produced identical densitometric patterns.
The cytochrome P-450 contents of the variously 
induced microsomes were measured and the results are 
shown in Table 6.2. Pretreatment with phenobarbitone 
or 20-methylcholanthrene each produced a two-fold 
induction of cytochrome P-450. A single dose of isosafrole 
produced a somewhat smaller induction of cytochrome P-450 
as shown by the water-isosafrole and oil-isosafrole 
combinations. Isosafrole microsomes, prepared from 
animals receiving three consecutive intraperitoneal 
injections of isosafrole, contained almost three times 
the cytochrome P-450 content of control microsomes. In 
contrast, phenobarbitone-isosafrole microsomes contained 
a lower level of cytochrome P-450 than was produced by 
phenobarbitone given alone and approximately the same 
as isosafrole administered alone. 20-methylcholanthrene- 
isosafrole elicited a four-fold induction of cytochrome 
P-450 relative to control levels and this inducing
TABLE 6,2.
Cytochrome P-450 content of microsomes from 
rats receiving different pretreatments .
Pretreatment Cytochrome P-450 (nmol/mg microsomal protein)
Phenobarbitone 1.33
Water 0.63
20-Methylcholanthrene 1.29
Oil 0.58
Isosafrole 1.66
Phenobarbitone-isosafrole 1.02
Water-isosafrole 1.11
20-Methylcholanthrene-isosafrole 2.50
Oil-isosafrole 1.08
The cytochrome P-450 content of microsomes from animals which 
received isosafrole was measured after complete dissociation 
of the isosafrole metabolite-cytochrome P-450 complex. This 
was achieved by incubation of the microsomes at 37°C for 20 min 
in the presence of 2-heptylbenzimidazole (200 jj.M) .
combination produced an additive effect of the increases 
in cytochrome P-450 content obtained when either 20-methyl- 
cholanthrene or isosafrole was injected alone.
6.2.6. Effect of MDP compounds on phenobarbitone-
induced cytochrome P-450
The effect of safrole and isosafrole on 
phenobarbitone-induced cytochrome P-450 containing 
haem labelled with 1 was investigated. Neither safrole 
nor isosafrole (each at a concentration of 1.0 mM) 
caused appreciable breakdown of 1^C-labelled haem (4% 
and 5.3% respectively) (Table 6.3.). This was assessed 
by the radioactivity present in crystalline haem isolated 
from in vitro incubations of safrole or isosafrole 
with 11,000 gav supernatants (from animals receiving 
phenobarbitone) and an NADPH regenerating system at 37°C. 
Under similar conditions allylisopropylacetamide, a 
compound which specifically breaks down the haem of 
phenobarbitone-induced cytochrome P-450, produces a 
loss of at least 30% of microsomal haem associated with 
cytochrome P-450 (De Matteis, personal communication).
6.3. DISCUSSION
The classical inducers of hepatic microsomal 
drug metabolizing enzymes, phenobarbitone and 20-methyl- 
cholanthrene have been shown to induce haemoproteins 
which can be separated on SDS polyacrylamide gels 
(Alvares and Siekevitz, 1973; Welton and Aust, 1974). 
Polychlorinated biphenyls, compounds whose inducing 
properties resemble those obtained by dosing
TABLE 6.3.
Effect of safrole and isosafrole on the degradation of 
1^C-labelled haem in phenobarbitone-induced microsomes
Radioactivity recovered in 
(dpm/extinction unit
crystalline haem 
of haem)
Addition to 
incubation mixture Minus NADPH Vlus NADPH % loss of haem
None 2.25 • 2.27 0
Safrole 2.26 2.18 4
Isosafrole 2.24 2.15 5.3
The microsomes used were prepared from phenobarbitone-induced rats 
which received 5-amino [ 4-* **0] laevulinate (37 nmol, 2 j-iCi) 2 h befor 
death. The incubation mixture and the isolation and determination 
of 14C-labelled haem are described in Methods (Chapter 2).
phenobarbitone and 20-methylcholanthrene concomitantly 
increased both the phenobarbitone-and 20-methylcholanthrene- 
inducible haemoproteins (Alvares and Siekevitz, 1973;
Ryan et at, 3 1977).
The results from data presented in this 
chapter suggest that isosafrole induces a different 
haemoprotein from that induced either by phenobarbitone 
or by 20-methylcholanthrene. The protein induced by 
isosafrole (molecular weight 54,000) had a relative 
mobility intermediate between that of the phenobarbitone- 
induced protein (50,000 mol. wt.) and the 20-methylcholanthrene- 
induced protein (58,000 mol. wt.).
Data from both rat (Birnbaum et at,3 1976) 
and mouse (Haugen et at,3 1976) hepatic microsomes
r
indicated that a PCN-inducible protein had a molecular 
weight intermediate between the phenobarbitone-and 20-methyl- 
cholanthrene-inducible proteins. However, in our system,
PCN induced a protein which had similar electrophoretic 
mobility to the band which was preferentially increased 
by phenobarbitone treatment (Fig. 6.4.). Thus the 
protein induced by isosafrole had a different molecular 
weight to the proteins induced by either phenobarbitone, 
20-methylcholanthrene or PCN.
Various microsomal proteins which are not 
related to cytochrome P-450 have molecular weights in the
45,000 - 60,000 mol. wt. region. Epoxide hydratase, 
with a reported molecular weight of 49,000 (Bentley and
Oesch, 1975), or 53,000 - 54,000 (Lu et at,3 1975), 
multiple forms of UDP-glucuronyltransferase (Bock 
et at, j 1977; Burchell, 1977) and stearoyl CoA desaturase 
(Strittmatter et at,3 1974) are examples of such proteins.
MDP compounds such as isosafrole, safrole and piperonyl 
butoxide have been reported to induce both epoxide 
hydratase (Vainio and Parkki, 1976) and UDP-glucuronyl- 
transferase (Parke and Rahman, 1970; Lucier et at,3 1971;
Vainio and Parkki, 1976). Induction of a protein of
49,000 mol. wt. by isosafrole was observed and this 
protein was possibly epoxide hydratase.
Isosafrole is a known inducer of monooxygenation 
processes (Parke and Rahman, 19 70) and its ability to 
increase levels of haemoprotein has been shown to be 
completely inhibited by protein synthesis inhibitors 
such as actinomycin D. Thus the increase in enzyme 
activity associated with isosafrole pretreatment may be 
attributed largely to synthesis of enzyme protein de novo.
Control microsomes contained barely detectable amounts
of the 54,000 mol. wt. protein induced by isosafrole,
but treatment with either phenobarbitone or 20-methylcholanthrene
produced slight increases in the 54,000 protein as
well as their own respective apoproteins.
Several methods have been used in an attempt 
to identify particular microsomal proteins as haemoproteins 
and hence apoproteins of cytochrome P-450. Siekevitz 
(1973) showed that very little radioactivity could be
detected when microsomal protein containing 3H-labelled 
haem (following injection of 3H-ALA?) was subjected to 
SDS-gel electrophoresis. However, by using milder 
solubilization and electrophoretic conditions, Welton 
and Aust (1974) showed that haem associated with 
particular microsomal proteins in the 45,000 - .60,000 
mol. wt. region could be detected by staining for 
peroxidase activity. Siekevitz (1973) showed that haem 
could be added to gels on which hepatic microsomes had 
been electrophoresed, and the haem specifically bound to 
proteins of about 50,000 mol. wt. at pH 7.4.
The results of experiments using the benzidine 
hydrogen peroxide mixture to detect haem showed that 
the isosafrole-induced protein with a mol. wt. of 54,000 
stained a brown colour as did the proteins induced by 
phenobarbitone and 20-methylcholanthrene. The TMBZ 
stain for peroxidase activity showed a much higher 
sensitivity for the residual haemoproteins in the
50,000 - 60,000 mol. wt. range eliciting an intense blue 
colouration; no other microsomal proteins were stained 
with the exception of a protein at about 15,000 mol. wt. 
Cytochrome bs has a molecular weight of 16,700 (Spatz 
and Strittmatter, 1971) and the protein stained by TMBZ 
in this region was probably this haemoprotein. Other 
experiments using microsomes containing haem labelled 
with llfC-ALA showed a similar pattern of radioactivity 
to the haem peroxidase staining techniques, thus 
*
ALA = 5-aminolaevulinate
identifying proteins in the 50,000 - 58,000 mol. wt. region 
as proteins derived from species of cytochrome P-450.
Various other MDP compounds were studied 
as possible inducers of the 54,000 mol. wt. protein.
Safrole and dihydrosafrole produced results similar to 
those for isosafrole in that pretreatment of rats with 
these compounds induced the novel protein whereas 
methylenedioxybenzene produced very slight induction 
of the protein. Piperonyl butoxide produced no increase 
in the 54,000 mol. wt. protein relative to controls.
These results are in agreement with those of Parke and 
Rahman (1970) who observed induction of fiionooxygenase 
activity with safrole and isosafrole. Piperonyl 
butoxide has been reported to induce monooxygenase 
activity in rats (Lake et al,3 1973; Franklin, 1976a) 
but this compound seems to be a much less potent inducer 
at comparable dose levels.
Lake and Parke (1972) observed the formation 
of the 455 nm redox difference spectral absorption 
maximum following pretreatment of rats with some MDP 
compounds. Only safrole and isosafrole administration 
produced the 455 nm maximum in vivoy piperonyl butoxide, 
piperonyl alcohol, piperonylic acid and piperonylacrylic 
acid did not produce this maximum (Lake and Parke, 1972). 
(In addition, Parke and Rahman (1970) found that 
administration of piperonyl alcohol, piperonal, piperonylic 
acid or piperonylacrylic acid did not result in enzyme
induction). Further evidence for the presence or absence 
of the MDP metabolite-cytochrome P-450 complex was obtained 
in this study by "off-balance" difference spectroscopy.
Only microsomes from rats treated with isosafrole, 
safrole or dihydrosafrole contained the metabolite 
complex i.e. they elicited oxidized and reduced 
difference spectra with absorbance maxima at 438 nm and 
455 nm, respectively. In contrast, microsomes from 
animals which received methylenedioxybenzene or piperonyl 
butoxide did not produce 438 nm or 455 nm absorbance 
changes.
It is possible therefore, that the induction 
of the novel haemoprotein of 54,000 mol. wt. may be related 
to the ability to form a stable MDP-metabolite complex 
with cytochrome P-450 which may be isolated in liver 
microsomes following treatment with certain MDP compounds.
To date, only compounds which induce the novel haemoprotein 
are capable of forming the 455 nm complex in vivo.
Franklin (1976a) has reported a 455 nm complex in 
microsomes from rats treated with piperonyl butoxide 
but much smaller AE^55-490 values were observed per mg 
of microsomal protein than those found in this study 
(Chapter 7). In addition, 24 h after the administration 
of piperonyl butoxide (500 mg/kg) , the AE 1*55-^90 value 
was only slightly higher than control levels 24 h after 
dosing with vehicle alone (Franklin, 1976a). At 1,000 mg/kg 
piperonyl butoxide, however, the 455 nm absorption maximum
is about 30% of that observed following a total dose of 
450 mg/kg of isosafrole. Thus the novel haemoprotein 
of 54,000 mol. wt. may be induced by piperonyl butoxide, 
but only following administration of a much higher dose 
of this MDP compound.
The 54,000 mol. wt. protein was further shown 
to be free of isosafrole metabolites which may have 
modified the electrophoretic mobility of existing 
haemoproteins. Since the MDP metabolite is probably 
bound to the haem of cytochrome P-450 (Philpot and 
Hodgson, 1971b, 1972; Franklin, 1971), and the haem is 
destroyed by treatment with 2% (w/v) SDS (Siekevitz,
1973) it was presumed that the MDP metabolite was 
released from cytochrome P-450 by SDS solubilization. 
Experiments using microsomes containing the isosafrole 
metabolite complex generated in vitro with phenobarbitone 
microsomes did not show an increase in a 54,000 mol. wt. 
protein relative to phenobarbitone microsomes. In 
addition, isosafrole microsomes in which the MDP-metabolite 
complex had been dissociated showed no decrease in the
54,000 mol. wt. protein when compared with undisplaced 
isosafrole microsomes, indicating that the protein was 
not complexed with isosafrole metabolite.
Microsomes prepared from animals dosed with 
isosafrole in combination with phenobarbitone or 20-methyl- 
cholanthrene showed greatly differing protein profiles 
in the 45,000 - 60,000 mol. wt. region on SDS-gels.
Measurement of the peak heights of the 
phenobarbitone (50,000 mol. wt.) and isosafrole (54,000 
mol. wt.) proteins from the densitometric scan of the 
phenobarbitone-isosafrole inducing combination showed that 
both proteins had been induced. However, the increased 
levels of cytochrome P-450 observed following treatment 
with this inducing combination were consistently lower 
than were observed for phenobarbitone alone and about 
the same as those noted following a single dose of iso­
safrole (Table 6.2.). This apparent decrease in the 
induction of cytochrome P-450 by phenobarbitone-isosafrole 
may be due to several factors; i) isosafrole might 
compete with phenobarbitone in the induction process 
albeit that the final haemoprotein is different. If this 
were the case, it may be hypothesized that both the
50,000 and 54,000 mol. wt. proteins would be decreased 
which does not appear to be the case. ii) isosafrole 
and phenobarbitone induce different cytochrome P-450 
species by separate mechanisms arid the observed decrease 
in haemoprotein levels below those of additive induction 
may have been due to interference with the synthesis or 
addition of haem to the cytochrome P-450 apoprotein or 
breakdown of the haem moiety of newly synthesized haemo­
protein. It is known that the haemoprotein induced 
by phenobarbitone is more susceptible to destruction by 
allyl compounds than control cytochrome P-450 or the 
20-methylcholanthrene induced haemoprotein. However, 
both isosafrole and safrole were found to produce
degradation of only a small portion of phenobarbitone- 
inducible cytochrome P-450 haem (about 5%). Isosafrole 
and safrole have also been reported as having no effect 
on the activity of ALA synthetase, (Ioannides and Parke, 
1976) . (Generally, potent destructive agents of 
phenobarbitone-induced cytochrome P-450 haem such as 
allylisopropylacetamide and allyl-substituted barbiturates 
also induce ALA synthetase).
The peak heights of densitometric scans of 
both 58,000 and 54,000 mol. wt. proteins were markedly 
increased by 20-methylcholanthrene-isosafrole treatment 
compared to animals receiving isosafrole alone (Fig. 6.9.). 
A corresponding increase in cytochrome P-450 concentrations 
was also observed; 20-methylcholanthrene-isosafrole 
induces cytochrome P-450 levels equivalent to the sum of 
those seen when either of the inducing agents were 
administered separately (Table 6.2.).
It is well established that phenobarbitone 
and 20-methylcholanthrene induce microsomal enzymes by 
different mechanisms (Gelboin, 1972). The inductive 
effects elicited by concomitant administration of these 
two agents are the sum of the monooxygenase activities 
produced when either compound is administered separately 
(Bidleman and Mannering, 1970). The similar additive 
effect on cytochrome P-450 content observed when 20-methyl- 
cholanthrene and isosafrole were given together indicates 
that these two agents also induce cytochrome P-450 
mediated activities by different mechanisms. It may
thus be conceivable that phenobarbitone and isosafrole 
have common features in their mechanism of induction, 
since no such additive effect on the P-450 concentration 
or in the gel electrophoretic pattern was observed 
following stimulation with phenobarbitone-isosafrole. 
Spectral changes observed in microsomes isolated following 
treatment with isosafrole together with phenobarbitone 
or 20-methylcholanthrene are described in the following 
chapter.
CHAPTER 7
SPECTRAL CHARACTERISTICS OF RAT AND MOUSE 
^HEPATIC MICROSOMES FOLLOWING TREATMENT WITH 
' ISOSAFROLE AND OTHER INDUCING AGENTS BEFORE 
AND AFTER DISSOCIATION OF THE ISOSAFROLE
METABOLITE-CYTOCHROME P-450 COMPLEX
7, SPECTRAL CHARACTERISTICS OF RAT AND MOUSE HEPATIC
‘ MICROSOMES FOLLOWING. TREATMENT WITH ISOSAFROLE 
" AND OTHER INDUCING AGENTS BEFORE AND AFTER 
DISSOCIATION OF THE ISOSAFROLE METABOLITE- 
CYTOCHROME P-450 COMPLEX
7.!. INTRODUCTION
Following the administration of certain chemical 
compounds, unusual absorption maxima were observed in the 
Soret region when liver microsomal preparations were studied 
spectrophotometrically. The initial experiments of Philpot 
and Hodgson (1971b) using mice and Schenkman et at. (1972b) 
using rats showed that stable cytochrome P-450 complexes 
with piperonyl butoxide and SKF-525A metabolites respectively were 
formed in vivo and were not destroyed by the procedure 
used to isolate hepatic microsomes. More recently, Elcombe 
et at. (1975a) have shown that safrole and isosafrole also
produce similar metabolite-cytochrome P-450 complexes in 
vivo which may be dissociated by certain Type I substrates.
Buening and Franklin (1976) have studied the 
reduced in vivo SKF-525A metabolite-cytochrome P-450 complex 
in the rat before and after dissociation of the 452 nm 
absorbing species by potassium ferricyanide oxidation and 
also after prior induction with phenobarbitone and 20-methyl­
cholanthrene, Since MDP compounds are known to produce 
different metabolite complexes with phenobarbitone microsomes 
and 20-methylcholanthrene microsomes in vitro (Elcombe, 1976 
and Chapter 4) it was decided to investigate the in vivo 
interactions of isosafrole in rat and mouse hepatic
microsomes both with and without prior induction by 
phenobarbitone and 20^methylchoTanthrene.
7.2. RESULTS
7.2.1. Carbon monoxide and ethylisocyanide spectra of
reduced hepatic microsomes from rats receiving 
different inducers
Table 7.1. shows that treatment with phenobarbitone,
20-methylcholanthrene and isosafrole increased the levels
of cytochrome P-450 relative to their appropriate controls.
The full extent of induction by isosafrole was not apparent
until the isosafrole metabolite was displaced from cytochrome
P-450. It should be noted that only microsomes from rats
treated with isosafrole showed an increase in the magnitude
of the reduced-carbon monoxide absorbance maximum observed
after incubation of the oxidized microsomes at 37°C for
20 min with 2-heptylbenzimidazole (200 jj.M) . Approximately
46% (42%-49%) of the cytochrome P-450 present in isosafrole
microsomes was present in the form of a metabolite complex.
The X of the reduced-carbon monoxide spectrum of max *
isosafrole microsomes was slightly shifted to the blue 
region when compared with that of control microsomes and underwent 
a further hypsochromic shift following dissociation of the 
metabolite complex (to 448.5 nm). No similar shift was 
observed with either control, phenobarbitone or 20-methyl­
cholanthrene pretreated microsomal preparations. A 
decrease in the ratio of the 430 and 455 nm absorption 
maxima measured following production of the reduced-ethyl- 
isocyanide spectrum after displacement of isosafrole microsomes
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was also noted) this decrease will be discussed in a later 
section of this chapter,
7,2.2, Carbon monoxide and ethyli so cyan ide spectra of
reduced rat hepatic microsomes from animals 
treated with isosafroie, phenobarbitone- 
isosafrole or 20-methy1chofanthrene-isosafrole 
before and after dissociation of the MDP 
metabolite complex
As can be seen in Table 7.2(i) only the 20-methy1- 
cholanthrene-isosafrole inducing combination produced marked 
induction of cytochrome P-450 before dissociation of the 
metabolite complex. After displacement, all the preparations 
showed an increased cytochrome P-450 content relative 
to control microsomes (Table 7.1.) although the extent of 
the increase varied. The cytochrome P-450 content of 
microsomes from animals treated with the control inducing 
combinations (oil-isosafrole t.and water-isosafrole) was 
increased by 43 and 34% respectively after displacement. 
Phenobarbitone-isosafrole microsomes underwent a 28% 
increase whereas 20-methylcholanthrene-isosafrole microsomes 
showed a 52% increase in cytochrome P-450 levels after 
displacement. The above figures represent the percentage 
of total cytochrome P-450 which was unreactive towards 
carbon monoxide before dissociation of the complex and 
hence is the proportion of haemoprotein which was bound in 
the form of the metabolite complex. The phenobarbitone- 
isosafrole pretreatment combination produced the same 
total concentration of cytochrome P-450 as its relative 
control (water-isosafrole) (Table 7.2(i)) and had a much 
smaller inductive effect than phenobarbitone given alone
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(Table 7.1,), In contrast, 20-methylcholanthrene-isosafrole 
produced approximately an additive induction of the cytochrome 
P-450 content given by either inducing agent administered alone.
All the inducing agents shown in Table 7.2(i) 
produced a slight hypsochromic shift of the reduced carbon 
monoxide absorption peak compared with control microsomes 
(peak at 449.5 nm). The shift was most pronounced after 
treatment with 20-methylcholanthrene-isosafrole, whereas 
the phenobarbitone-isosafrole combination elicited a 
very small shift. Little change in the position of the 
reduced carbon monoxide maximum was detectable after 
displacement.
In agreement with the increase in carbon 
monoxide binding, both the 430 nm and the 455 nm absorbance 
maxima elicited by the binding of ethylisocyanide to reduced 
cytochrome P-450 were increased after dissociation of the 
isosafrole metabolite-cytochrome P-450 complex (Table 7.2 (ii)). . 
However, whereas the increases in the AE^so-bSO an^
AE^55-590 observed after displacement were of a similar 
magnitude for both phenobarbitone-isosafrole microsomes 
(84% and 56% respectively) and 20-methylcholanthrene-isosafrole 
microsomes (77% and 64%), a different pattern was observed 
with microsomes from animals which received vehicles and 
isosafrole only. Water-isosafrole microsomes showed a 
15% increase in the AE4 30-490 spectral change and a 64% 
increase in the AEitss^go spectral change* oil-isosafrole 
microsomes showed a similar proportional change in these 
absorbance increases measured after displacement (AEi*30-490 
was increased by 2 0% and AE^g ^ g o  by 88%) .
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Hence, phenobarbitone-isosafrole microsomes 
and 20-methylcholanthrene-isosafrole microsomes showed 
unchanged AEi^o-if 9o/AE4 5 5^4 9 0 ratios before and after 
displacement (Table 7.2(i)). In contrast, a decrease 
in the 430/455 ratio was apparent after displacement 
in the cases of water-isosafrole microsomes and oil- 
isosafrole microsomes. 20-Methylcholanthrene-isosafrole 
microsomes elicited the lowest 430/455 ratio calculated 
from the reduced ethylisocyanide spectrum both before 
and after displacement.
The AEif2 7-4 9o an^ AElt2 7-itlO values of 
20-methylcholanthrene microsomes before and after displacement 
were greater than the corresponding values of oil-isosafrole 
microsomes (Table 7.3.). In contrast, no differences in 
these values were found when phenobarbitone-isosafrole 
microsomes and water-isosafrole microsomes were compared 
before and after displacement. However, when the AEi*27-1+90 
and AEit2 7-i+5 0 values of each group of microsomes obtained 
before displacement were compared with those observed after 
displacement, no differences in these measurements were 
noted (with the exception of the AE^ 2 7-1+90 values of 
20-methylcholanthrene-isosafrole microsomes).
Major differences in the magnitude of the 
AE4 5 5—1+ 9 0 values of the respective microsomal preparations 
were observed before displacement both when expressed as 
per mg of protein or per nmol of total cytochrome P-450 
(Table 7.3.). Water-isosafrole and oil-isosafrole
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pre-treatment regimens yielded similar AE455-490 values
with the phenobarbitone-isosafrole and 20-methylcholanthrene-
isosafrole microsomes being lower and higher than their
respective controls. Following dissociation of the
isosafrole metabolite-cytochrome P-450 complexes, the
AEif 5 5.^ 4 9 0 values were decreased to background levels
i.e. equivalent to the AE found after sodium dithionite
reduction of control (untreated) microsomes which
did not contain the 455 nm absorbance maximum. The
loss of the 455 nm maximum was accompanied by an increase
in carbon monoxide binding to reduced cytochrome P-450.
An extinction coefficient of 75 mM'"1 cm” 1 was calculated 
for the 455 nm absorbance peak in rats (assuming an
j
extinction coefficient of 91 mM*"1 cm-1 for the reduced 
carbon monoxide complex of cytochrome P-450. The £455-490 
value was determined by measuring the magnitude of the 
reduced carbon monoxide maximum before and after 
displacement and assuming that the difference between 
these two values was the amount of cytochrome P-450 which 
was bound to an isosafrole metabolite (spectrally 
manifested by the 455 nm maximum). The £1+55-490 value 
was applicable to microsomes prepared from isosafrole 
treated rats.
7.2,3. Relationship between the 455 nm absorbance maximum
and the 438 nm absorbance minimum found after 
dissociation of the isosafrole metabolite- 
cytochrome P-450 complex in rat hepatic microsomes
Table 7,4. shows the values obtained for the
initial rate of the displacement process and the extent of
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displacement (expressed as the maximal AEi*33-490 which 
occurred 20 min after the addition of the displacing 
agent (2-heptylbenzimidazole) to the variously treated 
microsomes incubated at 37°C. The change in absorbance 
at 455 nm in the sodium dithionite-reduced spectrum was 
found to be directly related to both the initial rate of 
displacement and the maximal absorbance change at 438 nm 
(Fig. 7.1.) .
7.2.4. Carbon monoxide and ethylisocyanide spectra of
reduced mouse hepatic microsomes
The results obtained following the induction of
cytochrome P-450 by phenobarbitone, 20-methylcholanthrene
and isosafrole in the mouse (Table 7.5.) were similar to
those found for the rat (Table 7.1.). However, none of
the inducing agents were as potent in the mouse as in the
rat and the characteristic blue shift of the reduced carbon
monoxide complex of 20-methylcholanthrene microsomes was
seen to a much lesser degree (only a 0.5 nm shift was
observed for 20-metftylcholanthrene mice microsomes, cf. a
1.5 nm shift for 20-methylcholanthrene rat microsomes).
An increase in the cytochrome P-450 content was observed
for microsomes from isosafrole pretreated mice when the
cytochrome P-450 level was measured using carbon monoxide
as a ligand following the addition of 2-heptylbenzimidazole and
incubation for 20 min at 37°C. A 1.0 nm hypsochromic shift in the
X of the reduced carbon monoxide spectrum and a decrease max ^
in the 430/455 ratio of the ethylisocyanide complex of the
FIGURE 7.1.
Relationship between the AEi* 55-1*90 reduced 
absorbance maximum before displacement and 
the final AEi*33-^90 absorbance change 
measured after displacement
120
100
80
60
.c. 40
20
80
AE455-490 absorbance maxima were measured 
from sodium dithionite-reduced spectra.
AE4 3 8-1*90 absorbance changes were measured 
after complete dissociation of the isosafrole 
metabolite-cytochrome P-450 complex as 
described in the legend to Table 7.1.
Microsomes were from rats treated with 
phenobarbitone-isosafrole, A; water-isosafrole, 
Of 20-methylcholanthrene-isosafrole, ♦; oil- 
isosafrole, ©f isosafrole (3 days), as 
described in Methods. Each point represents 
a different microsomal preparation.
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reduced microsomes was observed when displaced isosafrole 
microsomes were compared with undisplaced isosafrole 
microsomes.
Table 7,6. shows the cytochrome P-450 content,
the X of the carbon monoxide spectra and the ratio of max c
the 430 and 455 nm maxima of the ethylisocyanide spectra 
of reduced mouse hepatic microsomes from animals treated 
with isosafrole and other inducing agents. All microsomes 
from mice treated with isosafrole elicited displacement 
spectra in the presence of 2-heptylbenzimidazole (200 p.M) 
at 37°C. In all cases the cytochrome P-450 content was 
found to be greater after dissociation of the isosafrole 
metabolite-cytochrome P-450 complex. However, as shown 
in Table 7.7. the amount of cytochrome P-450 present in 
the form of the metabolite complex was smaller for the 
mouse when compared to the rat, regardless of the 
treatment with isosafrole and other inducing agents. The 
rat and the mouse were similar in that the greatest amount 
of the haemoprotein present as the complex was found for 
the 20-methylcholanthrene-isosafrole microsomes and the 
smallest for phenobarbitone-isosafrole microsomes.
The X of the reduced carbon monoxide spectra max *
of all the mice microsomal preparations showed a slight 
blue shift after displacement compared with the spectra 
obtained before displacement (Table 7.6.). . The reduced 
ethylisocyanide spectra of the water-isosafrole and the 
oil-isosafrole microsomes also showed small decreases of 
the 430/455 nm maxima ratio after displacement in agreement 
with data from rat microsomes (Table 7.2.).
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7.2.5. Sodium dithionite—reduced spectra of mouse
hepatic microsomes from animals treated 
with isosafroTe
Table 7.8. shows the results of dithionite 
reduction of variously treated mouse microsomes. In all 
cases, a maximum at 455 nm was observed in the sodium 
dithionite-reduced minus oxidized difference spectrum.
As for the rat, the largest AE^s-i^o was seen with 
20-methylcholanthrene-isosafrole microsomes. Although 
extensive experiments were not carried out with mouse 
liver microsomes, preliminary experiments suggested that 
the magnitude of the 455 nm absorbance peak was proportional 
both to the initial rate of displacement and the maximal 
AEi* 38 — i*go (cf. Fig. 7.1.).
The phenobarbitone-isosafrole and 20-methyl- 
cholanthrene-isosafrole microsomes showed increases in 
both the AE427-490 an^ AE4 2 7-410 values relative to their 
respective controls, water-isosafrole and oil-isosafrole 
microsomes.
7.2.6. Spin state of variously treated mouse hepatic
microsomes calculated from n-octylamine binding 
spectra
Table 7.9. shows the high spin/low spin ratios 
of the cytochrome P-450 content of variously treated mouse 
microsomes, calculated from n-octylamine binding spectra 
(Jefcoate et al.s 1970) as described in Chapter 2.
Following the addition of 2-heptylbenzimidazole (200 jjlM) 
to the different microsomal preparations, a Type I 
binding spectrum was observed accompanied by an increased 
high spin/low spin ratio (Table 7.9(i)). Phenobarbitone, 
isosafrole, water and oil microsomes all had similar high
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spin/low spin ratios both in the presence and absence of 
2-heptylbenzimidazole. However, 20^methylcholanthrene 
microsomes showed a greater proportion of high spin 
character both before and after addition of 2-heptylbenzimidazole.
When isosafrole was administered following the 
injection of phenobarbitone, 20-methylcholanthrene, water 
or oil (Table 7. 9(11)), the respective spin-state ratios 
were lower than the values obtained when the treatments 
were given without isosafrole. The isosafrole microsomes 
showed a similar decrease in the high spin/low spin ratio 
(relative to the control microsomes in Table 7.9(iJ) both 
before and after dissociation of the isosafrole-metabolite 
cytochrome P-450 complex by 2-heptylbenzimidazole. 
20-Methylcholanthrene-isosafrole microsomes had the 
greatest proportion of high-spin character when compared 
to microsomes from other isosafrole treated animals.
It should be noted that no differences were 
observed in the n-octylamine binding spectrum with variously 
induced rat hepatic microsomes, in agreement with the 
results of Levin et at. (1973c). Hence this method cannot 
be used to quantitate the spin-state of the cytochrome 
P-450 present in rat microsomes.
7,3, DISCUSSION
Isosafrole is known to be a potent inducer 
of rat hepatic microsomal cytochrome P-450 and associated 
monooxygenase activity (Wagstaff and Short, 1971* Lake 
et al,9 1973), However, the full extent of induction of
the haemoprotein in vivo is not seen by conventional 
measurement of the reduced carbon monoxide maximum, 
because of the presence of an isosafrole metabolite- 
cytochrome P-450 complex which renders a proportion of 
the cytochrome P-450 present unreactive towards carbon 
monoxide '(Parke and Rahman, 1971). However, the 
oxidized complex may be dissociated by certain substrates 
of cytochrome P-450 (Gray and Parke, 1973; Elcombe et al. s 
1976a) producing an apparent increase in cytochrome P-450 
content.
The results of this chapter show that the 
in vivo isosafrole metabolite-cytochrome P-450 complex is 
also formed when rats are pretreated with phenobarbitone 
or 20-methylcholanthrene and are subsequently dosed with 
isosafrole. However, 20-methylcholanthrene-isosafrole 
produced a considerably greater induction of cytochrome 
P-450 than phenobarbitone-isosafrole (Table 7.2.).
Further a large proportion (50%) of the total haemoprotein 
of 20-methylcholanthrene-isosafrole microsomes was present 
in the form of the 455 nm complex, compared with 
microsomes from rats treated with oil-isosafrole (33%) , 
water-isosafrole (42%) or phenobarbitone-isosafrole (23%) .
Thus a form of cytochrome P-450 which binds the isosafrole 
metabolite in vivo appears to be induced by 20-methylcholanthrene- 
isosafrole but is not present to such an extent in pheno­
barbitone-isosafrole microsomes.
Similar.experiments have been carried out 
following the administration of SKF-525A to phenobarbitone
and 20-methylcholanthrene treated rats (Buening and 
Franklin, 1976), The phenobarbitone-SKF-525A inducing 
mixture produced an increase in cytochrome P-450 levels 
and 41% of the haemoprotein was in the complexed form.
Animals which received SKF-525A alone contained 33% of 
the total haemoprotein as the complex whereas 20-methyl- 
cholanthrene-SKF-525A treated rats had only 3% of their 
cytochrome P-450 in the complexed form. These results 
suggest that the subpopulation of cytochrome P-450 which 
forms the in vivo metabolic complex with SKF-525A is not 
the same species which forms the in vivo isosafrole 
metabolite-cytochrome P-450 complex, and therefore at 
least two different species of haemoprotein are capable 
of forming metabolite complexes in vivo.
Interpretation of the slight differences in
the magnitude of the AE427-M90 an^ aeM27-mio absorbance
changes between the variously induced microsomes is
complicated by the presence of cytochrome bs which has
an absorbance maximum at 426 nm in the reduced form but it is 
not known.if this haemoprotein is induced by the treatments.
The marked increase in the magnitude of the 455 nm maximum 
of 20-methylcholanthrene-isosafrole microsomes relative 
to oil-isosafrole preparations (Table 7.3.) was clearly 
accompanied by a similar increase in cytochrome P-450 
content (Table 7.2.). This suggests that the species of 
cytochrome P-450 responsible for binding the isosafrole 
metabolite which produces an absorbance maximum at 455 nm 
is markedly induced by 20-methylcholanthrene-isosafrole.
Phenobarbitone-isosafrole microsomes contained a somewhat 
smaller amount of the 455 run complex than water-isosafrole 
microsomes and this too was reflected in the total 
haemoprotein content. The calculated extinction coefficient 
of the 455 nm complex in the rat (75 mM”1 cm”1) was 
applicable to all the various isosafrole pretreatments 
described in Table 7.2., suggesting that the species 
of haemoprotein which formed the metabolite complex in 
vivo was similar in all cases. Gel electrophoretic 
evidence also supported this hypothesis in that a novel 
haemoprotein was observed following administration of 
isosafrole* treatment with 20-methylcholanthrene-isosafrole 
caused a marked increase in this protein which was not 
inducible by phenobarbitone or 20-methylcholanthrene alone 
(Chapter 6).
Following induction by isosafrole, a consistent
hypsochromic shift of the reduced carbon monoxide absorption
spectrum (X ) was observed when compared to the Xmax max
of water or oil control microsomes (Tables 7.1. and 7.2.), 
indicative of the production of a haemoprotein with 
different spectral properties to both cytochromes P-450 
and P-448.
Further evidence for this hypothesis was noted 
by the observation of the changes in the ratio of the 430 
and 455 nm absorption maxima of the ethylisocyanide complex 
with the reduced haemoprotein. Levin et al. (1973c) have 
suggested that a decrease in the 430/455 ratio of the dual
absorption maxima may reflect an increase in the high-spin 
character of the cytochrome P-450 haemoprotein present in 
a microsomal -suspension. Thus, the decrease in the 430/455 
ratio observed after displacement in microsomal suspensions 
from rats treated with isosafrole alone (indicative of 
increased high-spin character) may have been due to the 
binding of the displacing agent to the Type I binding site. 
However, since dithionite reduction has been reported 
to destroy Type I binding sites (Schenkman et al.9 1967), 
another type of interaction of the displacer with the 
haemoprotein may have caused a change in spin-state. 
Alternatively, the removal of the isosafrole metabolite 
from cytochrome P-450 may bring about a change in spin- 
state.
A much greater (4-fold) increase in the 
magnitude of the 455 nm maximum of the reduced ethyliso­
cyanide spectrum (when compared with the increase of the 
430 maximum) was observed after displacement in the oil- 
isosafrole and water-isosafrole microsomal preparations 
(Table 7.2 (ii)). This indicates that the species or form 
of cytochrome P-450 which binds the 455 nm absorbing 
species of ethylisocyanide preferentially binds the 
isosafrole metabolite. That similar changes in the 
equilibrium of the 430 and 455 nm absorbances of the 
reduced ethylisocyanide spectrum were not observed for 
microsomes from phenobarbitone-isosafrole or 20-methyl- 
cholanthrene-isosafrole treated rats may be due to
overlapping spectra resulting from binding to other 
haemoproteins induced by phenobarbitone or 20-methyl- 
cholanthrene.
Piperonyl butoxide (a MDP insecticide 
synergist) has been shown to be an inducer and form an 
in vivo MDP metabolite-cytochrome P-450 complex in both 
the mouse (Philpot and Hodgson, 1971b) and the rat 
(Franklin, 1976a). Results presented in this chapter 
show that isosafrole is capable of inducing hepatic 
cytochrome P-450 in the rat and also of forming a 
metabolite complex similar to that in the mouse. However, 
both induction of cytochrome P-450 (90% in the mouse 
and 125% in the rat) and the proportion of the total 
cytochrome P-450 in the complexed form (21% in the mouse 
and 49% in the rat) are lower in the mouse than in the 
rat, suggesting that isosafrole is a less potent inducer 
of the species of haemoprotein in the mouse which may 
form the isosafrole metabolite-cytochrome P-450 complex 
in vivo. However, the relative clearance rates of 
isosafrole from the body of these two species may also 
present a partial explanation for these differences.
Levin et at. (1973c) using the method of 
Jefcoate et at. (1970) have shown that the shape of the 
Type II binding spectrum given by n-octylamine is 
affected by the spin-state of the cytochrome P-450 species 
present in mouse liver microsomes but not in rat liver 
microsomal preparations. The haemoprotein content of
20-methylcholanthrene mouse microsomes has been shown to 
be in a high spin state whereas phenobarbitone microsomes 
and control microsomes contain predominantly low spin 
cytochrome P-450. Table 7,9 (i) shows that isosafrole 
microsomes contain cytochrome P-450 in a predominantly 
low spin state. An increase in the high spin/low spin 
ratio was seen following the addition of the Type I 
substrate, 2-heptylbenzimidazole to all of the different 
microsomes. Presumably the increased high-spin 
character was due to the Type I binding of the substrate 
to the active site of oxidized cytochrome P-450 which 
has been shown to produce an increase in high spin nature 
both by difference spectroscopy (Waterman et al.3 1973) 
and EPR (Stern et al,9 1973), or to the dissociation 
of the low spin MDP metabolite-cytochrome P-450 complex 
by the displacement process. The decrease in the high 
spin/low spin ratios (observed both before and after 
displacement by addition of 2-heptylbenzimidazole to 
the microsomes in Table 7.9 (ii), is possibly due to 
the presence of an additional low spin haemoprotein induced 
by isosafrole. This would presumably decrease the overall 
high spin/low spin ratio of each type of microsome 
relative to its control in Table 7.9(i). Thus the 
microsomal cytochrome P-450 induced by isosafrole in 
mouse liver may be low spin in nature.
CHAPTER 8
INDUCTION OF MQNOOXYGENASE ACTIVITY BY 
ISOSAFROLE AND THE INCREASE IN ACTIVITY 
v FOLLOWING DISSOCIATION OF THE ISOSAFROLE
METABOLITE-CYTOCHROME P-450 COMPLEX
8. INDUCTION OF MONOOXYGENASE ACTIVITY BY ISOSAFROLE AND 
' THE INCREASE IN ACTIVITY FOLLOWING DISSOCIATION OF 
' THE ISOSAFROLE METABOLTTE-CYTQCHROME P-450 COMPLEX
8.i. INTRODUCTION
Several MDP compounds, including safrole, 
isosafrole and piperonyl butoxide, have been shown to be 
inducers of hepatic microsomal monooxygenase activity 
(see Hodgson and Philpot, 1974, for a review). Isosafrole 
in particular has been shown to increase cytochrome P-450- 
mediated activity in both hepatic and extrahepatic 
microsomal preparations (Parke and Rahman, 1970; Wagstaff 
and Short, 1971; Lotlikar and Wasserman, 1972; Lake et al.9 
1973, 1974; Vainio and Parkki, 1976).
In previous experiments, however, little 
consideration has been given to the nature of the cytochrome 
P-450 involved in the isosafrole metabolite-cytochrome P-450 
complex isolated from rats treated with isosafrole. As 
has been demonstrated in Chapters 5 and 7, cytochrome P-450 
complexed in this way is metabolically inactive but certain 
substrates of cytochrome P-450 can dissociate the oxidized 
complex, producing an apparent increase in the cytochrome 
P-450 content as measured by the magnitude of the 
reduced cytochrome P-450-carbon monoxide spectrum (Gray 
and Parke, 1973; Elcombe et 1976a).
The experiments reported in this chapter 
were designed to investigate further the pattern of 
induction of monooxygenase activity by isosafrole and 
also to determine whether the rate of reactions catalysed
by cytochrome P^450 could be increased following 
displacement. Since displacement did not occur under 
reduced conditions (e.g. in the presence of NADPH (Elcombe 
et al.j 1975a), dissociation of the isosafrole metabolite- 
cytochrome P-450 complex could be arrested by the addition 
of NADPH and metabolism of the displacing substrate was 
initiated.
Substrates metabolized predominantly by either 
phenobarbitone- or 20-methylcholanthrene-induced haemo- 
proteins were chosen in an attempt to study the metabolic 
capabilities of the species of haemoprotein complexed 
with an isosafrole metabolite observed after administration 
of isosafrole in vivo,
8.2. RESULTS
8.2.1. Monooxygenase activities induced by isosafrole
and a comparison with those induced by pheno­
barbitone and 20-methylcholanthrene
As already shown, isosafrole is a potent inducer 
of rat hepatic microsomal cytochrome P-450. However, about 
50% of the total cytochrome P-450 content of sodium dithionite- 
reduced microsomes from rats pretreated with isosafrole was 
not reactive towards carbon monoxide due to the presence of 
a metabolic intermediate complex (Chapter 7). This complex 
is manifested spectrally by the presence of an absorption 
maximum at 455 run in the sodium dithionite-reduced difference 
spectrum which is not evident following treatment with other 
types of inducing agent such as phenobarbitone or 20-methyl-
cholanthrene (Table 8,1.), The complex may be dissociated 
by certain Type I substrates, resulting in a loss of the 
455 nm absorbance peak and an apparent increase in the 
cytochrome P-450 content. A characteristic hypsochromic 
shift of the reduced carbon monoxide absorbance maximum 
was consistently observed after displacement.
Table 8.2. shows the results of induction 
experiments in which the inducing properties of isosafrole 
were compared with those of phenobarbitone or 20-methyl- 
cholanthrene. The various enzyme activities were compared 
with those found in microsomes from control (oil or saline 
treated) animals. The activities found for the isosafrole 
microsomal preparations were measured with undisplaced 
isosafrole microsomes i.e. containing the in vivo metabolite 
complex. Aminopyrine i!7-demethylation was induced after 
phenobarbitone administration but not by 20-methylcholanthrene. 
Isosafrole elicited an increase in this activity in one 
experiment but not in the other, and thus induction of 
aminopyrine tf-demethylase by isosafrole was not conclusively 
shown, Biphenyl 4-hydroxylase activity was increased after 
all three treatments, with phenobarbitone being the most 
potent and 20-methylcholanthrene the weakest inducing agent.
In contrast, biphenyl 2-hydroxylase was markedly enhanced 
by 20-methylcholanthrene treatment. Isosafrole administration 
also increased biphenyl 2-hydroxylase activity to a level 
greater than that produced by phenobarbitone treatment but 
less than that found after treatment with 20-methylcholanthrene.
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The three inducing agents enhanced the dealkylation of both 
7-ethoxycoumarin and 7-ethoxyresorufin. 20-Methylcholanthrene 
treatment produced the greatest increase in 7-ethoxycoumarin 
d-deethylation whereas isosafrole and phenobarbitone gave 
somewhat smaller increases in the metabolism of, this 
substrate. However, isosafrole seemed to be a slightly 
more potent inducer of 7-ethoxycoumarin metabolism than 
phenobarbitone, 7-ethoxyresorufin d-deethylase was greatly 
increased after 20-methylcholanthrene treatment. Isosafrole 
also produced marked induction of this enzyme activity, 
the increased activity being greater than that given by 
phenobarbitone treatment but less than the 20-methylcholanthrene 
stimulated activity.
Following partial dissociation of the isosafrole 
metabolite-cytochrome P-450 complex, the rate of metabolism 
of all the substrates tested was increased (Table 8.2.).
The cytochrome P-450 content of the isosafrole microsomes 
was also increased. However, although increases in 
metabolism were observed none of the enzyme activities 
measured were substantially enhanced following 
dissociation of a portion of the metabolite complex.
8.2.2. Dissociation of the isosafrole metabolite-cytochrome
P-450 complex and the consequential activation of
monooxygenation
The metabolism of 7-ethoxycoumarin and 4-nitro- 
anisole may be measured directly in a cuvette following the 
addition of substrate and NADPH to microsomal preparations.
These substrates are also capable of dissociating the 
metabolic intermediate complex of isosafrole microsomes 
in the oxidized state (Chapter 5). However, when NADPH 
was added to an isosafrole microsomal suspension containing 
an added exogenous displacing substance, the displacement 
process was arrested and the substrate was metabolized.
An experiment using 7-ethoxycoumarin as 
substrate is shown in Fig. 8.1. Isosafrole microsomes 
were preincubated at 37°C in the presence of 7-ethoxy- 
coumarin for various time periods and metabolism was then 
initiated by the addition of NADPH. The results showed 
that dissociation of the isosafrole metabolite-cytochrome 
P-450 complex (closed symbols, Fig. 8.1.) occurred with 
increasing incubation time in the presence of substrate 
alone. When the reduced cofactor (NADPH) was added at various 
times after the addition of 7-ethoxycoumarin, an increase 
in the metabolism of 7-ethoxycoumarin was observed which 
was dependent upon the time of preincubation in the presence 
of substrate alone. A maximal activation of 35% was 
attained for 7-ethoxycoumarin D-deethylase activity relative 
to the zero time activity (at which no displacement occurred).
The results of similar experiments using 
4-nitroanisole as substrate and displacer are shown in 
Fig, 8.2, As for 7-ethoxycoumarin, the dissociation of 
the isosafrole metabolite-cytochrome P-450 complex 
paralleled the increase of d-demethylation, and maximal 
activation of 4-nitroanisole metabolism was observed when the 
metabolite complex was completely dissociated. A maximal
FIGURE 8.1.
Dissociation of the in vivo produced isosafrole 
metabolite-cytochrome P-450 complex and the 
consequential increase of 7-ethoxycoumarin
d-deethylase
ISO'S
125 ® :r ■<20
100
30 302520
Time I
Isosafrole microsomes (1 mg protein/ml) in 
66 mM Tris-HCl (pH 7.4) were incubated at 
37°C in the presence of 7-ethoxycoumarin 
(200 yM) for various time periods. NADPH 
(250 yM) was added at various times to stop 
the displacement process and initiate 
metabolism of 7-ethoxycoumarin.
A - A , Dissociation of the complex as measured 
by the AEi* 38-*t9 0 absorbance change?
A-A, O-deethylation of 7-ethoxycoumarin 
expressed as % of activity at zero time i.e. 
no preincubation of the isosafrole microsomes 
with substrate.
FIGURE 8.2.
Dissociation of the in vivo produced isosafrole 
metabolite-cytochrome P-450 complex and the 
consequential increase of 4-nitroanisole 
. 0-demethylase
400
5 10 300 F
.2 20 200
30 10010 20 3025 35
Conditions as in Fig. 8.1., except that the 
substrate was 4-nitroanisole (200 yM).
©-©, Dissociation of the complex? 0-0, 0- 
demethylation of 4-nitroanisole. 4-NA, 4- 
nitroanisole.
2.5-fold increase in activity of 4-nitroanisole 0-demethylase 
was observed.
The time taken for either substrate to completely 
dissociate the isosafrole metabolite-cytochrome P-450 complex 
was similar (25 min for 7-ethoxycoumarin and 30 min for 
4-nitroanisole) despite the differences in metabolism rate 
enhancement with these two substrates. In contrast, no 
increase in activity of either 0-dealkylase was found by 
preincubating control, phenobarbitone or 20-methylcholanthrene 
microsomes with substrate for various times before the 
initiation of metabolism by NADPH.
8.2.3, Time course of the induction of the isosafrole
metabolite-cytochrome P-450 complex and the
induction and activation of biphenyl hydroxylase
From the results shown in Figs. 8.1. and 8.2., 
the increase in monooxygenase activity after the dissociation 
of the isosafrole metabolic intermediate complex was dependent 
on the amount of complex present. Figure 8.3. shows the 
time course of the development of the metabolite complex 
(measured as the AEi*55-490 absorbance change in the sodium 
dithionite-reduced difference spectrum). Microsomes were 
prepared from rats killed at different times after 
treatment with a single dose of isosafrole (150 mg/kg).
An absorbance peak at 455 nm in the reduced difference 
spectrum was observed 8 h after the administration of 
isosafrole which gradually increased with time after 
treatment of isosafrole (Fig. 8.3.). -With a high dose
of isosafrole (300 mg/kg), a shoulder at 455 nm and a
FIGURE 8.3.
The relationship between biphenyl 4-hydroxylase, 
appearance of the isosafrole metabolite- 
cytochrome P-450 complex and dissociation of the 
complex after administration of a single dose of
isosafrole to rats
0-1
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I I0 I I I  I2- 4 8 12 24
Tim e(h) after injection of isosafrole(l50mg/kg)
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0-0, Amount of metabolite complex, measured 
by the sodium dithionite-reduced difference 
spectrum and expressed as AEi*55^4 9o/mg 
microsomal protein. A-A, Biphenyl 4-hydroxy­
lase activity before dissociation of the complex 
by biphenyl. ©-©, Biphenyl 4-hydroxylase activity 
after dissociation of the complex by biphenyl. 
Displacement was effected by incubation of iso­
safrole microsomes (1 mg protein/ml) with biphenyl 
(1 mM) at 37°C for 30 min.
narrowing of the 427 nm absorbance maximum due to reduced 
cytochrome b5 was observed in the reduced difference 
spectrum 4 h after administration of the MDP compound. 
Substrate-elicited dissociation (i.e. a time-dependent 
increase in the Type I binding of a displacing substrate 
and a bathochromic shift of the trough of the binding 
spectrum from 420 to 438 nm) was also detectable at this 
4 h time point after treatment with 300 mg/kg isosafrole.
These features are indicative of the presence of a small 
concentration of in vivo metabolic complex. Microsomes 
prepared from animals pretreated with phenobarbitone or 
20-methylcholanthrene for varying times produced a broad 
maximum at 425-427 nm but failed to display a shoulder at 
455 nm following the addition of sodium dithionite.
Furthermore, no time-dependent increase or spectral shift 
of the binding spectrum was observed with these types of 
microsomes following the addition of a displacing agent.
The administration of the higher dose level 
of isosafrole (300 mg/kg) elicited the formation of 
greater amounts of the isosafrole metabolite-cytochrome 
P-450 complex than the lower dose level (150 mg/kg) 
at all time points i.e. increases in the magnitude of the 
455 nm peak height were 65% (8 h), 85% (12 h) and 40%
(24 h) higher for animals treated with 300 mg/kg isosafrole 
than for those which received 150 mg/kg isosafrole (Fig. 8.4a).
Figure 8,3. also shows the activity of biphenyl 
4-hydroxylase determined at different times after the
FIGURE 8.4(a)
Time course of the production of the 
reduced 455 nm absorbance maximum 
after administration of isosafrole
50 ( x10
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Time(h) after administration of isosafrole
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Isosafrole microsomes (1 mg protein/ml) in 
66 mM Tris-HCl (pH 7.4) from rats killed 
at different times after pretreatment with 
isosafrole (©-®, 150 mg/kg* 0-0, 300 mg/kg) 
were divided equally between two cuvettes. 
Sodium dithionite (1-2 mg) was added to the 
sample cuvette and the absorbance change 
AEi*55-1*90 was recorded.
administration of isosafrole (150 mg/kg), Initially an 
inhibition of biphenyl 4-hydroxylation was seen, with the 
most marked inhibition being 4 h after isosafrole treatment. 
At the same time, an activation of biphenyl 2-hydroxylase 
was observed, with maximal activation at 2 h. After this 
time an increase in the activity of both enzymes was 
observed and increasingly marked induction was seen 
after 12, 24 and 48 h. When biphenyl was preincubated 
at 37°C for 30 min with oxidized isosafrole microsomes 
(obtained at various times after dosing with isosafrole) 
prior to initiation of the hydroxylation reaction with 
NADPH, a greater increase in 4-hydroxylation was seen.
The magnitude of the increase in the 4-hydroxylation (above 
the levels found without preincubation) was always 
dependent upon the original amount of isosafrole 
complexation of cytochrome P-450 present.
The time course of biphenyl 4-hydroxylase 
activity in hepatic microsomes following a single dose 
of 300 mg/kg isosafrole followed a similar pattern to 
that observed after the administration of 150 mg/kg 
isosafrole (Fig. 8.4b). Up to 8 h after isosafrole 
treatment, inhibition of activity relative to control 
values was observed followed by induction after longer 
time periods. However, the maximal inhibition of biphenyl 
4-hydroxylation observed at the higher dose level was 
smaller (20% at 2 h) than that noted for the lower dose 
level (40%). The consequent induction of activity was 
greater at the 300 mg/kg level at 12 h (90%) and 24 h (220%) ,
FIGURE 8.4(b)
Time course of biphenyl 4-hydroxylase 
activity after administration 
of isosafrole
£00
§200
-o
' F v 7Q.
cq
488 12 24
Time(h) after administration of isosafrole
Biphenyl 4-hydroxylase activity was 
determined (as described in Methods) 
using microsomes from rats killed at 
different times after pretreatment 
with isosafrole (A-A, 150 mg/kg?
A - A ,  300 mg/kg). Results are expressed 
as % of values obtained with microsomes 
from control rats killed at corresponding 
time points.
cf. 20% and 95% for the corresponding time points after 
150 mg/kg isosafrole.
8,2,4, The formation of the isosafrole metabolite-
cytochrome P-450 complex by isosafrole 
microsomes before and after displacement 
using isosafrole as a displacer
When isosafrole (175 p.M) was added in vitro
to isosafrole microsomes in the presence of NADPH,
absorbance maxima at 427 and 455 nm were developed with
time. The final 427/455 ratio was 1.0. Addition of
isosafrole before the NADPH did not affect the rate of
formation of the 427 and 455 nm maxima or the final
extinction values of the two peaks. Addition of NADPH
alone to isosafrole microsomes produced dual absorbance
maxima at 427 and 455 nm, indicative of the presence
of the in vivo isosafrole metabolite-cytochrome P-450
complex. However, the addition of NADPH alone did not
produce a time-dependent intensification of these
absorption peaks.
The addition of isosafrole in vitro to
isosafrole microsomes in the oxidized state produced rapid
dissociation of the isosafrole metabolite-cytochrome P-450
complex (Chapter 5). When oxidized isosafrole microsomes
were preincubated at 37°C for 30 min in the presence of
isosafrole (to allow complete displacement to occur) and
NADPH was subsequently added, maxima at 427 and 455 nm
developed with time. However, the rates of formation of
the absorbance peaks were increased by 60% and 270%
respectively, when compared with isosafrole microsomes 
to which NADPH and exogenous isosafrole were added 
simultaneously. Further the respective magnitudes of the 
427 and 455 nm peaks were increased by 570% and 420% 
(comparing displaced with undisplaced isosafrole 
microsomes). The 427/455 peak ratio was also increased 
from 1.0 (before displacement) to 1.3 (after displacement) 
indicating that the 427 nm maximum was the dominant 
species observed after the displacement process had 
occurred.
8.3. DISCUSSION
The induction of hepatic drug metabolizing 
enzymes by isosafrole in the rat is well documented. 
However, the pattern of induction of cytochrome P-450- 
mediated reactions produced following isosafrole treatment 
has not been extensively studied. Evidence reported in the 
literature suggests that isosafrole generally induces 
similar enzyme activities to those which are increased 
by 20-methylcholanthrene treatment, although certain 
phenobarbitone-inducible enzymes are also induced by 
isosafrole (Hodgson and Philpot, 1974).
Wagstaff and Short (1971) and Vainio and 
Parkki (1976) have reported the marked induction of 
4-nitroanisole (7-demethylase by isosafrole by 
factors of 6- and 10-fold respectively. Vainio and 
Parkki (1976) also demonstrated a 2.5-fold induction 
of benzo(a)pyrene hydroxylase by isosafrole treatment
and a similar increase of this activity by isosafrole 
treatment was observed by Lake (1974, Table 8.3.). However, 
a 6-fold induction of benzo(a)pyrene metabolism by 
20-methylcholanthrene was noted by Lake et at, (1973)
(Table 8.3.). An enzyme activity typically induced by 
phenobarbitone, biphenyl 4-hydroxylase, was induced to a 
similar extent by isosafrole whereas administration of 
20-methylcholanthrene produced only a slight increase in 
this activity (Table 8.3.). In contrast, biphenyl 
2-hydroxylase is markedly induced by 20-methylcholanthrene 
pretreatment. Isosafrole treatment also caused a potent 
induction of biphenyl 2-hydroxylase, less active than 20-methyl- .
cholanthjpene in this respect and more active than phenobarbitone
\/
(Table 8.3.). Isosafrole has also been shown to induce 
acetanilide hydroxylation (Table 8.3.) a reaction 
preferentially increased by 20-methylcholanthrene.
A similar pattern of induction by isosafrole 
is shown in the present work. Typical phenobarbitone- 
inducible activities such as aminopyrine and ethylmorphine 
iV-demethylases were only weakly induced by isosafrole, 
but biphenyl 4-hydroxylase was increased by isosafrole 
treatment to a level similar to that found after the 
administration of phenobarbitone. The metabolism of 
7-ethoxycoumarin, inducible by both phenobarbitone and 
20-methylcholanthrene was increased by isosafrole 
pretreatment to a level intermediate between that given 
by phenobarbitone and 20-methylcholanthrene induction 
(Table 8.2.). Biphenyl 2-hydroxylation and 7-ethoxyresorufin
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0-deethylation, reactions preferentially induced by 
20-methylcholanthrene were also markedly increased by 
isosafrole, but to a lesser extent.
Table 8.2, shows that the cytochrome P-450 
species which is released after dissociation of the 
isosafrole metabolite-cytochrome P-450 complex is 
capable of supporting metabolism, producing an increased 
enzymic specific activity per mg of protein. However, 
none of the substrates tested appeared to be metabolized 
especially well by the displaced haemoprotein, suggesting 
that the cytochrome P-450 involved is unlike either the 
phenobarbitone-or 20-methylcholanthrene-inducible 
haemoprotein, although both cytochrome P-450 and P-448 
mediated reactions were increased after displacement.
Following complete dissociation of the metabolic 
intermediate complex by 4-nitroanisole, a 2.5-fold increase in 
activity of 4-nitroanisole (9-demethylation was observed, 
and thus the released haemoprotein seems to catalyse the 
metabolism of this substrate better than other cytochrome 
P-450 substrates. This finding may in part provide an 
explanation for the dramatic induction of 4-nitroanisole 
metabolism reported by other authors. A preincubation 
period of 5 min at 37°C for isosafrole microsomes in the 
presence of 4-nitroanisole resulted in a 100% increase 
in activity compared with samples to which NADPH was 
immediately added after the substrate.
The released haemoprotein did not appear to catalyse 
7-ethoxycoumarin metabolism to a great extent since increases 
of 25% and 35% were observed for respective increases in 
cytochrome P-450 content of 70% and 100% (Table 8.2. 
and Fig. 8,1,),
Biphenyl 4-hydroxylation was also increased 
following dissociation of the isosafrole metabolite- 
cytochrome P-450 complex by preincubation at 37°C for 30 min 
in the presence of biphenyl (Table 8.2. and Fig. 8.3.).
However, when microsomes were prepared from animals at 
different times after the administration of a single dose 
of isosafrole, biphenyl 4-hydroxylase was initially 
inhibited and then induced (Fig. 8.3.). Similar inhibition 
of this enzyme activity was reported by Jaffe et at. (1969)
following administration of piperonyl butoxide to mice 
over a 0-6 h period. These authors observed a return 
to control levels of activity 24 h after giving piperonyl 
butoxide, but no induction of biphenyl 4-hydroxylase 
was detected.
Jaffe et at. (1969) also observed a dose- 
dependent activation of biphenyl 2-hydroxylase activity 
and a concomitant inhibition of biphenyl 4-hydroxylation 
in the first hour after administration of piperonyl 
butoxide to mice. These authors interpreted their 
findings, as being due to an isozymic transformation, 
resulting in the preferential hydroxylation of substrate 
in the 2-position. My results with isosafrole also
showed a dose-dependent stimulation of biphenyl 
2-hydroxylation at 2 h. Recent results, however, have 
suggested that the supposed enhancement of biphenyl 
2-hydroxylase may in part be due to the formation of 
fluorescent MDP metabolites (Tong et ai.3 1977) which 
could interfere with the fluorimetric measurement of 
2-hydroxybiphenyl. Although the induction of biphenyl 
4-hydroxylase activity seen 8 h after isosafrole 
administration was dose-dependent, the initial inhibition 
of this activity during the first 8 h was smaller for 
the higher dose level (300 mg/kg isosafrole) (Fig. 8.4b). 
The reason for this is unknown, but one explanation may 
be that the maximal inhibitory effects at the higher 
isosafrole dose level were exerted earlier than the 2 h 
time point at which the enzyme activities were first 
measured. Alternatively enzyme induction may occur 
earlier at the higher dose level.
The magnitude of the 455 nm absorbance maximum 
was shown to be a dose-dependent phenomenon. Following 
administration of piperonyl butoxide to rats at dose 
levels of 500 and 1000 mg/kg, the in vivo metabolic 
intermediate complex was increased and persisted for a 
longer duration at the higher dose level (Franklin,
1976a), My experiments showed a similar increase in 
the complex when microsomes from rats which received 150 
or 300 mg/kg isosafrole were compared (Fig. 8.4a).
Further, the amount of metabolite complex could be related
to the degree of enzyme activation observed following 
dissociation of the complex (Figs. 8.1-3,), suggesting 
that the values obtained manifested the presence
of the inhibitory complex.
The time point at which the in vivo isosafrole 
metabolite-cytochrome P-450 complex was initially detected 
may also be crucial in understanding the nature of the 
cytochrome P-450 species involved in the MDP-metabolite- 
haemoprotein interaction. The results showed that the 
time was 8 h for the 150 mg/kg isosafrole dose and 
4 h for the 300 mg/kg isosafrole dose. Franklin (1976a) 
reported the presence of an in vivo piperonyl butoxide 
metabolite-cytochrome P-450 complex at 2-4 h. However, 
the AEif55— 4 9 o changes reported at these times (about 
0.005-0.007 E) (Franklin, 1976a) were not significantly 
different from the AEi*55^490 values for microsomes from 
animals which had not received a MDP compound (Table 8.1.). 
Further, the reducing agent used by Franklin (1976a) to 
visualize the 455 nm peak was NADPH rather than sodium 
dithionite. Thus, any residual substrate which may have 
been present in the liver microsomal preparations at short 
time intervals after the administration of piperonyl 
butoxide may have been metabolized in the presence of 
NADPH, producing a 455 nm absorbance.
It is well documented that treatment of 
rats, mice and insects with MDP compounds in vivo produces 
an apparent decrease in cytochrome P-450 content relative 
to control values up to 24 h after administration
(Fig, 8,4b, and Matthews et at,3 1970; Perry and Buckner, 
1970; Philpot and Hodgson, 1971b, 1972; Franklin, 1976a). 
This phenomenon is thought to be due to the formation of 
an MDP metabolite complex which has an absorbance 
maximum at 455 nm. However, although the formation of a 
stable, reduced MDP metabolite complex^ with cytochrome 
P-450 reaches a maximum in vitro after about 10-20 min, 
the 455 nm absorbance has not been conclusively observed 
in vivo at time periods of less than 4-8 h after 
administration of MDP compounds. This suggests that a 
novel haemoprotein may be involved in the dissociable in vivo 
interaction between a MDP metabolite and cytochrome P-450.
The reason for the apparent absence of a peak 
at 455 nm characteristic of a MDP metabolite-cytochrome 
P-450 complex shortly after treatment with a MDP 
compound may be due to the technique normally used to 
visualize the complex i.e. by means of a sodium dithionite 
reduced minus oxidized difference spectrum. Thus, if 
the MDP metabolite-haemoprotein complex was present in 
the reduced state, then the addition of sodium dithionite 
would not produce any change at 455 nm in the difference 
spectrum.
In summary, the interaction in vivo of MDP 
compounds with cytochrome P-450 may be as follows; 
at short .time intervals (less than 4 h) after MDP 
administration, existing haemoprotein may be complexed 
with MDP metabolite and trapped in the reduced state.
After a longer period (greater than 4-8 h) , de novo 
synthesis of haemoprotein. may occur, complexing further 
MDP metabolite and/or producing increased levels of 
cytochrome P-450 and associated monooxygenase activities. 
Thus, the newly synthesized haemoprotein may be specifically 
associated with a MDP metabolite or produced in order to 
maintain cytochrome P-450 mediated metabolism following 
the inactivation of existing cytochrome P-450 by means of 
complex formation.
Evidence for the de novo synthesis of a haemo­
protein which binds MDP metabolite following isosafrole 
treatment was provided by experiments which utilized 
isosafrole itself as a displacing agent. Marked 
increases in the rate and extent of production of the 
isosafrole metabolite-cytochrome P-450 complex were 
observed after displacement of isosafrole microsomes 
by isosafrole. The observed increase in the rate of 
metabolism of isosafrole (measured by the rate of 
formation of absorbance maxima at 427 and 455 nm) was much 
greater than the increases noted for other substrates of 
cytochrome P-450 (Table 8.2., Figs. 8.1-3.). This 
suggests that isosafrole may induce a species of 
cytochrome P-450 which preferentially catalyses isosafrole 
metabolism. A similar interpretation was suggested by 
Buening and Franklin (1976) following administration of 
SKF-525A in vivo. Their results suggested that the species 
of cytochrome P-450 which formed an SKF-525A metabolite 
complex in vivo was the same as that most active in
the formation of a 455 nm metabolite complex formation 
from amphetamine derivatives.
CHAPTER 9
THE APPARENTLY IRREVERSIBLE BINDING 
OF 1 -ISOSAFROLE-RELATED MATERIAL" 
TO RAT AND MOUSE PROTEINS
9. THE APPARENTLY IRREVERSIBLE BINDING OF 1 ^ C-ISOSAFROLE- 
' RELATED MATERIAL TO RAT AND MOUSE PROTEINS
9.1. INTRODUCTION
The apparently irreversible binding (frequently 
termed covalent binding) of foreign compounds to components 
of hepatic tissue was first demonstrated by Miller and 
Miller (1947) following the administration of the azo dye 
butter yellow to rats. Hultin (1957) demonstrated that 
1^C-butter yellow became preferentially bound to the hepatic 
microsomal fraction following treatment with this compound 
and subsequently showed (Hultin, 1959) that in vitro 
irreversible binding of 2-aminofluorene to rat hepatic 
microsomes was dependent on the presence of NADPH.
The apparently irreversible binding of foreign 
compounds to nucleic acids has been implicated in 
carcinogenic, mutagenic and teratogenic effects. However, 
a considerable amount of experimental evidence has 
accumulated which relates the covalent binding of drug 
metabolites to microsomal lipids and proteins with the 
implication that this may be linked with hepatotoxic 
events. Cytochrome P-450 has been shown to be essential 
for the formation of active metabolites of many xenobiotics 
which subsequently bind covalently to macromolecules. 
Furthermore, the ability of hepatic microsomal enzymes 
to produce toxic metabolites is modified by inducers and 
inhibitors of cytochrome P-450-dependent monooxygenation.
The work of Mitchell and others (Mitchell et aZ., 1973; 
Mitchell and Jollow, 1975) has demonstrated the covalent
binding to proteins of a number of widely used 
therapeutic agents (e.g. paracetamol, phenacetin, 
furosemide) following overdoses of these compounds. These 
authors have also shown how the hepatotoxic effects.of such 
compounds may be modified by known inducers and inhibitors 
of cytochrome P-450 mediated reactions.
Safrole and isosafrole have been shown to 
elicit hepatotoxic and carcinogenic effects (Taylor et al.3 
1964; Hagan et at., 1965), and the work of the Millers 
(Borchert et aZ., 1973a,b; Wislocki et al.3 1976) has 
suggested a number of electrophilic metabolites of safrole 
arising from oxidation of the allyl side-chain to be probable 
proximate and/or ultimate carcinogenic metabolites in 
the mouse. Certain of these components have been shown 
to bind to mouse hepatic macromolecules and hence may be 
instrumental in causing toxic, mutagenic and carcinogenic 
responses (Wislocki et at.9 1977). Since isosafrole has 
already been shown to bind irreversibly to hepatic 
macromolecules in the rat (Elcombe et at.3 1976b) it 
was decided to investigate further the covalent binding 
of this MDP compound in the rat and the mouse.
9.2. RESULTS
9.2.1. The binding of [a>-ltfC] isosaf role-related material
to rat hepatic microsomes and tissues in vivo
Table 9.1. shows the amounts of covalently bound 
[a)-1 ^ Cjisosafrole-related material to various rat tissues 
following the administration of 14C-isosafrole (6.33 jiCi,
185 jjmol) in vivo. The binding of 1 **C-labelled material
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was considered to be covalent if 1 ^ C activity was 
detectable in the protein sample after the exhaustive 
solvent extraction procedure described in Chapter 2 
(Kappus and Reminer, 1975). A considerable amount of 
14C-label was irreversibly bound to the hepatic microsomal 
fraction and to kidney, lung, spleen, heart and testes,
24 h after the administration of 1^C-isosafrole.
Consistently higher levels of radioactivity were bound to 
all tissues from the two groups of animals which received 
vehicles plus isosafrole alone (water-1^C-isosafrole 
and oil-1^C-isosafrole treated rats) than to tissues from 
animals which received phenobarbitone or 20-methylcholanthrene 
before the administration of 14C-isosafrole. Liver 
microsomes and kidney contained much of the bound 14C- 
isosafrole-related material, lung and spleen about half 
the amount found in the kidney, and heart and testes had 
smaller amounts of bound radiolabel (Table 9.1.).
9.2.2. The binding of 1^C-isosafrole-related material to
rat hepatic microsomes in vitro
The results of experiments designed to study the 
covalent binding of 14C-isosafrole in vitro to various 
hepatic microsomal preparations are shown in Table 9.2.
A two-fold increase in the total ll+C bound to hepatic 
microsomal protein relative to control values was given 
by phenobarbitone and safrole-induced microsomes. 
20-methylcholanthrene microsomes produced a smaller 
increase in the amount of covalently bound 1^C-material.
Table 9.2. Covalent binding of 1 ^C-isosafrole-related 
material to variously induced rat hepatic 
microsomal suspensions in vitro.
Treatment nmol bound/mg microsomal protein
Oil 10.38
Phenobarbitone 21.37
20-Methylcholanthrene 14.44
Safrole 24.36
Microsomes were incubated with 1 ^C-isosafrole (180 jjM) 
at 37°C for 30 min in the presence of an NADPH- 
regenerating system.
Figure 9.1. illustrates the kinetics of the covalent binding 
of isosafrole using variously induced microsomes as the 
enzyme source. Control (water or oil) and 20-methylcholanthrene 
microsomes exhibited similar Km values (163 jllM  and 143 jjlM  
respectively) whereas phenobarbitone microsomes had a 
Km value of 66p.M. Phenobarbitone microsomes also had a 
V v value (0.24 nmol/min/mg protein) greater than the
IuaX
value of that given by control (0.14) or 20-methylcholanthrene 
(0.15) microsomes. Experiments using isosafrole microsomes 
showed that both Km (111 jj.M) and Vmax (0.19 nmol/min/mg 
protein) values were intermediate between those of 
phenobarbitone and control microsomes.
9.2,3. The time-course of the binding of 1^C-isosafrole-
related material to mouse liver in vivo
Figures 9.2. and 9.3. show the effects of various 
pretreatments on the apparently irreversible binding of 
14C derived from isosafrole to mouse liver, and the time- 
course of the binding process. The results in Fig. 9.2. 
show that animals pretreated with phenobarbitone alone had 
a greater capacity for binding 14C-isosafrole-related 
material to liver proteins than control microsomes at 2,
4 and 8 h after the administration of 14C-isosafrole 
(460 nCi, 28 jimol) . Livers from water-1^C-isosafrole 
treated animals showed an initial decrease at 4 h followed 
by an increase in covalent binding at 8 h compared with 
that at 2 h and similar activity was obtained for both water- 
and phenobarbitone-14C-isosafrole livers 12 h after 
receiving 14C-isosafrole. Control levels of binding were
FIGURE 9.1.
Kinetics of the covalent binding of lt+C-isosafrole- 
related material to variously induced rat hepatic 
microsomal suspensions in vitro
mg
X 20-MC
PB
002
Rat hepatic microsomes (1 mg protein/ml) in 
66 mM Tris-HCl were incubated with a range 
of 1 **C-isosafrole concentrations (50 yM - 
1.0 mMf 70-340 nCi) in the presence of an 
NADPH-regenerating system. The reaction was 
stopped with ethanol (5.0 ml) and the 
microsomes were extracted as described in 
Methods. Microsomes were from rats treated 
with oil (c), 20-methylcholanthrene (20-MC) 
or phenobarbitone (PB).
FIGURE 9.2.
Time course of covalent binding of 1^C- 
isosafrole related material in vivo to 
livers from mice treated with 
phenobarbitone or water
Effect of Phenobarbitone on ^C-isosafrole Covalent 
Binding in vivo, in the Mouse
70-i
pretreatment 
• control (water)
60-
PB
8 30-
20 -
0 2 4  8 12 2U
Time (hours) 
after C-isosafrole i.p .
Livers were removed from mice which were 
treated with phenobarbitone or water for 
3 days followed by 1^C-isosafrole (28 ymol, 
460 nCi) on the fourth day. Animals were 
killed at various times after the admin­
istration of 1^C-isosafrole and the livers 
were homogenized, extracted and samples were 
taken for radiometric assay as described in 
Methods.
FIGURE 9.3.
Time course of covalent binding of 1**C- 
isosafrole related material in vivo to 
livers from mice treated with iso­
safrole, 20-methylcholanthrene or oil
Effect of 20-MC and Isosafrole on ^C-isosafrole Covalent 
Binding in vivo. in the Mouse
70-i
pretreatment60-
5
>
■+ isosafrole 
•o 20-MCo>
CL
control (oil)
?  30-
8
f  20-0
1  10-
2A0 2 A 8 12
Time (hours) 
after C-isosafrole i.p.
Livers were removed from mice which were treated 
with isosafrole, 20-methylcholanthrene or oil for 
3 days followed by 14C-isosafrole (28 ymol, 460 
nCi) on the fourth day. Animals were killed at 
various times after the administration of 14C- 
isosafrole and the livers were processed as 
described in Methods.
maintained at 24 and 48 h at between 53 and 60 nmoles 
of isosafrole bound/g of liver whereas phenobarbitone- 
treated animals showed a marked decrease in covalently 
bound material at 48 h. Animals which received corn 
oil followed by 1 ^ C-isosafrole showed a somewhat higher 
level of hepatic bound radioactivity over the first 24 h 
(Fig. 9.3.) than water-14C-isosafrole livers. 20-methyl­
cholanthrene treated mouse livers showed an initial 
increase of irreversible binding up to 8-12 h after the 
radioactive dose followed by a gradual decrease below 
the corresponding control levels at 48 h (Fig. 9.3.).
In contrast, animals which received unlabelled isosafrole 
before the administration of 1^C-isosafrole had considerably 
smaller amounts of covalently bound 14C than oil-llfC- 
isosafrole livers up to 12 h after the injection of 
radiolabelled MDP compound. However, the levels of 
covalent binding found in livers from isosafrole 
pretreated (150 mg/kg for 3 days) animals were maintained 
up to 48 h after receiving 1^C-isosafrole whereas a 50% 
decrease was observed for the oil-1^C-isosafrole livers.
9.2.4. Effect of various pretreatments on epoxide
hydratase and glutathione' S-epoxide transferase 
activity in mouse hepatic microsomes and 
soluble fraction
Table 9.3. shows the results obtained when the 
various pretreatments used in this study were tested for 
their effects on mouse.hepatic microsomal epoxide hydratase 
activity and the soluble glutathione (GSH)-S-epoxide
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transferase activity. Only phenobarbitone treatment 
produced any stimulation of epoxide hydratase activity, 
and a two-fold increase of GSH-S-epoxide transferase 
activity by phenobarbitone was observed. 20-methylcholanthrene 
treatment produced a slight decrease in activity of both 
enzymes relative to control values. Isosafrole 
administration produced a 20% increase in GSH-S-epoxide 
transferase activity but no change in epoxide hydratase 
levels.
9.3. DISCUSSION
Following the administration of [w-1 ] isosafrole 
to rats in vivo, 1uC-isosafrole-related material was 
irreversibly bound to liver microsomal proteins and a 
number of tissues isolated from the treated animals 
(Table 9.1.). Isosafrole has been shown to be a weak 
hepatocarcinogen (Hagan et al.> 1965) and a considerable 
amount of 1 ^ C-radioactivity was covalently bound in this 
organ, especially to the microsomal fraction. Elcombe 
(1976) showed that about 40% of covalently bound 1^C- 
isosafrole-derived activity in the liver was bound to 
the endoplasmic reticulum, following a subcellular 
fractionation of rat liver after 14C-isosafrole treatment 
in vivo.
Although chemically reactive metabolites that 
bind covalently to liver macromolecules are probably 
formed in the liver, this is not necessarily the case 
for metabolites which are covalently bound in extra- 
hepatic tissues. Thus if an active metabolite is
relatively stable it may be transported in the blood to 
other organs of the body, e.g. safrole epoxide is 
sufficiently stable in vivo to circulate in the blood 
and be excreted in the urine (Stillwell et at., 1974).
At the other extreme, the metabolite may be so chemically 
reactive that it never leaves the tissue in which it or a 
precursor is formed by the monooxygenase system. Since the 
presence of cytochrome P-450 has been demonstrated for 
all the organs in Table 9.1. (Wickramsinghe, 1975) it is 
not clear which of the above interpretations of the 
in vivo covalent binding of 1 derived from radiolabelled 
isosafrole is correct.
Table 9.2. and Figure 9.1. illustrate that 
phenobarbitone pretreatment produced a greater amount of 
the isosafrole metabolite which bound irreversibly in vitro 
to rat hepatic microsomal proteins than pretreatment with 
20-methylcholanthrene or vehicles alone. Thus the form 
of cytochrome P-450 which is inducible by phenobarbitone 
appears to be more active than control cytochrome P-450 
or cytochrome P-448 (inducible by 20-methylcholanthrene) 
in producing the covalently bound 1^C-labelled isosafrole 
metabolite in vitro. Treatment with MDP compounds such 
as safrole (Table 9.1.) or isosafrole (Fig. 9.1.) in vivo 
increased the rate and extent of in vitro irreversible 
binding of 1 derived from radiolabelled isosafrole 
compared with controls. Approximately 30-40% of the 
cytochrome P-450 population in rat hepatic microsomes
is complexed with safrole or isosafrole metabolites 
following in vivo treatment with either of these two 
inducing agents. However, the amount of uncomplexed 
haemoprotein was still greater than that of control P-450 
and this may account for the observed increase in the 
rate and extent of covalent binding.
An alternative explanation is that the metabolic 
profile for isosafrole is altered in different ways following 
treatment with phenobarbitone, 20-methylcholanthrene or 
MDP compounds. The experiments described in Chapter 4 
showed differences in the formation of the active 
metabolite which bound reversibly to the haem of cytochrome 
P-450 when either phenobarbitone- or 20-methylcholanthrene- 
microsomes were used as the enzyme source. In support of 
this hypothesis, studies on the liver necrosis caused by 
bromobenzene-3,4-epoxide (the chemically reactive 
metabolite of bromobenzene) have been used to illustrate 
the effects of different pretreatments on covalent binding 
and hepatotoxicity. Treatment of animals with phenobarbitone 
increased the rate of formation of the 3,4-epoxide and the 
associated toxicity, whereas 20-methylcholanthrene treatment 
caused the preferential production of the unstable 2,3- 
epoxide which rapidly decomposed to 2-bromophenol 
(Zampaglione et aZ.3 1973; Jollow et al.^ 1974). Thus, 
treatment with 20-methylcholanthrene markedly decreased 
the toxicity and covalent binding of bromobenzene derivatives. 
Hence, alteration of the primary routes of metabolism by
different inducing agents may explain the observed 
differences in covalent binding of isosafrole metabolites 
in vitro.
14C~isosafrole was also metabolized to 
irreversibly-bound metabolites following administration 
of the radiolabelled compound to mice in vivo. 
Phenobarbitone treatment increased the cytochrome P-450 
content in mouse liver and presumably this was the 
reason for the initial increase in covalent binding 
noted up to about 8 h after administration of 1^C- 
isosafrole in vivo (Fig. 9.2.). The subsequent decrease 
at 48 h may have been a manifestation of the increased 
protein turnover induced by phenobarbitone (Gelboin,
1972). Induction of haemoprotein by 20-methylcholanthrene 
together with the inducing effects of the 14C-isosafrole 
which have been shown to enhance markedly the cytochrome 
P-450 concentrations in the rat and mouse (Chapters 6 
and 7), may have elicited the elevated covalent binding 
shown by 20-methylcholanthrene-1^C-isosafrole treated 
mice at the 8 and 12 h time points (Fig. 9.3.). The 
low levels of li+C binding to mouse liver after isosafrole 
treatment followed by 14C-isosafrole may be because of 
the presence of the cytochrome P-450-isosafrole 
metabolite complex in vivo, rendering part of the 
haemoprotein metabolically inactive. The gradual increase 
in the covalently bound 1IfC may be explained by the 
inductive effects of the 14C-isosafrole or dissociation
of the in vivo isosafrole metabolite-cytochrome P-450 
complex, the latter process making more cytochrome P-450 
available for metabolism.
It should be noted that none of the changes 
in covalent binding observed after the various 
pretreatments were markedly different from the control 
(water- or oil-14C-isosafrole) time profile. Interpretation 
of the results is complicated by the inducing effect of 
1^C-isosafrole itself together with the formation of the 
potentially reversible in vivo metabolic intermediate 
complex with cytochrome P-450.
It appeared that very little correlation 
could be drawn between the in vitro and the in vivo covalent 
binding of 1^C-isosafrole related material. Induction 
by either phenobarbitone or 20-methylcholanthrene in 
the rat or the mouse led to slightly lower levels of 
radioactivity bound to rat hepatic microsomes and other 
tissues in vivo (Table 9.1.) and mouse liver in vivo 
(Figs. 9.2. and 9.3.). In contrast, in vitro incubations 
with rat hepatic microsomes suggested that production of 
the covalent binding metabolite was catalysed preferentially 
by phenobarbitone microsomes rather than by control or 
20-methylcholanthrene microsomes (Table 9.2. and Fig. 9.1.). 
In addition, isosafrole pretreatment enhanced in vitro 
covalent binding to rat hepatic microsomes but decreased 
in vivo binding to mouse liver. Hence, the results from 
the in vivo experiments in the rat and the mouse appear 
to be similar, whereas results in vitro are not comparable.
The probable explanation for this is that the in vitro 
microsomal system lacks the in vivo conjugating systems, 
e.g. GSH-S-transferase, sulphotransferases and the 
cofactors necessary for glucuronyltransferase to function 
which are soluble enzyme systems. Thus a considerably 
greater amount of covalent binding to microsomal protein 
is detected in vitro than in vivo. Preliminary covalent 
binding experiments with 1 ^ C-isosafrole and liver cells 
in vitro (Elcombe et al.3 1976b) suggested that hepatocytes, 
which retain functional conjugating activity, represent 
a much closer approximation of the true in vivo system 
than hepatic microsomes.
What are the metabolites of isosafrole which 
are formed in vitro and in vivo which bind irreversibly 
to macromolecules? A detailed study of the metabolism 
of another MDP compound, safrole, has been reported and 
a number of electrophilic metabolites have been identified 
which are capable of binding covalently to hepatic 
nucleic acids and proteins (Wislocki et at.3 1976, 1977).
Fig. 9.4, illustrates the in vivo metabolites of safrole 
(a) which are suggested to be the proximate and ultimate 
carcinogens. A proximate carcinogen derived from safrole 
is 1'-hydroxysafrole (b), which has been shown to be more 
carcinogenic than safrole itself (Borchert et at. ^ 1973a,b). 
Possible ultimate carcinogenic metabolites of safrole 
include safrole 2 1,31-epoxide (c), 1 1-ketosafrole 
(d), the sulphate ester of safrole (e), and 11-hydroxysafrole- 
2'3'-epoxide (f), all of which are electrophilic as 
shown by their reaction with guanosine (Wislocki et al.j
vFIGURE 9.4.
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ultimate carcinogenic metabolites of safrole in the
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1976) and (c) and (f) are mutagenic to certain strains 
of Salmonella typhimurium.
A similar metabolic profile may be proposed 
for isosafrole (Fig. 9.5.). Epoxidation of the double 
bond may occur as for safrole metabolism. Cytochrome 
P-450-dependent hydroxylation of the I1 or 3* carbon atoms 
would lead to hydroxylated metabolites which could be 
conjugated with glutathione, sulphate or glucuronate. 
Glucuronate (Borchert et al.3 1973a; Stillwell et al.> 
1974) and sulphate (Wislocki et al.3 1977) conjugates 
of 11-hydroxysafrole have been identified as in vivo 
metabolites of safrole. Intramolecular rearrangements 
of isosafrole metabolites to safrole metabolites may also 
occur, thus providing active metabolites of safrole 
which are known to bind covalently.
A second range of putative active metabolites 
of isosafrole which would be capable of reacting with 
a number of tissue macromolecules may be formed by 
metabolism of the methylene group. Various mechanisms 
resulting in the production of reactive species such 
as carbene, free radical, carbonium ion or carbanion 
have been described in Chapter 4. However, it should 
be emphasized that the interaction involved in the 
covalent binding of the reactive isosafrole species 
to proteins is almost certainly not the same as that 
involved in the formation of the in vivo isosafrole 
metabolite-cytochrome P-450 complex. The latter complex
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is readily dissociable in the oxidized state, whereas
the 1^C-isosafrole binding which, as described in this chapter,
produced an apparently irreversible complex.
In summary, the metabolism of isosafrole 
produced a derivative which bound irreversibly to rat 
and mouse proteins in vivo. The administration of 
inducing agents elicited different amounts of covalent 
binding in the rat and the mouse e.g. pretreatment of 
animals with phenobarbitone or 20-methylcholanthrene 
produced a slightly lower amount of in vivo covalent 
binding 24 h after the 14C-isosafrole dose (Table 9.1. 
and Figs. 9.2. and 9.3.). An initial marked decrease 
in covalent binding of 1^C-isosafrole related material 
to mouse hepatic tissue was noted in animals following 
pretreatment with isosafrole. It is interesting to 
note that pretreatment with low doses of safrole or 
11-hydroxysafrole has recently been reported by 
Wislocki et at, (1977) to produce a decrease in the 
covalent binding and associated toxicity of a subsequent 
high dose of 11-hydroxysafrole in the mouse.
The levels of hepatic protein bound 
derivatives from 1'-hydroxysafrole (Wislocki et al,3
1977) and isosafrole are surprisingly high considering 
that 1'-hydroxysafrole and isosafrole are relatively 
weak hepatocarcinogens in adult rats and mice. Marked 
discrepancies between the amount of irreversibly bound 
derivatives and the number of tumours which developed
have been reported (Wislocki et al.9 1977). It seems 
likely that a major part of the macromolecules covalently 
bound are not involved in the induction of hepatic 
tumours and results of covalent binding studies should 
therefore be interpreted with care. Characterization of 
the bound derivatives and the macromolecules involved 
should help to elucidate the significance of this covalent 
binding data.
CHAPTER 10 
FINAL DISCUSSION
10. s FINAL' DISCUSSION
The present study has demonstrated the formation 
of MDP metabolite>roytochrome P-^450 complexes in vitro and 
in vivo % These complexes exhibit absorption maxima at 
427 and 455 nm in the reduced state and at 438 nm in the 
oxidized form* Studies on the preservation of these spectra 
with time suggest that the complexes are more stable when 
the cytochrome P^450 is in the reduced (Fe2+) state.
The studies described in Chapter 4 suggest that 
whereas the in vitro MDP metabolite-cytochrome P-450 complex 
is stable when formed by phenobarbitone-inducible cytochrome 
P-450, the complex produced by metabolism in the presence 
of 20-methylcholanthrene-induced microsomes is somewhat 
less stable. The administration of MDP compounds to animals 
in vivo elicits the formation of the MDP metabolite complex. 
The in vivo complex is stable enough to survive the 
preparation of hepatic microsomes and is present in the 
oxidized (Fe3+) state in isolated microsomes. Dissociation 
of this in vivo MDP metabolite-cytochrome P-450 complex may 
be effected by the addition of certain Type I substrates to 
the oxidized microsomes but not the reduced microsomes.
Thus the in vivo MDP metabolite-cytochrome P-450 complex 
appears to have intermediate stability between the in vitro 
phenobarbitone(P-450-) and 20-methylcholanthrene(P-448-)
MDP metabolite complexes. The fact that the MDP metabolite 
can be displaced by substrates when it is generated in vivo
(jorvWoV o'" (\*L I c. To So
but not when it is formed in v i t r o ould be explained by
the formation of a novel haemoprotein inducible bv MDP 
compounds (Chapter 5),
Isosafrole has been shown to induce cytochrome 
P—450 and associated monooxygenation in several laboratory cxntm 
species, A part of the cytochrome P-450 present in microsomes 
from animals treated with isosafrole is metabolically inactive 
due to the presence of the inhibitory isosafrole metabolite 
complex. The cytochrome P-450 complexed with a MDP 
metabolite can be released in vitro by the addition of a 
displacing substrate and the resultant haemoprotein has been 
shown to be metabolically competent (Chapter 8).
The pattern of metabolism induced by isosafrole 
appears to be unlike that induced either by phenobarbitone 
or 20-methylcholanthrene. Instead, the particular mono­
oxygenase reactions increased by administration of isosafrole 
suggest that both phenobarbitone- and 20-methylcholanthrene- 
inducible monooxygenation processes are increased by treatment 
with isosafrole. Polychlorinated biphenyls (PCBs), which also 
induce a mixed type of induction profile, have been shown to 
increase the amounts of microsomal proteins induced by the 
concomitant administration of phenobarbitone and 20-methyl­
cholanthrene. In contrast, isosafrole treatment results 
in the induction of a protein with a different electrophoretic 
mobility from both the phenobarbitone- and the 20-methylchol— 
anthrene^inducible proteins (Chapter 6), This protein is 
also induced following treatment with a combination of either 
phenobarbitone and isosafrole or of 20-methylcholanthrene and 
isosafrole.
The findings may be rationalized by' hypothesizing 
that the hepatic microsomal protein induced by the 
administration of isosafrole and some other MDP compounds 
may be a form of haemoprotein which is associated with a 
MDP metabolite in vivo i.e. the MDP metabolite-cytochrome 
P^450 complex.
The displacement phenomenon is detectable with 
hepatic microsomes from animals treated in vivo with 
isosafrole alone or in combination with phenobarbitone or 
20-methylcholanthrene (Chapter 7), It appears that the best 
displacing agents are lipophilic and have a high affinity 
for the Type I binding site of cytochrome P-450. A point 
of major interest is that when homologous series of displacers 
are tested an optimal displacing compound is found for each 
series. Furthermore, molecular models of these optimal 
displacing agents show that all are sterically similar.
The particularly potent displacing activity of 2-n-heptyl- 
benzimidazole may be explained in the light of the postulated 
bidentate ligand nature of the isosafrole metabolite when 
complexed with cytochrome P-450 (Chapter 5) in that 2-n-heptyl 
benzimidazole may also be capable of interaction with both 
Type I and Type II binding sites. Certain steroids were 
also shown to be good displacing agents and it may be 
postulated that the steroid nucleus possesses a carbon chain 
which is sterically comparable with the best displacing 
agents of each series of compounds.' Hence a possible role 
for the displacement process in vivo may be suggested.
Dissociation of the isosafrole metabolite—cytochrome P—450 
complex in vivo by endogenous steroids (or fatty acids) might 
be a physiologically significant means of releasing a 
metabolically competent cytochrome P-450 which is then 
available for metabolism of substrates.
If the synthesis of a novel haemoprotein is 
induced by treatment with MDP compounds, then the initial 
production of a MDP metabolite-cytochrome P-450 complex 
will be with existing haemoproteins leading to inhibition 
of cytochrome P-450-mediated metabolism. Thus the metabolism 
of endogenous substrates will be decreased and more cytochrome 
P-450 may be synthesized to compensate for the complexed 
haemoprotein. The induced haemoprotein may be responsible 
for metabolizing the administered MDP compound removing 
it from the system by producing increased metabolism. This 
novel cytochrome P-450 may provide a different site of 
metabolic oxidation of the MDP compound or may form the MDP 
metabolite-cytochrome P-450 complex more readily than 
endogenous haemoproteins, thus reducing complexation with 
other forms of cytochrome P-450.
Further information regarding substrate 
metabolism by isosafrole-induced cytochrome P-450 and the 
displacement phenomenon could be obtained by isolating the 
haemoprotein in a purified form. The metabolic capabilities 
of the form of cytochrome P-450 inducible by isosafrole could 
then be compared with those of control and phenobarbitone- 
inducible cytochrome P-450 and 20-methylcholanthrene-inducible
cytochrome P-448, By investigating the metabolism of 
isosafrole in vitro by these purified preparations a better 
understanding of. the importance of some of the multiple 
forms of cytochrome P-450 involved in the formation of 
in vivo MDP metabolite-haemoprotein complexes would be 
obtained. The relevance of the displacement phenomenon 
in vivo may also be elucidated by attempting to dissociate 
the MDP metabolite-cytochrome complexes formed in the 
presence of the purified haemoproteins. These experiments 
would provide further information on the stability of the 
complexes,
Further work is also necessary to establish the 
identity of the isosafrole metabolite-related material which 
is released from cytochrome P-450 following the dissociation 
of the MDP metabolite complex. This might be accomplished 
by the use of radio-gas chromatographic techniques following 
the administration of 3H-isosafrole of high specific activity 
to rats and releasing 3H-labelled material from hepatic 
microsomes by the displacement process. The 3H-labelled 
substance could also be isolated by thin layer chromatography 
and identified by gas chromatography-mass spectrometry. This 
could also provide information on the nature of the isosafrole 
metabolite which binds to the haem iron of cytochrome P-450.
Following the administration of 14C-isosafrole 
to rats and mice, a considerable amount of 1^C-isosafrole- 
related material has been shown to bind to the proteins 
of a number of rat tissues and mouse livers. This apparently
irreversible binding may. be related to the hepatotoxicity 
of certain MDP compounds such as safrole and isosafrole. 
Identification of the covalently bound MDP metabolite and 
the macromolecules to which it is bound would help to 
elucidate the role of covalent binding in the carcinogenic 
action of MDP compounds such as safrole and isosafrole.
REFERENCES
Al-Gailany, K,A,S, (1975) Ph,D, Thesis, University of Surrey.
Al-Gailany, K.A.S., Wilson, A.G.E, and Bridges, J.W. (1974) 
Biochem. Soc. Trans.' 2,, 113—117,.
Alvares, A.P. , Bickers, D.R, and Kappas, A. (1973) Proc. 
Natl. Acad. Sci, U.S.A.vTO, 1321-1325,
Alvares, A,P,,.Schilling, G.R,, Levin, W. and Kuntzman, R. 
(1967) Biochem, Biophys. Res. Commune 29, 521-526.
Alvares, A.P, and Siekevitz, P. (1973) Biochem. Biophys. 
Res. Commun. 54^ , 923-929.
Anders, M.W, (1971) Ann. Rev. Pharmacol. .11, 37-56.
Anders, M.W. and Mannering, G.J. (1966) Mol. Pharmacol. 2, 
319-327.
Arnett, C.D., Callery, P.S. and Zenker, N, (1977) Biochem. 
Pharmacol. 26^ , 377-380.
Axelrod, J. (1955) J. Biol. Chem, 214, 753-763.
Bejnarowicz, E.A. and Kirch, E.R. (1963) J. Pharm. Sci.
52, 988-993.
Benedetti, M.S., Malnoe, A, and Broillet, A.L. (1977) 
Toxicology, 69-83.
Bentley, P. and Oesch, F. (1975) FEBS Lett.>59, 291-295.
Bidleman, K, and Mannering, G.J, (1970) Mol, Pharmacol, 
v 6, 697—701,
Birkett, D.J. (1977) Clin, Exp, Pharmacol, Physiol."
221-222.
Birnbaum, L.S., Baird, M,B, and Massie, H.R. (1976) Res, 
Comm, Chem, Path. Pharmacol, 115, 553-562.
Black, 0., Cantrell, E.T. , Buccino, R.J, and Bresnick, E.
(1971) Biochem. Pharmacol." 20, 2989-2998.
Blumberg, W.E, and Peisach, J. (1971) in Probes and
Structure and Function of Macromolecules and - Membranes 
(Chance, B., Yonetani, T. and Mildvan, A.S., eds,),
Vol. 2, pp.215-229, Academic Press, New York.
Bock, K.W., von Clausbruch, U.C., Josting, D. and Ottenwalder, 
H. (1977) Biochem. Pharmacol. 26, 1097-1100.
Bond, E.J. and De Matteis, F. (1969) Biochem. Pharmacol.
18, 2531-2549,
Boobis, A.R., Nebert, D.W. and Felton, J.S. (1977) Mol. 
Pharmacol. L3, 259-268.
Borchert, P., Wislocki, P.G., Miller, J.A. and Miller, E.C. 
(1973a) Cancer Res." 33, 575-589,
Borchert, P., Miller, J.A,, Miller, E.C, and Shires, T.K. 
(1973b) Cancer Res," 33, 590—600,
Buening, M.K, and Franklin, M.R, (1976) Drug Metab. Disp. 
N <4, 244-255,
Burchell, B, (1977) FEBS Lett.";78, 101-104,
Burke, M,Dt and Bridges, J.W, (1975) Xenobiotica, 5,
357-376,
Burke, M.D, and Mayer, R.T. (1975) Drug Metab. Disp. 3^, 
245-253.
Burke, M.D., Prough, R.A. and Mayer, R.T. (1977) Drug Metab. 
Disp. 5j 1-8.
Casida, J.E. (1970) J. Agric. Food Chem. 18, 753-772.
Casida, J.E,, Engel, T.T., Essac, E.G., Kamienski, F.X.
and Kuwatsuka, S. (1966) Science, 153, 1130-1133.
Chang, C.K. and Dolphin, D. (1976a) J. Am. Chem. Soc.
98, 1607-1609.
Chang, C.K. and Dolphin, D. (1976b) Proc. Natl. Acad.
Sci. U.S.A. 73, 3338-3342.
Chaplin, M.D. and Mannering, G.J. (1970) Mol. Pharmacol.
6, 631-640.
Chevion, M,, Peisach, J. and Blumberg, W. (1977) J. Biol. 
Chem.’ 352, 3637-3645,
Collman, J.P., Sorrell, T.N, and Hoffman, B.M, (1975)
J, Am. Chem. Soc,v97, 913-914.
Comai, K, and Gay lor,- J.L. (1973) J. Biol, Chem.' 348, 
4947-4955.
Conney, A.H, (1967) Pharmacol. Rev,' "19, 317-366.
Conney, A,H,, Levin, W, , Jacobson, M. and Kuntzman, R.
(1969) in Microsomes and Drug Oxidations (Gillette 
J.R., Conney, A,H., Cosmides, G.J., Estabrook, R.W. 
Fouts, J.R. and Mannering, 'G.J.-, eds.) , pp.279-295, 
Academic Press, New York and London.
Conney, A.H,, Lu, A.Y.H., Levin, W., Somogyi, A., West, S 
Jacobson, M., Ryan, D. and Kuntzman, R* (1973)
Drug Metab. Disp. 1, 199-208.
Cooper, D.Y., Schleyer, H,, Rosenthal, 0., Levin, W. , Lu, 
A.Y.H., Kuntzman, R. and Conney, A.H. (1977) Eur. 
J. Biochem. 7_4, 69-75.
Correia, M.A. and Mannering, G.J. (1973) Drug Metab. 
Disp. 1, 139-149.
Creaven, P.J. and Parke, D.V. (1966) Biochem. Pharmacol. 
15, 7-16.
Creaven, P.J,, Parke, D.V. and Williams, R.T, (1965) 
Biochem, J, _96, 879-885.
De Matteis, F. (1970) FEBS L e t t 343-345.
Dent, J.G. and Johnson, P, (1974) in Liquid Scintillation 
Counting (Crook, M,A. and Johnson, P. , eds.) , Vol. 3, 
pp.122-131, Heyden,
DiAugustine, R.P., Eling, T.E. and Fouts, J.R. (1970) 
Chem-Biol. Interactions" 2, 17-27.
Dickins, M. and Bridges, J.W, (1976) Naunyn-Schmiedebergfe 
Arch. Pharmacol." 293 (Suppl.) R53.
Dickins, M., Elcombe, C.R., Nimmo-Smith, R.H. and Bridges, 
J.W, (1975) Biochem, Soc, Trans.\3, 970-972.
Diehl, H., Capalna, S. and Ullrich, V. (1969) FEBS Lett. 
99-102.
Diehl, H., Schadelin, J. and Ullrich, V. (1970) Hoppe- 
Seyler's Z. Physiol. Chem. 351, 1359-1371.
Dignam, J.D. and Strobel, H,W. (1977) Biochemistry, 16, 
1116-1123.
Dixon, M. and Webb, E.C. (1958) Enzymes, pp. 25-27. 
Longmans, Green and Co., London and New York.
Duppel, W. and Ullrich, V, (1976) Biochim. Biophys. Acta. 
426, 399-407,
Eagleson, C, (1942) Soap Sanit, Chem. Ij3, 125-127 . 
Elcombe, C.R, (1976) Ph.D. Thesis, University of Surrey.
Elcombe, C,R,, Bridges, J.W.., Gray, T.J.B. , Nimmo-Smith, 
R.H, and Netter, K.J, (1975a) Biochem. Pharmacol.
^24, 1427-1433,
‘Elcombe, C.R,, Bridges, J.W. , Nimmo-Smith, R.H. and
Werringloer, J. (1975b) Biochem. Soc, Trans.' _3, 
967-970.
Elcombe, C.R., Bridges, J.W, and Nimmo-Smith, R.H. (1976a) 
Biochem, Biophys, Res. Commun. 71, 915-919,
Elcombe, C.R., Bridges, J.W. , Dickins, M., Sweatman, B.C., 
Nimmo-Smith, R.H. and Netter, K.J. (1976b) Naunyn- 
Schmiedeberg*s Arch. Pharmacol. 293 (Suppl.) R50.
Eling, T.E. and DiAugustine, R.P. (1971) Biochem. J. 123, 
539-549.
Epstein, S.S., Andrea, J., Clapp, P., Mackintosh, D. and 
Mantel, N. (1967a) Toxicol. Appl. Pharmacol. 11, 
442-448.
Epstein, S.S., Joshi, S., Andrea, J., Clapp, P., Falk, H. 
and Mantel, N. (1967b) Nature, 214, 526-528.
Estabrook, R.W., Baron, J,, Peterson, J, and Ishimura, Y. 
(1972a) in Biological Hydroxylation Mechanisms 
(Boyd, G.S, and Smellie, R.M.S. , eds.), pp.159-185, 
Academic Press, New York and London,
Estabrook, R.W.., Cooper, D.Y, and Rosenthal, 0, (1963) 
Biochem, Z .>338, 741—755.
Estabrook, R.W,, Hildebrandt, A,G., Baron, J., Netter, K.J. 
and Leibman, K.C. (1971) Biochem, Biophys. Res, 
Commun."Vl2, 132-139,
Estabrook, R.W,, Peterson, J,, Baron, J, and Hildebrandt, A. 
G. (1972b) in Methods in Pharmacology (Chignell,
C.F. , ed.) , Vol. 2, pp.303-350, Meredith Corporation, 
New York.
Fasco, M.J., Piper, L.J. and Kaminsky, L.S. (1977) Arch. 
Biochem. Biophys. 182, 379-389.
Fishbein, L. and Falk, H.L. (1969) Environ. Res. 297-308.
Fishbein, L., Falk, H.L., Fawkes, J., Jordan, S. and 
Corbett, B. (1969) J. Chromatog. 41, 61-79.
Franklin, M.R. (1971) Xenobiotica, 1, 581-591.
Franklin, M.R. (1972) Biochem. Pharmacol. 21, 3287-3299.
Franklin, M.R, (1974a) Xenobiotica,'£, 133-142.
Franklin, M.R. (1974b) Xenobiotica, jl, 143-150,
Franklin, M.R. (1974c) Drug Metab, D i sp.2, 321-326,
Franklin, M.R, (1974d) Mol, Pharmacol." 10, 975-985.
Franklin, M.R. (1976a) Environ. Hlth. Persp.'14, 29-37.
Franklin, M.R, (1976b). Chem-Biol, Interactions" 14, 337-346,
Franklin, M.R. and Estabrook, R.W, (1971) Arch. Biochem. 
Biophys," "143, 318—329.
Fujii, K,, Jaffe, H., Bishop, Y,, Arnold, E., Mackintosh,
P. and Epstein, S.S. (1970) Toxicol, Appl. Pharmacol, 
'-"lie, 482-494.
Furia, T.E, and Bellanca, N, (1971) in Fenarolits Handbook 
of Flavour Ingredients, Cleveland, Ohio, Chemical 
Rubber Company, p.610,
Garfinkel, D, (1958) Arch. Biochem. Biophys. 77' 493-509.
Garfinkel, D. (1963) Comp. Biochem. Physiol. 8r 367-379.
Gelboin, H.V, (1972) in Fundamentals of Drug Metabolism and
Disposition (La Du, B.N,, Mandel, H.G. and Way, E.L. 
eds,), pp.279-307, Williams and Wilkins, Baltimore.
Gelboin, H.V., Wiebel, F. and Diamond, L. (1970) Science, 
170, 169-171.
Gillette, J.R. (1963) Prog. Drug Res. 6, 11-73.
Gillette, J.R,, Brodie, B.B. and La Du, B.N. (1957) J. 
Pharmacol. Exp. Ther," 119, 532-540,
Goldstein, J.A,, Hickman, P., Bergman, H., McKinney, J.D. 
and Walker, M.P. (1977) Chem-Biol, Interactions,
"-"17, 69-87,
Gray, T,JtB. (1972) Ph.D.. Thesis, University of Surrey,
Gray, T.J.B. and Parke, D.V. (1973) 9th Int. Congress 
Biochem, (Stockholm), Abs. p,341,
Griffin, B,W, and Peterson, J.A, (1975) J, Biol. Chem, 
"350, 6445-6451.
Guengerich, F.Pt, Ballou, D.P, and Coon, M.J, (1976) 
Biochem. Biophys. Res. Comrnun." 70, 951-956.
Hagan, E,C., Jenner, P.M., Jones, W.I., Fitzhugh, O.G., 
Long, E.L., Brouwer, J.G. and Webb, W.K. (1965) 
Toxicol. Appl. Pharmacol. J7, 18-24.
Hansch, C. (1968) J. Med. Chem. 11, 920-924.
Hart, L.G. and Fouts, J.R. (1963) Proc. Soc, Exp, Biol. 
Med. 114, 388-393.
Hart, L.G. and Fouts, J.R. (1965) Biochem. Pharmacol. 14 
263-272.
Haugen, D ,A. and Coon, M.J. (1976) J. Biol. Chem. 254, 
7929-7939.
Haugen, D.A., Coon, M.J. and Nebert, D.W. (1976) J. Biol 
Chem."-251, 1817-1827.
Haugen, D.A., Van der Hoeven, T,A, and Coon, M.J, (1975) 
J, Biol. Chem,v 250, 3567-3570.
Hayaishi, 0, (1962) in Oxygenases, pp.1-29, Academic Press, 
London and New York,
Hennessy, D,J, (1965) J. Agric. Food Chem. i3^ , 218-220.
Hildebrandt, A,G. (1973) Drug Metab. Disp," JL, 182-183.
Hildebrandt, A.G., Leibman, K.C, and Estabrook, R.W. (1969) 
Biochem, Biophys, Res, Comrnun. 37, 477-485,
Hill, H.A.O., Roder, A. and Williams, R.J.P, (1970) 
Naturwissenschaften," 57, 69-72.
Hodgson, E. (1974) in Survival in Toxic Environments
(Khan, M.A.Q. and Bederka, J.P. , eds.), pp.230-232, 
Academic Press, New York and London.
Hodgson, E. (1976) in Essays in Toxicology (Hayes, W.J. , ed) , 
Vol. 7, pp.79-80, Academic Press, New York and London,
Hodgson, E, and Philpot, R.M. (1974) Drug Metab. Rev, _3, 
231-301.
Hodgson, E., Philpot, R.M., Baker, R.C, and Mailman, R.B,
(1973) Drug Metab. Disp. 1, 391-401.
Holder, G.M., Little, P.J., Ryan, A.J. and Watson, T.R.
(1976) Biochem, Pharmacol. 25, 2747-2750.
Holland, V.R., Saunders, B.C., Rose, F.L. and Walpole, A.L.
(1974) Tetrahedron," 30, 3299-3302,
Hrycay, E.G. and O'Brien, P.J, (1971a) Arch, Biochem. 
Biophys." 147, 14-27,
Hrycay, E.G. and 0*Brien, P.J. (1971b) Arch* Biochem.. 
Biophys^ T47, 28-35.
Hrycay, E.G., Gustafsson, J,-£,, Ingelman-Sundberg, M. and 
Ernster, L. (1975a) FEBS. Lett.^56, 161-165.
o
Hrycay, E.G., Gustafsson, J.-A,, Ingelman-Sundberg, M. and 
Ernster, L. (1975b) Biochem. Biophys, Res, Comrnun.
' '£6, 209-216,
Hrycay, E.G., Gustafsson, J.-A., Ingelman-Sundberg, M. and 
Ernster, L. (1976) Eur. J. Biochem. 61, 43-52.
Hultin, T. (1957) Exp. Cell Res. 13, 47-59.
Hultin, T. (1959) Exp. Cell Res. 18, 112-125.
IARC Monographs on the Evaluation of Carcinogenic Risk
of Chemicals to Man (1976) Vol. 10, pp.231-244,
Lyon, France: International Agency for Research
on Cancer.
Ichikawa, Y. and Yamano, T. (1967) Biochim, Biophys. Acta. 
131, 490-497.
Ikeda, M., Tanaka, S. and Katayama, T. (1968) Mol.
Pharmacol. 4^, 38-43.
Illing, H.P.A, and Netter, K.J, (1975) Xenobiotica,\5, 1-15.
Imai, Y, and Sato, R, (1966) Biochem. Biophys. Res.
Comrnun,‘' 22, 620-626.
Imai, Y, and Sato, R, (1967a) Eur, J. Biochem.' lf 419-426.
Imai, Y. and Sato, R. (1967b) J, Biochem/ 52, 239-
Imai, Y, and Sato, R. (1974a) J. Biochem,' 75/ 689-697.
Imai, Y. and Sato, R, (1974b) Biochem. Biophys. Res.
Comrnun,' 6C), 8-14.
Ioannides, C, and Parke, D.V. (1976) Chem-Biol, Interactions 
14, 241-249.
Ivanetich, K.M., Bradshaw, J,J., Marsh, J.A,, Harrison,
G.G. and Kaminsky, L.S. (1976) Biochem, Pharmacol.
25, 773-778.
Jacobson, M., Levin, W,, Lu, A.Y.H., Conney, A.H. and
Kuntzman, R. (1973) Drug Metab. Disp. 1, 766-774.
Jaffe, H., Fujii, K., Guerin, H., Sengupta, M. and Epstein,
5.5. (1969) Biochem. Pharmacol. 18^ , 1045-1051.
Jaffe, H., Fujii, K., Sengupta, M., Guerin, H. and Epstein,
5.5. (1968) Life Sci. 7, 1051-1062.
James, M.O., Fouts, J.R. and Bend, J.R. (1976) Biochem. 
Pharmacol. 2J5, 187-193.
Jansson, I., Orrenius, S., Ernster, L. and Schenkman, J.B. 
(1972) Arch. Biochem. Biophys/ 151, 391-400,
Jefcoate, C.R.E., Calabrese, R.L. and Gaylor, J.L. (1970)
Mol. Pharmacol./ 6, 391-401,
Jefcoate, C.R.E, and Gaylor,, J.L, (1969) Biochemistry,\8, 
3464-3472..
Jefcoate, C.R.E,, Gaylor, J.L, and Calabrese, R.L, (1969) 
B i o c h e m i s t r y 3455-3463.
Johnson, E.F. and Muller-Eberhard, U, (1977) Biochem. 
Biophys. Res. Comrnun. 76, 652-659.
Jollow, D.J. , Mitchell, J.R,, Zampaglione, N. and Gillette,
. J.R. (1974) Pharmacology, 11, 151-169.
Joly, J.G,, Ishii, H., Teschke, R., Hasumura, Y. and
Lieber, C.S. (1973) Biochem. Pharmacol. 2^ 2, 1532-1535.
Joly, J.G., Villeneuve, J.P. and Mavier, P. (1977)
Alcoholism, 1, 17-20.
Jonsson, J. and Lindeke, B. (1976) Acta. Pharm. Suecica 
13, 313-320.
Kadlubar, F.F., Morton, K.C, and Ziegler, D.M, (1973)
Biochem. Biophys, Res. Comrnun. 54^ , 1255-1261.
Kampffmeyer, H. and Kiese, M. (1963) Naunyn-Schmiedeberg1s 
Arch. Pharmacol. 244, 375-383.
Kampffmeyer, H, and Kiese, M, (1964) Naunyn-Schmiedeberg1s 
Arch, Pharmacol. 246, 397-402,
Kappus, H. and Remmer, H. (1975) Biochem. Pharmacol./ 24, 
1079-1084,
Katagiri, M,, Gongali, B,N, and Gunsalus, I.e. (1968)
J, Biol, Chem./24 3, 3543—3546.
Kawalek, J.C., Levin, W,, Ryan, D,, Thomas, P.E. and Lu,
A.Y.H, (1975) Mol, Pharmacol,' 1L, 874-878.
Klingenberg, M. (1958) Arch, Biochem. Biophys/ 75, 376-386.
Labbe, R.F. and Nishida, G. (1957) Biochim. Biophys. Acta. 
^26, 437.
Laemmli, U.K. (1970) Nature, 227, 680-685.
Lake, B.G. (1974) Ph.D. Thesis, University of Surrey.
Lake, B.G., Hopkins, R., Chakraborty, J., Bridges, J.W.
and Parke, D.V. (1973) Drug Metab. Disp. 1, 342-349.
Lake, B.G. and Parke, D.V. (1972) Biochem, J, 130, 86P.
Leibman, K.C. and Estabrook, R.W. (1971) Mol. Pharmacol.
7, 26-32.
Leibman, K.C, and Ortiz, E. (1973) Drug Metab. Disp. 1, 
775-779.
Levin, W., Jacobson, M., Sernatinger, E. and Kuntzman, R. 
(1973a) Drug Metab. Disp, 1, 275-284.
Levin, W., Lu, A.Y.H., Jacobson, M., Kuntzman, R., Poyer,
J.L, and McCay, P.B. (1973b) Arch. Biochem. Biophys.
Levin, W., Ryan, D,, West, S.B, and Lu, A.Y.H, (1973c)
Drug Metab. Disp/ ly 602—605.
Levin, W, , Ryan, D., West, S.B. and Lu, A.Y.H. (1974) J.
Biol, Chem. 249, 1747-1754,
Lichtenberger, F., Nastainczyk, W, and Ullrich, V. (1976) 
Biochem, Biophys. Res. Comrnun. 70, 939-946.
Lineweaver, H. and Burk, D. (1934) J. Am, Chem. Soc. 56, 
658-666.
Lipscomb, J.D, and Gunsalus, I.C.(1973) Drug Metab. Disp.
<L, 1-5.
Long, E.L., Nelson, A.A., Fitzhugh, O.G. and Hansen, W.H.
(1963) Arch. Path. 75, 595-604.
Lotlikar, P.D. and Wasserman, M.B. (1972) Biochem. J.
129, 937-943. .
Louis-Ferdinand, R.T. and Fuller, G.C. (1970) Biochem.
Biophys. Res. Comrnun. 38_f 811-816.
Louis-Ferdinand, R.T. and Fuller, G.C. (1972) Toxicol.
Appl. Pharmacol. 23^ , 492-500.
Lowry, O.H, , Rosebrough, N.J., Farr, A.L, and Randall, R.J. 
(1951) J. Biol. Chem/ T93, 265-275.
Lu, A.Y.H, and Coon, M.J, (1968) J. Biol. Chem." 243, 1331-1332.
Lu, A.Y.H, and Levin, W. (1974) Biochim, Biophys. Acta. 344, 
205-240,
Lu, A.Y.H., Levin, W, , Ryan, D., West, S.B,, Thomas, P.E., 
Kawalek, J , Kuntzman, R . and Conney, A.H, (1976)
Ass, Scient. Publ.., Amsterdam, pp. 169-183.
Lu, A.Y.H,, Levin, W., Selander, H. and Jerina, D.M, (1974) 
Biochem,. Biophys, Res. Comrnun/ 51, 1348-1355.
Lu, A.Y.H,, Ryan, D,, Jerina, D.M., Daly, J.W, and Levin, W.
(1975) J. Biol. Chem. 250, 8283-8288.
Lucier, G.W,, McDaniel, O.S. and Matthews, H.B. (1971)
Arch. Biochem. Biophys/ 145, 520-530.
Mahler, H.R. and Cordes, E.H. (1971) Biological Chemistry, 
2nd edn., pp.674-675, Harper and Row, New York and 
London.
Mailman, R.B. and Hodgson, E. (1972) Bull. Environ.
Contam. Toxicol. £5, 186-192.
Mailman, R.B., Kulkarni, A.P,, Baker, R.C. and Hodgson, E.
(1974) Drug Metab. Disp. 2 , 301-308.
Maines, M.D. and Kappas, A. (1975) J. Biol. Chem. 250, 
4171-4177.
Maines, M.D, and Kappas, A, (1977) Proc. Natl. Acad. Sci. 
U.S.A,"74, 1875-1878,
Mansuy, D,, Nastainczyk, W. and Ullrich, V, (1974) Naunyn- 
Schmiedberg*s Arch. Pharmacol."28j>, 315-324,
Marsh, J.A., Bradshaw, J.J,, Sapeika, G.A., Lucas, S.A., 
Kaminsky, L,S, and Ivanetich, K,M. (1977) Biochem. 
Pharmaco 1,/ 2 6, 1601-1606,
Mason, H.S, (1957) Adv. Enzymol/ 19, 79-233.
Mason, H.S,, Fowlks, W.L, and Peterson, E. (1955) J. Am.
Chem, Soc. TV, 2914-2915.
Mason, H.S., North, J.C, and Vanneste, M, (1965) Fed.
Proc. 24, 1172-1180.
\/ x V
Matthews, H.B., Skrinjaric-Spoljar, M. and Casida, J.E. (1970) 
Life Sci. 9, I, 1039-1048.
Mayer, R.T, and Burke, M.D. (1976) Pest. Biochem. Physiol.
6, 377-385.
Mayer, R.T. and Prough, R.A, (1976) Toxicol. Appl.
Pharmacol, 3_8, 439-454.
Metcalf, R.L. (1967) Ann. Rev. Entomol. L2, 229-
Miller, E.C. and Miller, J.A. (1947) Cancer Res. 1_, 39-42.
Mitchell, J.R. and Jollow, D.J. (1975) Gastroenterology,
68, 392-410.
Mitchell, J.R., Jollow, D.J., Gillette, J.R. and Brodie,
B.B. (1973) Drug Metab. Disp.^l, 418-423.
Narasimhulu, S, (1975a) in Cytochromes P-450 and b5 Structure, 
Function and Interaction (Cooper, D.Y,, Rosenthal, 0., 
Snyder, R. and Witmer, C., eds>) , pp.271-286, Pleunum 
Press, New York and London,
Narasimhulu, S, (1975b) in Cytochromes P-450.and b 5 Structure, 
Function and Interaction (Cooper, D.Y., Rosenthal, 0., 
Snyder, R. and Witmer, C, , eds.) , pp.331-332, Plenum 
Press, New York and London.
Narasimhulu, S., Cooper, D.Y, and Rosenthal, 0. (1965)
Life S c i / 4^, 2101-2107.
Nash, T. (1953) Biochem, J. 55, 416-422.
Nebert, D.W. , Kumaki, K,, Sato, M. and Kon, H. (1976) 
Hoppe-Seyler1s Z. Physiol. Chem. 357 1044-1045.
Netter, K.J. (1960) Naunyn-Schmiedeberg1s Arch. Exp. Path. 
Pharmakol/ 238, 292-300.
Netter, K.J, and Seidel, G. (1964) J, Pharmacol. Exp.
Ther. 146, 61-65.
Niwaguchi, T. and Inoue, T. (1975) Chem. Pharm. Bull.
23, 1300-1303.
Oesch, F., Jerina, D.M. and Daly, J.W. (1971) Biochim,
Biophys. Acta. 227, 685-691,
Omura, T, and Sato, R, (1962) J, Biol. Chem/ 237, 1375-1376.
Omura, T, and Sato, R. (1964a) J, Biol, Chem,v 239, 2370-2378
Omura, T. and Sato, R. (1964b) J, Biol. Chem.' 239, 2379-2385
Orrenius, S, (1965) J, Cell Bjol.v 26, 713-723.
Orrenius, S,, Wilson, B. J, , von Bahr, C, and Schenkman, J.B.
(1972) in Biological Hydroxylation Mechanisms (Boyd, 
G.S, and Sine Hie, R.M.S., eds.) , pp.55-77, Academic 
Press, London and New York.
Palmer, E, D , and Cawthorne, M,A. (1974) Xenobiotica, 4,
209-217.
Parke, D.V, (1975) in Enzyme Induction (Parke, D.V., ed.) , 
pp.207-271, Plenum Press, London and New York.
Parke, D.V. and Rahman, H. (1970) Biochem, J. 119, 53P.
Parke, D.V. and Rahman, H. (1971) Biochem. J. 123, 9P.
Paul, K.G., Theorell, H. and Akeson, A. (1953) Acta. Chem. 
Scand. 1284-1287.
Peisach, J., Appleby, C.A. and Blumberg, W.E. (1972) Arch. 
Biochem. Biophys. 150, 725-732.
Peisach, J, and Mannering, G.J. (1975) Mol. Pharmacol. 11, 
818-823,
Peisach, J,, Stern, J.O, and Blumberg, W.E, (1973) Drug 
Metab, Disp,' 1, 45-57,
Perry, A.S, and Buckner, A.J, (1970) Life Sci, II,
335-350.
Peterson, J.A, (1971) Arcfu Biochem. Biophys, 144, 678-693.
Peterson, J.A. and Griffin, B,W. (1973) Drug Metab. Disp.
H ,  14-19.
Philleo, W.W, , Schonbrod, R.D. and Terriere, L.C. (1965)
J, Agric, Food Chem. 13, 113-115,
Philpot, R.M, and Hodgson, E., unpublished work cited in 
Hodgson, E. and Plapp, F.W. (1970) J. Agric. Food 
Chem. 18, 1048-1055.
Philpot, R.M. and Hodgson, E. (1971a) Life Sci. 10, II, 
503-512.
Philpot, R.M. and Hodgson, E. (1971b) Chem-Biol.
Interactions, £, 185-194.
Philpot, R.M. and Hodgson, E. (1972) Mol. Pharmacol. 8_, 
204-214.
Pohl, L.R., Porter, W.R., Trager, W.F., Fasco, M.J. and
Fenton, J.W. (1977) Biochem. Pharmacol. _2£, 109-114.
Poland, A. and Glover, E, (1974) Mol. Pharmacol. 10, 349-359.
Pool, W.O., Harwood, H.J. and Ralston, A.W. (1937) J. Am, 
Chem, Soc.vS9, 178-179,
Pousada, C.R, and Lechner, M.C. (1972) Biochem. Pharmacol.
X  U » y j . a  , V3. \ J L 2 I J 1  U  . i  O ,  /  /  ,
Rahimtula, A,D, and O l'Br.ien, P.J. (1974a) Biochem, Biophys, 
Res, Commune ISO, 440-447,
Rahimtula, A ,D , and 0 ^Brien, P ,J . (1974b) Biochem, Biophys, 
Res, Commun,v62, 268^275.
Rahimtula, A,D, and 0*Brien, P.J, (1977) in Microsomes and 
Drug Oxidations (Ullrich, V. , Roots, I,, Hildebrandt,
A.G., Estabrook, R.W. and Conney, A.H. , eds.) , pp.210- 
217, Pergamon Press, Oxford and New York.
Raison, J.K. (1972) Bioenergetics, £, 559-583.
Remmer, H. (1972) Eur. J. Clin. Pharmacol. 5, 116-136.
Remmer, H., Schenkman, J.B,, Estabrook, R.W., Sasame, H. , 
Gillette, J.R., Narasimhulu, S., Cooper, D.Y. and 
Rosenthal, 0. (1966) Mol. Pharmacol. 2, 187-190.
Ryan, D., Lu, A.Y.H., Kawalek, J., West, S.B, and Levin, W.
(1975) Biochem. Biophys, Res. Commun. €4, 1134-1141.
Ryan, D.E., Thomas, P.E, and Levin, W. (1977) Mol. Pharmacol. 
13, 521-532.
Sarles, M.P., Dove, W.E. and Moore, D.H, (1949) Am. J. 
Tropical Med." 29, 151^
Schenkman, J.B. (1970) Biochemistry/ 9y 2081^2091,
Schenkman, J,B., Cinti, D.L., Moldeus, P.W. and Orrenius,
S. (1973) Drug Metab. Disp. 1, 111-119.
Schenkman, J.B,, Cinti, D.L,, Orrenius, S., Moldeus, P. and 
Kraschnltz, R. (1972a) Biochemistry/ 11, 4243-4250.
Schenkman, J.B,, Greim, H,, Zange, M, and Remmer, H. (1969) 
Biochim. Biophys. Act a. "-171, 23-31.
Schenkman, J.B,, Jansson, I. and Robi-Suh, K.M. (1976)
Life Sci, 19, 611-624.
Schenkman, J.B., Remmer, H. and Estabrook, R.W. (1967)
Mol, Pharmacol, 3_, 113-123.
Schenkman, J.B. and Sato, R. (1968) Mol. Pharmacol, 4_, 
613-620.
Schenkman, J.B., Wilson, B.J. and Cinti, D.L. (1972b) 
Biochem. Pharmacol, 21r 2373-2383.
Seifert, J. and Vacha, J v (1970) Chem.-Biol. Interactions, 
2, 297-307.
Seiler, J.P. (1972) Mutation Res. Ij5, 273-276.
Seiler, J.P. (1973) Mutation Res. JL7, 21-25.
Seiler, J.P. (1975) Mutation Res. 3J2, 151-168.
Seiler, J.P. (1976) Anal. Biochem. 75, 45-52.
Selander, H.G., Jerina, D.M, and Daly, J.W. (1975) Arch. 
Biochem, B i o p h y s T68, 309-321.
Selye, H. (1970) Rev, Can, Biol," 29, 49- ,
Siekevitz, P, (1973) J. Supramolec, Struct.."/L, 471-489.
v ✓ V
Skrinjaric-Spoljar, M, , Matthews, H.B., Engel, J.L. and
Casida, J,E( (1971) Biochem. Pharmacol/ 20, 1607-1618.
Spatz, L, and Strittmatter, P. (1971) Proc. Natl. Acad.
Sci, U.S.A." S8, 1042-1046.
Spitz, S., Maguigan, W.H. and Dobringer, K. (1950) Cancer,
"-3, 789,
Staudt, H., Lichtenberger, F, and Ullrich, V. (1974) Eur.
J. Biochem.v46, 99-106.
Stern, J.O. and Peisach, J. (1974) J. Biol. Chem. 249, 
7495-7498.
Stern, J.O., Peisach, J., Blumberg, W.E,, Lu, A.Y.H. and
Levin, W. (1973) Arch. Biochem. Biophys.-156, 404-413.
Stier, A. (1976) Biochem. Pharmacol. 2J5, 109-113.
Stillwell, W.G., Carman, M.J., Bell, L. and Horning, M.G.
(1974) Drug Metab. Disp. 2, 489-498.
Stripp, B., Menard, R.H., Zampaglione, N.G,, Hamrick, M.E.
and Gillette, J.R. (1973) Drug Metab. Disp. 1, 216-221.
Strittmatter, P., Spatz, L., Corcoran, D., Rogers, M.J. ,
Setlow, B. and Redline, R. (1974) Proc. Natl. Acad.
Strobel, H,W,, Lu, A.Y.H,, Heidema, J, and Coon, M.J. (1970) 
J. Biol, Chem." 2*45 , 4851-4854,
Tang, S.C,, Koch, S., Papacfthymiou, G.C., Foner, S., 
Frankel, R.B., Ibers, J.A. and Holm, R.H. (1976)
J. Am. Chem, Soc." ^ 3, 2414-2434,
Taylor, J.M,, Jenner, P.M. and Jones, W.I. (1964) Toxicol, 
Appl, Pharmacol," £, 378-387,
Temple, D.J. (1971) Xenobiotica, 1, 507-520.
Thomas, P.E,, Lu, A.Y.H., Ryan, D,, West, S.B., Kawalek, J. 
and Levin, W. (1976a) Mol. Pharmacol. jL2, 746-758.
Thomas, P.E., Ryan, D. and Levin, W. (1976b) Anal. Biochem. 
75, 168-176.
Tocco, D. J. , Egerton, J.R., Bowers, W., Christensen, V.W. 
and Rosenblum, C. (1965) J. Pharmacol. Exp. Ther.
149, 263-271.
Tong, S., Ioannides, C. and Parke, D.V. (1977) Biochem,
Soc. Trans. _5, 1372-1374.
Tsai, R,, Yu, C.A., Gunsalus, I.C., Peisach, J. , Blumberg,
W., Orme-Johnson, W.H, and Beinert, H, (1970) Proc, 
Natl. Acad. Sci. U.S.A.' 6£, 1157-1163.
Tyler, T.R, , Lee , J.T,, Flynn, H. and Vandenheuvel, W.J.A.
(1976) Drug Metab, Disp.v4, 177-179.
Uehleke, H %, Hellirter, K.H, and Tabarelli, S, (1973) 
Xenobiotica,^3, 1—11,
Ullrich, V., Frommer, V. and Weber, P. (1973) Hoppe- 
Seyler^s Z, Physiol, Chem.; 354, 514-520,
Ullrich, V,, Nastainczyk, W, and Ruf, H.H, (1975a) Biochem 
Soc. Trans.v3, 803-807.
Ullrich, V. and Schnabel, K.H. (1973) Drug Metab. Disp. 1, 
176-183.
Ullrich, V, and Weber, P.. (1972) Hoppe-Seyler1 s Z. Physiol 
Chem.-353, 1171-1177,
Ullrich, V,, Weber, P. and Wollenberg, P. (1975b) Biochem. 
Biophys, Res. Commun. £4, 808-813.
Vainio, H. and Parkki, M.G. (1976) Toxicology, 5^, 279-286.
Vore, M., Lu, A.Y.H., Kuntzman, R. and Conney, A.H. (1974) 
Mol. Pharmacol. 10, 963-974.
Warburg, 0. (1949) Heavy Metal Prosthetic Groups and
Enzyme Action, Clarendon Press, London and New York.
Wagstaff, D.J, and Short, C.R. (1971) Toxicol. Appl. 
Pharmacol." "19, 54-61,
Waterman, M.R,, Ullrich, V. and Estabrook, R.W, (1973)
Arch. Biochem. Biophys,' 155, 355-360,
Wattenberg, L.W.., Page, M.A. and Leong, J.L, (1968) Cancer 
Res/28, 934-937,
Weil, A,T, (1965) Econ. Botany, 1£, 194-201,
Welton, A.F, and Aust, S,D. (1974) Biochem, Biophys, Res. 
Commun.v56, 898-906,
Wendel, R.G., Hoegg, U,R. and Zavon, M.R. (1974) J. Urol. 
vill, 607-610.
Werringloer, J, and Estabrook, R.W. (1973) Life Sci. 13,
1319-1330.
Werringloer, J. and Estabrook, R.W, (1975) Arch. Biochem.
Biophys. 167, 270-286.
Whysner, J.A., Ramseyer, J. and Harding, B.W. (1969)
J. Biol. Chem. 245, 5441-5449.
Wickramasinghe, R.H. (1975) Enzyme, JL9, 348-376.
Wiebel, F.J. and Gelboin, H.V. (1975) Biochem. Pharmacol.
24, 1511-1515.
Wilkinson, C.F., Hetnarski, K., Cantwell, P. and DiCarlo,
F.J. (1974a) Biochem. Pharmacol. 23, 2377-2386.
Wilkinson, C.F., Hetnarski, K. and Hicks, L.J. (1974b) Pest, 
Biochem. Physiol, 299-312,
Wilkinson, C.F., Hetnarski, K, and Yellin, T.O. (1972) 
Biochem. Pharmacol." 21, 3187-3192,
Wilson, B.J, and Orrenius, S, (1972) Biochim. Biophys. Acta, 
V251, 94-101,
Wislocki, P,G,, Borchert, P., Miller, J.A, and Miller, E.C.
(1976) Cancer Res."36, 1686—1695.
Wislocki, P.G., Miller, E,Cy, Miller, J.A,, McCoy, E.C. and 
Rosenkranz, H.S. (1977) Cancer Res.v37, 1883-1891.
Witmer, C., Nehls, P., Krauss, P., Remmer, H. and Snyder, R.
(1975) in Cytochromes P-450 and b5 Structure, Function 
and Interaction (Cooper, D.Y., Rosenthal, 0., Snyder,
R. and Witmer, C. , eds.) , pp.175-188, Plenum Press,
New York and London,
Wolf, C.R,, Mansuy, D., Nastainczyk, W., Deutschmann, G.
and Ullrich, V. (1977) Mol. Pharmacol. 13, 698-705.
Yang, C.S., Strickhart, F.S, and Kicha, L.P. (1977) Biochim. 
Biophys. Acta. 465, 362-370.
Yasukochi, Y. and Masters, B.S.S. (1976) J. Biol. Chem.
-251, 5337-5344.
Yoshida, Y. and Kumaoka, H. (1975) J. Biochem. 7j8, 455-468.
Yu, S.J. and Terriere, L.C. (1974) Pest. Biochem. Physiol.
4, 160-169,
Zampaglione, N., Jollow, D.Jt, Mitchell, J.R,, Stripp, B., 
Hamrick, M. and Gillette, J.R, (1973) J, Pharmacol.
Exp. Ther. 157, 218-227,
